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Abstract 
FoxP3 expressing regulatory T-cells (Treg) are essential for preventing 
autoimmunity by the immune system. The dynamics and signalling 
requirements for Treg development in the thymus are not well understood but are 
thought to integrate TCR, co-stimulatory and cytokine signalling. Previous 
studies have been hampered by the difficulty of distinguishing peripheral 
homeostasis from de novo thymic generation of Treg, To circumvent this 
problem, we used mice bearing both a FoxP3 reporter allele (FoxP3GFP) and in 
which Zap70 expression is controlled by a Tet-inducible transgene (TetZap70), 
induced by administration of antibiotic doxycycine (dox). Zap70 deficient 
thymocytes are arrested at the CD4+CD8+ double positive stage of 
development. Induction of Zap70 expression by dox therefore restores positive 
selection and allows analysis of de novo Treg development independently of 
existing peripheral Treg. In timecourses of Zap70 induction of TetZap70 
FoxP3GFP mice, we found that Treg develop after day 4 and remained in the 
thymus until day 10, at which time GFP+ Treg were first detected in peripheral 
lymphoid organs. To investigate the requirement for TCR signals for Treg 
development we used a pulse of the tetracycline analog methacycline, which 
resulted in a tight 48h window of Zap70 induction. Remarkably, confining Zap70 
expression to the first two days of thymic development was sufficient for normal 
development 4 days later. Using the TetZap70 FoxP3GFP mice we also 
investigated the temporal requirement for TGFβ, IL-2 and CD40 signalling 
during Treg development. Neither TGFβ nor CD40 signalling were required for 
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de novo thymic Treg development. Using blocking antibodies and the addition of 
cytokine-antibody complexes revealed an essential role for IL-2 as well as a 
semi redundant role for IL-15. Blockade of IL-2 had no effect on induction of 
FoxP3 or the number of Treg induced during development. However, induction of 
CD25 by FoxP3+ Treg was entirely IL-2 dependant. Using mixed bone marrow 
chimeras we show evidence supporting a hematopoietic source of thymic IL-2. 
We therefore propose a model of thymic Treg development in which TCR signals 
alone are sufficient to induce FoxP3 expression but that continued development 
of Treg is reinforced by IL-2.  
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Chapter 1 
Introduction 
1.1 Evolution of the immune system 
1.1.1 Evolution  
Life began on earth approximately 3.5 billion years ago with the appearance of 
single-cell organisms such as eubacteria, archae-bacteria and eukaryotes. 
Around 600 million years ago the first multicellular organisms, metazoans, 
began to appear. Following this milestone in our evolutionary history, rising 
oxygen levels in the atmosphere led to a rapid expansion and diversification of 
the organisms present on earth. Since then these organisms have flourished 
and evolved into the plethora of organisms which populate the planet today. 
Increased complexity led to the evolution of dedicated immune defence 
systems. The next several hundred million years led to the evolution of a vast 
array of immunological defence strategies. Most organisms deploy these 
simultaneously in order to efficiently protect themselves from infection by 
pathogens. In response to this many micro-organisms evolved the ability to 
exist within hosts without triggering strong immune responses. Known as 
parasitism, this lead to the selection of less lethal strains of micro-organisms, as 
host survival was evolutionary advantageous (Anon 2004). The diversification 
and increased complexity of the metazoans was associated with the 
development of a wide variety of cell surface molecules, some of which could 
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behave as barriers to pathogenic infection. These therefore became the first 
early example of the simplest form of protection from micro-organisms, barrier 
formation. Relentless evolutionary pressure and diversification most likely led to 
the incorporation of these cell surface proteins into signalling pathways, leading 
to the development of the innate immune system as we know it.  
1.1.2 Innate 
The invertebrate immune system relies on the innate immune response in order 
to control invading pathogens. These immune responses are surprisingly 
complex and compare with invertebrate immune responses in terms of 
complexity (Boehm 2012)(Flajnik & Pasquier 2004). Innate immune responses 
rely on a combination of factors to control pathogenic infection, one of which is 
pattern recognition receptors (PRRs). Hosts detect specific bacterial 
components such as peptidoglycan, lipopolysaccharide, outer-membrane 
proteins and a wide variety of other proteins expressed by bacteria. Janeway 
first termed these pathogen associated molecular patterns (PAMPs) (Medzhitov 
& Jr 2013). The innate immune system recognises these PAMPs using pattern 
recognition receptors (PRRs) such as toll-like receptors (TLRs) and 
peptidoglycan recognition receptors (PGRPs). Signalling through these 
receptors then triggers downstream signalling pathways, activating cellular and 
humoral effectors (Reviewed in Leulier & Lemaitre 2008)(Reviewed in Royet et 
al. 2011). While phagocytes ingest cells which are damaged or expressing 
markers associated with pathogenic bacteria, humoral defences constitute a 
chemical-based mechanism to destroy pathogens. This response includes the 
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production of AMPs which lyse cells and ROS which oxidise lipids and damage 
DNA. AMPs and ROS are widely used in both vertebrates and invertebrates and 
appear to be conserved throughout evolution (Krasity et al. 2011)(Dowling et al. 
2009)(Ausubel 2005).  
1.1.3 Adaptive 
Vertebrates make up a small fraction of all known animal species and can be 
subdivided into 2 groups. The jawless vertebrates which consist of 
approximately 100 species of hagfish and lamprey (Janvier 2010) and the jawed 
vertebrates which are made up of approximately 60,000 species (Mora et al. 
2011). While invertebrates rely solely on the innate immune response for 
clearance of pathogens, vertebrates have coevolved a second adaptive arm to 
their immune response. The innate immune system comprises generic 
receptors which recognise conserved patterns on a variety of pathogens in-
order to trigger an inflammatory response. The vertebrate-specific adaptive 
immune response by contrast depends on somatic diversification of genes 
which encode antigen receptors. This creates a huge repertoire of cells each 
expressing a slightly different antigen receptor. Interestingly the types of genes 
which undergo somatic diversification vary in the jawless and jawed vertebrates.  
Jawless vertebrates rely on leucine rich repeats containing antigen receptors 
termed variable lymphocyte receptors (VLRs) (Boehm 2012). These develop 
from a form of homologous recombination that is initiated by DNA double 
stranded breaks and results in non-reciprocal transfer of genetic information 
(Nagawa et al. 2007). Antigen receptor repertoire in jawed vertebrates however 
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is the result of combinational and junctional diversity through V(D)J 
recombination (Schatz 2004). Junctional diversity is an important difference 
between the two mechanisms as it introduces non-templated sequence 
elements. Vertebrate-specific genetic variations were also accompanied by the 
development of new cell types including lymphocytes and dendritic cells (DCs) 
as well as the development of new specialised tissues such as the thymus and 
spleen. A key feature of the co-evolution of the innate and adaptive immune 
responses is there ability to co-operate in-order to mount effective immune 
responses against potentially pathogenic micro-organisms (Web et al. 2013).  
1.1.4 V(D)J Recombination 
Lymphocytes detect antigens using either antibodies located on the surface of 
B-cells, or T-cell receptors (TCR) expressed by T-cells. Antibodies are 
composed of 4 polypeptides, 2 heavy chains (H) and 2 light chains (L), held 
together by disulphide bonds (R.Porter 1973). The sequence of the N-terminus 
of the polypeptide chains varies greatly from one antibody to the next (V 
region). However the C-terminal regions remain strikingly similar (C-region) 
(Hilschmann & Craig 1966). This diversity in sequence ensures antibodies are 
able to responds to a variety of antigens. The exon which encodes the V-region 
of the antibody is composed of 2 or 3 individual gene segments (S. Tonegawa 
1983). These are known as the variable (V), diversity (D) (only present in heavy 
chains) and joining (J) regions (Weigert MG,1970)(Sakano H, 1981)(Brack et al. 
1978). In order to obtain a fully functional V-region, firstly recombination of D 
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and J occurs, resulting in a DJ fragment. This is followed by recombination with 
a V region, giving a fully functional V(D)J fragment (Reviewed in Nishana 2012). 
Similar to antibodies TCRs contain 2 glycoprotein subunits each individually 
encoded by a somatically rearranged gene. These subunits can be either αβ or 
γδ pairs. At the N terminal of the TCR subunits there is a V region followed by a 
J region. However in TCRβ or TCRδ chains these are also interrupted by a D 
segment. Somatic rearrangement of the TCR chains occurs by a similar 
mechanism to that of antibodies, with a D-J recombination preceding that of a 
V-DJ recombination event on the heavy chain. TCRβ chain rearrangement 
always precedes TCRα rearrangement, occurring at the very early stages of 
development. Strict adherence to the chronological order of these 
recombination events is maintained by strict expression of the required 
enzymes as well as chromosomal activity of the participating gene loci (Bassing 
et al. 2002).  
Recombination is initiated by RAG1 and RAG2 proteins. These bind to 
recombination signal sequence (RSS) residues which are adjacent to each sub-
exon. These consist of a palindromic heptamer (CACAGTG) and an AT rich 
nonomer (ACAAAAACC) (Sakano H, 1979). The heptamer and nonomer 
regions are separated by either 12bp or 23 bp spacer regions. Generally only a 
12bp RSS can combine with a 23bp RSS, helping prevent non-productive 
rearrangements (Sakano H, 1981). Once bound to the RSS, RAG1 and RAG2 
induce a single stranded nick between the RSS and coding segment (Schlissel 
et al. 1993). The 3’ OH on the coding strand then becomes covalently linked 
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with the opposite non-coding strand phosphodiester bond, in a trans-
esterification reaction. This results in a hairpin structure at the coding end and 
the blunt signal end (Roth et al. 1993). The signal ends remain closely 
associated with RAG proteins resulting in the ‘post-cleavage complex’ (Agrawal 
& Schatz 1997). The coding ends are then joined to create the exon. 
1.2 The lymphoid compartment 
1.2.1 Lineage Specification in bone morrow 
The main components of the adaptive immune response are lymphocytes. 
There are two main types of lymphocyte, the B-cells which are bone marrow 
derived and the T-cells which develop in the thymus. Both B-cells and T-cells 
develop from multi-potent progenitors within the bone marrow. These give rise 
to both the myeloid compartment and multi-potent lymphoid progenitors (Pelayo 
et al. 2006; Pelayo et al. 2005). Common lymphoid progenitors then give rise to 
B-cells, T-cells and NK cells, however some dendritic cells populations are 
generated from the same progenitors (Baba et al. 2004). A tightly regulated 
network of transcription factors expressed within the lymphoid progenitors 
determines the fate of the cells. E2A, EBF and Pax5 expression cause a 
commitment to becoming a B-cell whereas GATA-3 and Notch-1 signalling 
specify a T-cell fate (Pelayo et al. 2006; Pelayo et al. 2005). T-lymphoid 
progenitors then leave the bone marrow and enter the thymus where they 
continue their development into fully mature T-cells.  
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1.2.2 T-cell development 
Seeding of the thymus by progenitors probably occurs as early as embryonic 
day 11.5 in mice. The thymus consists of 2 nodules each of which contains an 
outer cortical region and a central medulla. The thymus contains large numbers 
of developing T-cell precursors which are embedded in a network of epithelial 
cells known as the thymic stroma. In the post-natal thymus T-lymphoid 
progenitor cells enter the thymic parenchyma which are found mainly in the 
cortico-medullary junction, where the vasculature is well developed (Lind et al. 
2001). Thymocytes then migrate out of the cortico-medullary junction to the 
subcapsular region of the thymic cortex (Lind et al. 2001). The chemokine 
receptors CXCR4, CCR7 and CCR9 are suggested to be involved in this 
process (Misslitz et al. 2004; Plotkin et al. 2013). Here progenitor cells are 
signalled to differentiate into T-cells via notch signalling. Un-committed 
thymocytes gradually commit to the T-cell lineage under the influence of the 
thymic microenvironment, resulting in the induction of T-cell receptor gene 
rearrangement (Dik et al. 2005). All T-cell lineages arise from thymocytes which 
express neither CD4 or CD8 co-receptors, known as double negative 
thymocytes (DNs). DN thymocytes have been further categorised depending on 
their expression of the markers CD25, CD44 and Kit. DN1 cells initially express 
CD44 and Kit but not CD25. Transition from the DN1 to the DN2 stage of 
development is associated with the initiation of TCR δ, γ and β gene 
rearrangement as well as the expression of CD25. The process of gene 
rearrangement is completed in DN3 cells which subsequently decrease 
expression of CD44 and Kit (Livák et al. 2013). DN3 cells which successfully 
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rearrange either their TCR δ and γ, or β chains are able to signal through their 
TCRs, rescuing them from apoptosis and stimulating proliferation (Michie & 
Zúñiga-pflücker 2002; Kruisbeek et al. 2000). Cells either form TCR δγ 
receptors committing them to the δγ lineage or successfully rearrange their β-
chain which pairs with a surrogate pre-TCRα chain, initiating a commitment to 
the TCRαβ lineage. Completion of the β-selection and δγ selection checkpoints 
are accompanied by CD5 and CD27 expression as well as an increase in cell 
size. Successful formation of a TCR defines the transition from DN3a-DN3b 
stages of development (Taghon et al. 2006). TCR δγ cells lineage cells remain 
double negative but down regulate expression of CD24 following maturation.  
Cells expressing a pre-TCRαβ form a complex with CD3 allowing TCR 
signalling, leading to proliferation, the expression of both CD4 and CD8 and the 
arrest of further β-chain rearrangement. These double positive thymocytes 
(DPs) make up over 80% of total thymocytes. Cells also undergo α locus 
rearrangement immediately after pre-TCR signalling. However full scale α locus 
rearrangement is not in place until the cells become quinescent DP cells. Cells 
undergo various rounds of α locus rearrangement until an α-chain which forms 
an MHC-restricted receptor when paired with the β-chain is obtained (Petrie 
1993). The generation of a TCRαβ which successfully binds MHC is thought to 
occur relatively infrequently, therefore most DPs express surface TCR but 
remain undifferentiated (Petrie, 1993). When a successfully rearranged TCRαβ 
receptor is obtained cells must undergo positive selection in order to continue 
development. 
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1.2.3 Positive and negative selection in the thymus 
After successful TCRαβ rearrangement, developing T-cells undergo MHC 
mediated positive and negative selection. Positive and negative selection in the 
thymus is crucial for self tolerance and therefore the avoidance of autoimmunity 
(Werlen 2013)(Reviewed in Starr et al. 2003). A careful balance must therefore 
be struck, between selecting ‘useful’ TCR clones which are able to recognise 
foreign protein epitopes. Clones which are likely to mount immune responses to 
self and cause autoimmunity must be purged. Positive selection of developing 
T-cells is initiated by TCR ligation to peptide-MHC complex’s with a low affinity. 
The signalling strength of this interaction is crucial as peptide ligands which 
strongly interact with the TCR will stimulate apoptosis and negative selection. 
However partial interaction causes positive selection (Induce et al. 2012).  
When cells progress to the DP stage of development and have undergone 
TCRα rearrangement all developmental decisions are instructed by TCR-
peptide/MHC interactions. These are displayed by thymic stromal cells within 
the thymic microenvironment. Thymocytes whose TCR fail to interact with 
peptide/MHC complexes undergo death by neglect. In fact the loss of the vast 
majority of cells within the thymus is attributed to neglect, far exceeding that 
observed in negative selection (Surh & Sprent 1994). Positive selection of cells 
in the thymus appears to occur as a result of 2 mechanisms. Firstly TCRs 
present on developing thymocytes appear to have an intrinsic affinity for 
peptide/MHC complexes despite undergoing random rearrangements 
(Blackman et al. 1986; Zerrahn et al. 1997). Secondly multiple rounds of TCRα 
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rearrangement allow DP cells to generate TCRs with several distinct 
specificities (Petrie, Livak, Schatz, Strasser, Crispe & Shortman 1993). Despite 
this it is estimates that 90-95% of thymocytes are lost due to failed positive 
selection and death by neglect (Huesmann et al. 1991; B. K. Shortman et al. 
1991). 
1.2.4 The signalling pathways required for thymic selection. 
Several Src and Syk family proteins have been described to be essential for 
proximal signalling during TCR induced positive selection. The kinase Lck is 
required for β-selection at the DN3 stage of thymic development, but is also 
required for positive selection (Sohn et al. 2001; Hashimoto et al. 1996). Zap70-
/- mice show strongly impaired positive selection also, indicating a key role in the 
induction of downstream TCR signalling events. One of the main targets of 
Zap70 kinase activity is the adaptor protein LAT. LAT-/- mice show defects in 
both β-selection and positive selection (W. Zhang et al. 1999). This has 
hindered studies which have aimed to assess the role of LAT in positive and 
negative selection. Following phosphorylation of LAT by Zap70, LAT begins 
recruitment of several proteins involved in the TCR signal transduction pathway. 
These include GADs, SLP76, Grb2 and PLCγ1 (Reviewed in Wange 2000). 
Activation of PLCγ1 results in diacylglycerol (DAG) and IP3 generation. IP3 can 
then cause increases in intracellular Ca2+ causing activation of the calcineurin 
pathway. The calcineurin pathway has then shown to be a crucial activator of 
the transcription factor NFAT. The additional target of PLCγ1 signalling, DAG, 
can then cause Ras activation via the RasGRP, class of guanine nucleotide 
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exchange factors (Reviewed in Starr et al. 2003). Successful positive selection 
of TCRαβ expressing T-cells signals proliferation, survival and CD4+ or CD8+ 
SP fate determination.   
Survival and differentiation are outcomes of TCR signalling for some DP 
thymocytes. However not all TCR signalling events lead to this.  The ligands 
which positively select thymocytes during development are not generally 
stimulatory for mature T-cells. Ligands which normally stimulate T-cells outside 
of the thymus cause clonal deletion when expressed intra-thymically. Known as 
negative selection, this is the primary mechanism of eliminating self-reactive 
thymocytes during development. This deletion of auto reactive thymocytes was 
thought to occur primarily in the medulla where medullary thymic epithelial cells 
(mTECs) express tissue specific antigens promiscuously. However more recent 
reports suggest that negative selection can occur throughout development, with 
DPs undergoing clonal deletion in the cortex (Stritesky 2013; Daley 2013). If 
developing SP thymocytes express a TCR which interacts strongly with self-
peptide/MHC complexes then T-cells are stimulated to undergo apoptosis. This 
is discussed in more detail in section 1.4.1. 
1.2.5 CD4/CD8 lineage decision 
Positively selected DP thymocytes have potential to become either CD4+ SP or 
CD8+ SP T-cells. Elucidating the mechanisms and signalling cues which lead to 
T-cells committing to either of these lineages has long been the focus of many 
investigations. TCR signalling has been shown be essential for commitment to 
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either lineage. Various models have been proposed describing the signalling 
cues required for the divergence of developing thymocytes into either lineage.  
A strength of signal instructional model for describing the signalling 
mechanisms which instruct CD4 or CD8 co-receptor expression was initially 
favoured. This model predicted that the strength of the TCR signal received 
during positive selection instructed commitment to either the CD4+ SP or CD8+ 
SP lineage (Itano & Robey 2000). As the cytoplasmic tail of CD4 binds more 
Lck than the CD8 co-receptor, it was proposed that the relative strength of these 
signals led to developing T-cells turning off either CD4 or CD8 gene expression 
(Itano & Robey 2000). This model was based on experiments using CD8α 
‘chimeric’ co-receptors engineered to express the cytosolic domain of CD4. In 
vivo expression of these chimeric co-receptors resulted in MHCI restricted CD4+ 
SP T-cells (Itano & Robey 2000). Studies involving the manipulation of the 
activity of the intracellular kinases Lck led to similar conclusions (Hernández-
Hoyos et al. 2000). More recent investigations have analysed in more detail 
these studies, finding no effect on CD4/CD8 lineage choice of developing cells 
(Erman et al. 2006). One recent model however describes thymocytes 
becoming increasingly more sensitive to TCR ligation. Using mice containing an 
inducible tetracycline transgene of Zap70, it was found that thymocytes up-
regulate Zap70 expression as DP cells mature (Saini et al. 2010). Therefore as 
DPs mature they become more sensitive to TCR ligation. Therefore a strong 
TCR signal would lead to the early development of CD4+ SPs leaving weaker 
signalling CD8+ SPs to develop later. This model suggests an important role for 
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the timing and strength of TCR signalling during lineage decisions in the 
thymus. 
More contemporary models suggest the duration of signalling directs the 
CD4/CD8 lineage decision. The kinetic signalling model explains the finding that 
CD4+ CD8Lo thymocytes are lineage uncommitted precursors of both CD4+ SP 
and CD8+ SP T-cells (Brugnera et al. 2000). It has been shown that DP 
thymocytes upon positive selection decrease cd8 transcription irrespective of 
MHC restriction, signalling strength or duration of the positive selection signal. 
DP thymocytes then assess the ability of the thymocytes to signal in the 
absence of cd8 transcription. If TCR signals persist then cells maintain cd4 
expression while switching off cd8, causing a commitment to the CD4+ lineage. 
However if TCR signals cease then cells re-express cd8 and commit to a CD8 
lineage. This simple mechanism allows developing cells to assess their ability to 
signal without the CD8 co-receptor and therefore determine appropriate co-
receptor expression (Reviewed in Singer et al. 2008). For the kinetic signalling 
model to be true positive selection and CD4/CD8 lineage decisions must be 
separate events. First positive selection of developing thymocytes causes cd8 
down regulation, while the presence/absence of further TCR signalling events 
signals commitment to the CD4 or CD8 SP lineages.  
Singer and colleagues have further shown that differentiation of CD8+ SP T-
cells requires signalling through the IL-7 receptor (J.-hyun Park et al. 2010). In 
these studies the authors constitutively activate the IL-7R dependant signalling 
pathway. They show the development of CD8+ SPs in the absence of Zap70 
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signalling, concluding that development of CD8+ SPs is IL-7 dependant while 
remaining TCR independent. However IL-7R expression has been shown to be 
modulated by developmental TCR-dependant signals during positive selection 
(Sinclair et al. 2011). Singer and colleagues therefore fail to address if IL-7 
responsiveness by developing thymocytes in caused by TCR signals. Further to 
this, studies in Zap70-/- mice which express an adenosine deaminase driven 
Zap70 transgene show that TCR signalling is required throughout T-cell 
development.  Zap70 expression is limited to DPs in these mice, consequently 
they fail to develop any mature CD8+ SP T-cells (X. Liu et al. 2003).  
 
1.2.6 Development of T-cell populations by agonist signalling. 
TCR signals of distinct strength guide the thymic development of CD4 and CD8 
lineages (discussed in section1.2.4). However TCR signals are also thought to 
guide development of additional more specialised cell fates. Strong signalling 
through the TCR are proposed to guide commitment of NKT, CD8αα and MAIT 
cells (Mucosal associated invariant T-cells). NKT cells are a thymus dependant 
T-cell subset which are developmentally and functionally distinct from CD4+ and 
CD8+ T-cells. NKT cells are thought to develop from CD4+ CD8+ DP T-cells in 
the thymic cortex (Gapin et al. 2001). During development randomly rearranged 
NKT TCRs recognise glycolipid antigens presented by CD1d. CD1d is an MHC-
class-I like molecule which is expressed by both thymic epithelium and DP 
thymocytes (Coles & Raulet 2003). Interestingly NKT cells seem to be selected 
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by CD1d- glycolipid complexes expressed on DP thymocytes. When expression 
of a CD1d transgene is limited to DP thymocytes in Cd1d-/- mice, the NKT cell 
pool remains unchanged (Wei et al. 2005). This mode of selection differs from 
that of conventional T-cells which are selected by the thymic epithelium. The 
thymic epithelium also expresses CD1d (Xu et al. 2003; Forestier et al. 2003). It 
therefore remains to be determined if epithelial cells also play a role in NKT cell 
development.  
Development of mucosal associated invariant T cells (MAIT) is analogous to 
that of NKT cells also. MAIT cells express an invariant TCRα chain and similar 
to NKT cells, display TCRs with limited diversity. These are restricted to the 
MHC-like molecule MR1 (Treiner et al. 2005). MAIT cells are selected intra-
thymiclly by hematopoietic cells which present endogenous ligands bound to 
MR1 (Martin et al. 2009). MAIT cell development remains poorly understood 
however it is thought to involve a stepwise development in the thymus followed 
by peripheral expansion (Martin et al. 2009). Indeed MAIT cell accumulation in 
the gut requires MR1 expression by B-cells and commensal flora (Treiner et al. 
2003).  
CD8αα T-cells also develop in the thymus following strong TCR signalling 
(Pobezinsky et al. 2012). CD8αα T-cells constitute a large percentage of the 
IELs located within the small intestine. IELs are antigen experienced cells which 
typically express activation markers such as CD44 and CD69. They function as 
the first line of defences against invading pathogens located within the gut. 
They are typically heterogeneous and vary widely in their distribution within the 
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small and large intestine (Reviewed in Cheroutre et al. 2011). A commitment to 
the CD8αα T-cell lineage is thought to result from chronic TCR signalling during 
thymic development. Thymocytes which are prevented from undergoing clonal 
deletion by either over-expressing anti-apoptotic factors or removing CD28 co-
stimulation are diverted to become anergic CD4- CD8- DN thymocytes. These 
DN TCRαβ T-cells then preferentially migrate to the small intestine where they 
differentiate into CD8αα IELs.  
An alternative fate for thymocytes which undergo strong thymic selection 
signals is commitment to becoming an nTreg. Increased avidity for MHC/self-
peptide complexes displayed by the thymic stroma during thymic selection has 
been shown to be essential for nTreg differentiation. It has also been suggested 
that Treg development requires an IL-2 signal for FoxP3 expression, which 
subsequently instructs a commitment to the Treg lineage allowing Treg in dampen 
immune responses in the periphery (discussed in 1.4.2).  
1.3. Peripheral T-cell subsets 
Upon response to an acute infection antigen specific T-cells undergo clonal 
expansion and differentiate into effector T-cells. Many of these cells can then 
enter the blood and migrate to the area of infection.  
1.3.1 CD8+ subset 
Infections with viruses are focussed primarily on the type I response involving 
CD8+ SP cytotoxic T-lymphocytes (CTLs). CD8+ SP T-cells recognise peptide 
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fragments from cytosolic pathogens bound to MHC class I molecules on 
infected cells. These interactions promote differentiation of naïve CD8+ SP T-
cells into in CTLs (Reviewed in Kaech & Cui 2012). On interaction of a CTL with 
a target cell there is direct exocytosis of the CTL granules into the extracellular 
space between the two cells. CTL granules contain both perforin and 
granzymes proteins, which together cause target cell death. Perforin is a 67 
kDa multi-domain protein which oligermerises on target cells, forming pores in 
the target cell surface (Tschopp J, Masson D 1986). Subsequent entry of 
granzyme A and B into the target cell induces cell death. Cell death is initiated 
via cleavage of pro-caspase molecules, resulting in the release of cytochrome c 
and the initiation of the intrinsic cell death pathway (Reviewed in Barry & 
Bleackley 2002). CTLs express high levels of surface FASL (CD96) and are 
therefore able to induce cell death via the extrinsic cell death pathway. Upon 
engagement with FAS, expressed on the target cell surface, Pro-caspase-8 is 
recruited via FADD adapter protein (Fas-associated death domain protein). 
Caspase 8 is then cleaved and activated initiating apoptosis via caspase 9 and 
recruitment of proapoptotic proteins such as BID and BAX (Barry & Bleackley 
2002). As well as killing target cells, upon activation CTLs secrete cytokines 
such and IFNγ and TNF. 
1.3.2 CD4+ subset 
CD4+ effector subsets were initially described by Mossman and Coffman in the 
1980s in the Th1 and Th2 paradigm. Th1 cells were described as a subset of 
mature CD4+ SPs which secreted predominantly IL-2 and IFNγ. While a second 
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subset of cells, later named Th2 cells helped B cells secrete IgE by producing a 
specific B cell stimulating factor, later called IL-4 (Carty 1986; Cher & Mosmann 
1987). Blocking of Th2 mediated IgE secretion by the Th1 factor IFNγ later gave 
rise to the Th1/Th2 paradigm, in which each subset exert distinct immune 
responses while regulating the other subset. Th1 cells promote cell-mediated 
responses to cells infected with viruses and bacteria, secreting IFNγ, TNFα and 
IL-2. Th1 cells have also been shown to support some B-cell help, mainly 
causing IgG2a secretion in mice (Mosmann TR 1989)(Coffman 2006). Th2 cells 
have been shown to produce IL-4, IL-5 and IL-13 signature cytokines and 
provide help in IgE secretion by B-cells for clearance of extracellular pathogens. 
Th2 cells have also been implicated in various forms of allergy (Mosmann TR 
1989)(Coffman 2006). Further to the seminal work carried out by Mosman and 
Coffman, a diverse range of CD4+ effector states are now known to exist. These 
include the discussed Th1 and Th2 lineages as well as the more recently 
discovered Th17, Th9, Th22, Treg TR1 and TFH subsets. Th17 cells are a more 
recently identified class of effector T-cells that have been shown to produce IL-
17 (A-F) as well as IL-21 and IL-22. IL-17 production is implicated in various 
autoimmune disease such as multiple sclerosis, rheumatoid arthritis, psoriasis, 
IBD and allergic responses (Langrish et al. 2005). Th9 cells are an even more 
recent helper T-cell subset to be described. These cells generate high levels of 
IL-9 and IL-10. They share common features with Th2 cells however are distinct 
with their IL-9 production (Awasthi et al. 2009; Veldhoen et al. 2008). Regulatory 
T-cells oppose the activity of all of these pro-inflammatory T-effector cell 
subsets by dampening down immune responses.  
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1.4 Tolerance 
1.4.1 Central tolerance 
Recent studies have suggested that as many as six times more cells undergo 
negative selection than complete positive selection. It is thought that 
approximately 75% of these negatively selected cells are deleted at the DP 
stage of development (Stritesky et al. 2013). Both the thymic cortex and medulla 
are therefore thought to be able to contribute to central tolerance via the 
deletion of auto-reactive cells. The thymus provides a an environment which is 
critical to the establishment of tolerance (Reviewed in Kyewski & Klein 
2006)(Reviewed in Anderson et al. 2007). In the medullary region of the thymus 
mTECs and thymic dendritic cells (tDCs), display tissue specific self-antigens 
and together support the negative selection of self-reactive thymocytes. The 
expression of these tissue specific antigens by mTECs is thought in part to be 
due to the transcriptional factor Autoimmune Regulator (AIRE) (M. S. Anderson 
et al. 2002). In both humans and mice AIRE deficiency has been shown to lead 
to a failure in the establishment of central tolerance through negative selection 
(Blechschmidt et al. 1999; Shuichi Asakawa 1997). Thymic DCs cross present 
mTEC derived tissue specific antigens, while a small proportion of thymic DCs 
migrate into the thymus from the periphery. This allows thymic import of self-
antigens from peripheral tissues (Bonasio et al. 2006). Therefore co-operation 
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between tDCs and mTECs leads to deletion of auto-reactive thymocytes and 
the establishment of central tolerance.  
It seems clear that a TCR signal is essential for both positive and negative 
selection. However the mechanism by which cells interpret signals of varying 
strength to differentiate between survival and death remains unclear. A 
threshold for TCR signalling strength in order to discriminate between positive 
and negative selection has been described. The difference in affinity between 
the weakest ligand causing negative selection and the strongest ligand causing 
positive selection has been reported to be very close (Naeher et al. 2007). 
However the mechanism by which proximal signalling events are regulated to 
differentiate between strengths of TCR signalling is not well understood. It has 
been proposed that negative selection induces Erk phosphorylation at the cell 
membrane while positive selection induces Erk phosphorylation in the 
cytoplasm, possibly at the Golgi (Daniels et al. 2006). However more recently 
an alternative mechanism for differentiating TCR signals of varying strength in 
CD8+ SP thymocytes has been proposed. This model states that in order for a 
self-antigen to induce negative selection it must co-ligate TCR and CD8 co-
receptor for a minimum time. TCR and CD8 align through a zipper region on the 
TCRα and CD8β regions. This allows lck which is attached to the CD8α, time to 
access the ITAMs located on the CD3 chains, allowing full ζ chain 
phosphorylation. TCR antigen interactions which occur for less than the time 
needed for the TCR/co-receptor zipper action results in positive selection via the 
mechanisms described above, while complete phosphorylation of the ζ chain 
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results in negative selection (Palmer & Naeher 2009). It is thought that complete 
phosphorylation of the CD3 ζ chain during negative selection results in fully 
phosphorylated LAT leading to Grb2 and Sos1 recruitment in addition to Slp76, 
Gads, and PLCγ1 recruited during positive selection. This leads to strong 
transient activation of Erk along with p38and JNK activation, as opposed to the 
weak prolonged expression observed during positive selection (Starr et al. 
2003).  
 
1.4.2 Peripheral tolerance 
Negative selection of developing thymocytes based on their strong interaction 
with peptide/MHC complexes is fundamental to the establishment of central 
tolerance. A second form of tolerance known as peripheral tolerance is also 
essential for preventing auto-immunity. Peripheral tolerance is maintained by 2 
principle mechanisms, T-cell anergy (passive) and the induction of Treg (active). 
Treg act to restrain pathogenic immune responses, stopping the outgrowth of 
potentially autoimmune T-cells which may have escaped negative selection. 
Although several subsets of cells have been implicated in restraining immune 
responses, FoxP3+ Treg are the only currently known dedicated cell type which 
function in this way. Early investigations into the existence of Treg revealed the 
presence of a thymus derived cell type capable of mediating tolerance as 
observed in neonatal thymectomy experiments of chicken-quail chimeras (Ohki 
H et al. 1987). In studies involving the neonatal thymectomy of mice, it was 
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observed that thymectomy between days 2 and 4 of birth resulted in 
autoimmunity and T-cell mediated lesions. Subsequent transfer of thymocytes 
from adult mice alleviated the observed pathology (Nishizuka Y 1969; B. Y. S. 
Sakaguchi, Takahashi & Nishizuka 1982a; Life 1996a). Following this it was 
found that a subset of CD4+ SP cells with high surface expression of the α-
subunit of the IL-2 receptor (CD25) were capable of suppressing immune 
responses (S. Sakaguchi et al. 1995). Further understanding of the Treg lineage 
came from investigations into the human autoimmune disorder IPEX (immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). It was 
discovered that mutations in the X-chromosome encoding the FoxP3 gene were 
responsible for IPEX, as well as the corresponding mouse mutant scurfy 
(Chatila et al. 2000; Brunkow et al. 2001; Wildin et al. 2001). It was 
subsequently revealed in later studies that stable FoxP3 expression was 
restricted to Treg where it was essential for Treg function and differentiation 
(Fontenot et al. 2003)(Hori 2013). Loss of FoxP3 expression by Treg leads to a 
loss of suppressor function and the gain of effector T-cell properties (Williams & 
A. Y. Rudensky 2007). 
1.4.3 Mechanisms of Treg immune suppression 
Several sophisticated mechanisms are used in order to prevent autoimmunity, 
maintain immune homeostasis and moderate inflammation. One of the principle 
cell types involved in maintenance of peripheral tolerance are Treg. Much work 
has gone into understanding the mechanisms by which Treg supress immune 
responses. This has allowed insight into the control processes involved in 
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tolerance but also offered potential therapeutic targets. In order to moderate 
immune responses Treg can release inhibitory cytokines such as IL-10 and 
TGFβ. IL-10 and TGFβ are themselves suppressive cytokines, however they 
are also able to induce peripheral Treg development. nTreg are thought to 
function primarily in a contact dependant manner, it therefore remains 
contentious as to the exact role IL-10 and TGFβ play in nTreg mediated 
suppression (Thornton & Shevach 1998; Shimon Sakaguchi 1998). There have 
however been reports in allergy models suggesting that both nTreg and induced 
antigen specific Treg control disease, which is part dependent on IL-10 
(Reviewed in Hawrylowicz et al. 2005). It therefore remains to be determined 
the exact role IL-10 and TGFβ play in nTreg immune suppression. A further 
mechanism for suppression is by cytolysis. Cytotoxic activity is mainly described 
in NK cells and CTLs (discussed in more detail in section 1.3.1). However 
naturally occurring human Treg cells have also been shown to express granzyme 
A. Human Treg have been shown to induce target cell death through perforin and 
granzyme A activity, via CD18 adhesion (Grossman et al. 2013).   
Suppression by Treg has also been shown to occur by a group of mechanisms 
which when broadly grouped together cause ‘metabolic disruption’ of target 
effector T-cells. One of these mechanisms, remains a source of considerable 
debate. As Treg express high levels of CD25 it is proposed that Treg deplete local 
IL-2, depriving effector T-cells of IL-2 mediated survival signals (Thornton & 
Shevach 1998). This mechanism has recently been proposed to be essential in 
Treg mediated control of NK cells (Gasteiger et al. 2013). Prior studies have 
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however disputed this as a mechanism for Treg mediated suppression (Fontenot, 
2005)(Duthoit et al. 2005). Further suppression by Treg can occur via the 
intracellular or extracellular release of adenosine nucleosides by ectoenzymes. 
CD39 and CD73 have been shown to generate pericellular adenosine which 
can suppress effector T-cells by binding the Adenosine 2A receptor (A2AR) 
(Deaglio et al. 2007). Binding the A2AR both inhibits T-cell activation and 
stimulates TGFβ release. Release of TGFβ is then able to induce iTreg 
generation (Zarek et al. 2008). Treg have also been shown to target effector T-
cells directly through transfer of the inhibitory secondary messenger cAMP. 
During cell-cell contacts with target cells, Treg are able to release cAMP through 
gap junctions (Bopp et al. 2007). 
In addition to direct effects by Treg on effector T-cells, more recently it has 
become apparent that Treg are able to modulate APC function. In doing so Treg 
are able to reduce T-cell activation. Treg express high levels of cytotoxic T 
lymphocyte antigen 4 (CTLA-4). CTLA-4 is able to interact with CD80/86, a 
characteristic it shares with the stimulatory receptor CD28. CTLA-4-CD80/86 
interaction was initially thought to supply an inhibitory signal to DCs, reducing 
their ability to activate T-cells (Reviewed in Rudd & Rudd 2009). However more 
recently it has become apparent that CTLA-4 can actually capture CD80/86 
from the cell surface of DCs. These CTLA-4-CD80/86 complexes are then 
endocytosed by the CTLA-4 expressing cells and degraded (Qureshi et al. 
2011). This results in impaired CD28 co-simulation of effector T-cells and the 
dampening of the immune response. Some studies have also suggested a role 
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for lymphocyte activation gene 3 (LAG3) in Treg suppression of DCs. LAG3, 
expressed in the Treg surface is thought to interact with MHC class II molecules 
with high affinity where it may block DC maturation (Huang et al. 2004). There 
have been many described mechanisms for Treg immune suppression. It 
currently remains unclear which, if any, are the most crucial for Treg to moderate 
immune responses. Treg suppression seems relies on cell-cell contact, however 
the relative contribution by the numerous mechanisms remains the focus of on 
going research.  
1.4.4 FoxP3+ Regulatory T-cells 
The X-chromosome encoded transcription factor FoxP3 is the lineage defining 
transcription factor for Treg. FoxP3 is a member of the forkhead winged-helix 
family of transcription factors. Expression of FoxP3 is indispensible for the 
differentiation and function of Treg cells (Williams & A. Y. Rudensky 2007). Mice 
with a T-cell specific deletion of FoxP3 lack Treg and subsequently succumb to 
an overwhelming autoimmune pathology (Fontenot, Rasmussen, Williams, et al. 
2005). The FoxP3 locus is comprised of 11 exons, the last of which remains un-
transcribed (Ying Wang et al. 2008). The FoxPs locus also contains 3 proximal 
conserved non-coding sequences (CNS1-3) within several intronic sequences. 
These are reported to play a prominent role in the regulation of stable FoxP3 
expression. CNS3 contains a DNase I hypersensitive site and enriched with 
histones associated with promoter regions (H3K4me1). Nf-κB element c-Rel is 
reported to bind to CNS3 and regulate the FoxP3 promoter (Y. Zheng et al. 
2010). CNS1 deficiency leads to impaired peripheral FoxP3 induction in 
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peripheral Treg (A. Y. Rudensky 2011). CNS2 also known as the Treg specific 
demethylated region (TSDR) contains a CpG island the methylation status of 
which correlates with the stability of FoxP3 expression. The TSDR remains 
demethylated in ex-vivo FoxP3+ Treg but fully methylated in conventional T-cells 
(Floess et al. 2007; Kim & Leonard 2007).  
1.5 FoxP3+ Treg compartment 
1.5.1 iTreg cells and their development 
FoxP3+ Treg play a critical role in controlling auto-reactive immune responses. 
However the FoxP3+ compartment contains more than one lineage of cell. While 
FoxP3 expression in the thymus leads to nTreg development, induction of FoxP3 
in CD4+ naïve T-cells in the periphery leads to generation of iTreg. The 
differentiation of nTreg is caused by increased self-reactivity of developing 
thymocytes. However iTreg generation most likely occurs upon interaction of 
naïve CD4+ T-cells with allergens and commensal microbiota (Lathrop et al. 
2011). iTreg are thought to develop in response to distinct TCR and ligand 
specificity, however their exact role in the mediation of immune tolerance still 
remains to be completely understood (Lathrop et al. 2008). It has been shown 
that TCR transgenic T-cells which begin to express FoxP3 after administration 
of cognate antigen are able to alleviate antigen induced airway inflammation 
(Mucida et al. 2005). iTreg may therefore function to control allergen induced 
inflammation particularly at mucosal membranes.  
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As well as strong TCR signalling and suboptimal co-stimulation, generation of 
iTreg from naïve CD4+ T-cells depends on TGFβ signalling (S. G. Zheng et al. 
2004). TGFβ signalling leads to activation of the smad signalling pathway. The 
CNS1 region within the FoxP3 locus (discussed in section 1.3.4) contains both 
NFAT, smad3 and RARα binding sites. Analysis of CNS1 deficient mice shows 
defects in the generation of peripheral Treg. However CNS1 deletion does not 
result in detectable auto-immunity (Y. Zheng et al. 2010). This could suggest a 
non-redundant role for peripherally generated iTreg compared to thymically 
derived nTreg (Y. Zheng et al. 2010). FoxP3 induction after strong exposure to 
antigen and TGFβ is accompanied by decreased proliferation. This can be 
explained by the observation that TCR and TGFβ signalling stop recruitment of 
the cell cycle dependant methyl transferase (Dnmt 1) to the FoxP3 locus (most 
likely CNS2). This allows the FoxP3 locus to remain demethylated, stabilising 
expression (Josefowicz et al. 2012). Therefore sustained FoxP3 expression in 
iTreg relies on a combination of TCR and TGFβ signalling, as well as reduced 
cellular proliferation.  
1.5.2 Thymically derived ‘natural’ Treg  
Naturally occurring regulatory T-cells (nTreg) are a subset of CD4+ SP T-cell 
which develop in the thymus. They are characterised by high surface 
expression of the α-subunit of the IL-2 receptor CD25, as well expressing high 
levels of GITR and CTLA-4. They constitute approximately 5-10% of total CD4+ 
SP T-cells in the periphery. nTreg function by maintaining self-tolerance and 
immune homeostasis by tempering immune responses to infectious agents 
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(Reviewed in Josefowicz & A. Rudensky 2009). Strictly speaking nTreg are not a 
subtype of effector T-cell as they are not formed form naïve T-cells in 
inflammatory conditions. However naïve T-cells can give rise to alternative 
forms of regulatory T-cells known as iTreg and Tr1 cells. iTreg develop in the 
presence of TGFβ following TCR stimulation and produce large amounts of IL-
10 and TGFβ. Unlike most other CD4+ T-cell populations, iTreg display immune 
suppressive activity with minimal antigen specificity (Reviewed in Weiner & 
Weiner 2001). Tr1 cells are an additional type of suppressive cell induced 
induced to form from naïve CD4+ SP T-cells. These cells however differ from 
nTreg and iTreg by lacking expression of the transcription factor FoxP3 (Vieira PL, 
2004).  
 
1.5.3.1 TCR signal strength in nTreg development 
During thymic T-cell development TCR avidity and duration instruct commitment 
to the CD4+ and CD8+ lineages (Reviewed in Singer et al. 2008). As well as 
CD4 and CD8 fate determination TCR signalling can instruct the development of 
specialised T-cell populations such as NKT cells and CD8αα T-cells (Leishman 
et al. 2002; Moran, Holzapfel, Xing, Cunningham, Maltzman, Punt & K. A. 
Hogquist 2011). It therefore comes as no surprise that TCR signalling also 
instructs the intra-thymic development of Treg. TCR signals have been shown to 
be essential for thymic Treg development. Studies show that thymic Treg 
development only occurs in TCR transgenic mice following the introduction of a 
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second transgene encoding the cognate ligand (Jordan et al. 2001). Previous to 
this it was shown that TCR transgenic mice specific for myelin basic protein, 
which cannot undergo endogenous rearrangement due to being RAG deficient, 
develop brain lesions. However in RAG sufficient hosts the inflammatory brain 
lesions are prevented by cells which posses endogenous TCRs (Yijie Wang & 
Lafaille 1998; Lafaille et al. 1994). Therefore TCR dependant signals are 
essential for Treg development and the establishment of tolerance. It is proposed 
that strong TCR signals, of a strength between that normally needed for positive 
and negative selection, cause FoxP3 expression and a Treg lineage 
commitment. Early evidence of this came from the observation that Treg express 
high levels of CD25, CD5 and CTLA-4, all of which are induced by TCR 
signalling. Further evidence for this came from retroviral transfer of Treg or naïve 
T-cell TCRα libraries into RAG-/- TCR transgenic T-cells. Treg derived TCRs 
were more able to induce expansion and auto-immunity upon transfer into 
lymphopenic hosts however only able mount weak in vitro responses to 
syngenic APCs, when compared to the reaction to ‘foreign’ peptide recognised 
by their transgenic TCRs (C.-song Hsieh et al. 2004). Therefore the affinity 
range of conventional T-cells which recognise antigen during immune 
responses appears to be higher than that of Treg TCRs for self antigens. Treg 
development is likely to be instructed by TCR signals above that which normal 
cause positive selection of non-regulatory T-cell populations, but below that of 
negative selection. An instructive role for TCR signalling is also demonstrated 
by sequence analysis of mice bearing a single transgene encoded TCRβ chain. 
These mice show very little overlap between TCRα sequences of Treg and non-
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Treg (C.-song Hsieh et al. 2004). This suggests TCRs of distinct affinity for self 
ligands instruct development into either a conventional T-cell or a Treg. Studies 
using TCR transgenic mice which express a single Treg derived TCR suggest 
clonal completion between Treg for these high affinity self-ligands in the thymus. 
Normally Treg TCR transgenic mice contain very few Treg, however when 
precursor numbers are reduced, efficient Treg generation is observed.  
Suggesting that developing thymocytes compete for high affinity peptide ligands 
during development. In conditions of high clonal completion, such as in TCR 
transgenic mice this can lead to inefficient Treg induction (Bautista et al. 2009). 
The studies discussed above suggest an important role for TCR signalling in the 
thymic selection of regulatory T-cells. However others have argued against this 
being the case. It was observed that in 3A9 and KRN TCR transgenic mice 
thymocytes underwent negative selection rather than differentiating into Treg 
when exposed to cognate antigen, encoded for by a second transgene in the 
thymus (Shih et al. 2004). The use of AND TCR transgenic mice further support 
this. Increasing the dose of TCR cognate ligand, cytochrome c, whose 
expression is under control of doxycycline, led to similar numbers of Treg. 
However Treg percentages were elevated owing to increased negative selection 
of conventional T-cells (Santen et al. 2004). A further study also suggested 
commitment to the Treg lineage occurs in the DN stage of development prior to 
full TCR rearrangement (D.Pennington, A.Hayday 2006). Therefore there was a 
period of time when the role which TCR signalling played in Treg selection 
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remained unclear. However more recently a significant body of work seems to 
support a clear role for TCR specificity in thymic Treg selection.  
1.5.3.2 Role of co-stimulation in nTreg development 
In addition to TCR signals, CD28 co-stimulation appears to play a crucial cell 
intrinsic role in FoxP3 induction. Both CD28-/- and CD80/86-/- mice show severe 
reductions in Treg frequencies (Solomen et al. 2000)(Tai et al. 2005). Removal of 
the lck binding domain present on the cytoplasmic tail of CD28 is also required 
for FoxP3 induction (Tai et al. 2005). This suggests that an important role for 
the co-operation of TCR and CD28 signalling in Treg selection. Further 
supporting this is the observation that many transcription factors usually 
associated with TCR and CD28 activation have been shown to contain binding 
sites on the FoxP3 locus. NFAT and AP1 bind to the FoxP3 promoter following 
increases in intracellular Ca2+ after TCR and CD28 activation (Mantel et al. 
2006). Various components of the TCR dependant NF-κB signalling pathway 
have also been shown to affect FoxP3 expression. Knockouts of CARMA1, 
PKCθ, Bcl10 and IKK2 have all been shown to reduce Treg frequencies 
(Reviewed in Josefowicz & A. Rudensky 2009). In addition to this Foxo1 and 
Foxo3 have also been shown to bind to the FoxP3 promoter (Ouyang, Beckett, 
Ma, Paik, et al. 2010). Previous studies have implicated a wide array of 
transcription factors associated TCR and CD28 signalling in FoxP3 induction. 
However the mechanism by which FoxP3 induction actually occurs remains 
incompletely understood. 
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1.5.3.3 Cytokine signals in nTreg development 
TCR sequence appears crucial for instructing commitment to the Treg lineage, 
however TCR signalling alone is insufficient for efficient Treg development. Only 
small percentages of thymocytes in TCR transgenic mice on a RAG deficient 
background differentiate into Treg, the rest become anergic T-cells (Apostolou et 
al. 2002). Also sequence analysis of TCR repertoires expressed on Treg and 
conventional T-cells show a partial overlap, suggesting TCR sequence alone is 
insufficient to ensure a commitment to the Treg lineage (C.-song Hsieh et al. 
2004). Treg generation has been shown to be delayed in neonatal mice 
compared to conventional T-cell populations (Fontenot et al. 2005). This is 
despite a relative enrichment of auto-reactive T-cells in neonates due to lack of 
terminal deoxynucleotidyl transferase expression. In addition neonates contain 
high frequencies of CD25Hi FoxP3- Treg precursors (Chan-Wang Joaquim Lio & 
C.-S. Hsieh 2008). Delayed Treg differentiation has therefore been suggested to 
be due to the lack of a cytokine signal. 
The primary cytokine thought to play a role in thymic Treg differentiation is IL-2. 
Mice deficient in the high affinity α-subunit of the IL-2 receptor (CD25) or the IL-
2Rβ (CD122) exhibit lethal autoimmunity, displaying an approximate 50% 
reduction in Treg frequencies (Sadlack et al. 1993)(Suzuki H et al. 1995). The IL-
2 receptor is also comprised of a third subunit, the common gamma chain (γc). 
The other γc cytokines IL-15 and IL-7 have also been described to play a role in 
thymic Treg differentiation. The IL-15R structure is related to that of the IL-2R, 
sharing both CD122 and γc components. The IL-15Rα chain in mTEC trans 
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presents IL-15 to developing thymocytes (Stonier & Schluns 2010). Whereas IL-
2-/- mice show a 50% reduction in Treg frequencies, IL-15-/- and IL-7-/- show no 
defects in the size of the Treg compartment (Vang et al. 2008). However γc-/- 
mice contain no Treg whatsoever (Vang et al. 2008). Although Treg differentiation 
appears inhibited in IL-2-/- mice, Treg are not completely absent. This suggests 
some degree of overlap in the roles γc cytokines play in Treg differentiation. 
Studies have shown that young IL-2-/- and IL-2Rα-/- mice contain normal CD4+ 
FoxP3+ Treg frequencies. In contrast IL-2Rβ-/- and IL-15-/- IL-2-/- double ko mice 
contain severely reduced CD4+ FoxP3+ Treg frequencies (Burchill et al. 2007). 
Perhaps suggesting a redundant role for IL-2 and IL-15 in Treg differentiation. IL-
7 may also play a role, although most studies report no affect on Treg 
frequencies in IL-7-/- mice, unpublished data from Bayer and Malek suggest 
reduced Treg frequencies in IL-7R-/- mice (Malek 2008 unpublished data). Also 
thymic-stromal derived lymphopoietin which is itself implicated in human Treg 
development utilizes the IL-7Rα chain. It therefore remains possible that IL-7R 
signaling in tandem with IL-2 act as the γc cytokines regulating Treg 
differentiation (Hanabuchi et al. 2010). 
Developing CD4+ FoxP3+ Treg express IL-2Rβ, IL-7Rα and IL-15Rα and have 
been shown to respond to IL-7 and IL-2 and to a much lesser extent IL-15 
(Vang et al. 2008). The molecular mechanisms of γc cytokine signalling involved 
in Treg cell development remain incompletely understood. There appears to be 
an important role for STAT5 signalling as this is activated downstream of γc 
cytokine signalling and contains binding sites on both the FoxP3 promoter and 
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CNS2 region (M. a Burchill et al. 2008). Although IL-2-STAT5 signalling appears 
to play an essential role in Treg development it remains unclear whether STAT5 
directly drives FoxP3 expression, induces changes in chromatin structure at the 
FoxP3 locus or promotes survival and proliferation of FoxP3+ Treg. Deletion of a 
conditional STAT5 allele at the DP stage of development results in a dramatic 
decrease in FoxP3+ Treg frequencies (M. A. Burchill et al. 2007). However there 
is some suggestion that introduction of a Bcl-2 transgene into STAT5 deficient 
cells results in the rescue of STAT5 deficient Treg (Josefowicz & A. Rudensky 
2009- personal communication with S.Malin and M. Busslinger). This firstly 
shows STAT5 independent Treg differentiation and secondly suggests a role for 
STAT5 signalling in regulating survival and proliferation. 
In addition to its role in FoxP3 induction in thymic Treg development, IL-2 is 
suggested to play a role in Treg homeostasis. IL-2-/- and IL-2R-/- mice contain 
ten-fold reductions in CD4+ FoxP3+ Treg in the periphery. These cells express 
low levels of FoxP3 and CD25, suggesting IL-2 plays an important role in 
enhancing FoxP3 expression (Fontenot, Rasmussen, Gavin & A. Y. Rudensky 
2005)(Bayer et al. 2007)(Dennis Adeegbe,* Allison L. Bayer,*† Robert B. Levy 
n.d.). Gene expression profiling of Treg from IL-2-/- mice before and after IL-2 
treatment showed up regulation of mRNAs related to growth as opposed to 
immune function (Fontenot, Rasmussen, Gavin & A. Y. Rudensky 2005). In 
addition to this BrdU uptake was lower in peripheral Treg from mice with 
impaired expression of IL-2R (Malek et al. 2002)(Bayer et al. 2007). Peripheral 
Treg production is also dependant on IL-2 as adoptively transferred CD4+ T-cells 
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from IL-2-/- mice but not IL-2Rα-/- mice protect IL-2 sufficient hosts from EAE, 
leading to an increase in donor CD4+ CD25+ T-cells, that were dependant on 
host derived IL-2 (Furtado et al. 2002). Thus IL-2 in the periphery seems to play 
an important role in Treg growth and proliferation, as well as enhancing FoxP3 
expression.  
Transforming growth factor β (TGFβ) is a regulatory cytokine with pleiotropic 
functions in control of the immune system. The TGFβ-Smad pathway plays a 
pivotal role in development, maintenance, survival and function of T-cells (M. O. 
Li & R. A. Flavell 2008). There are 3 isoforms of TGFβ in mammals, TGFβ1, 
TGFβ2 and TGFβ3. These signal through two trans-membrane serine-threonine 
kinase receptors, TGFβR1 and TGFβR2. TGFβ1 is expressed predominantly 
during regulation of the immune system (Govinden & Bhoola 2003). Mice with a 
T-cell specific deletion of TGFβ1 or TGFβR1 develop early fatal autoimmunity, 
highlighting an important role for TGFβ in regulating immune tolerance (Shull et 
al. 1992)(Marie et al. 2005). T-cells appear to be the main cause of the 
autoimmunity associated with TGFβ ablation as CD4+ or CD8+ depletion 
alleviates the inflammatory phenotype (Letterio et al. 1996). However, as 
TGFβ1 is able to modulate multiple cell types it was previously unclear whether 
TGFβ1 was directly or indirectly responsible for the observed inflammation (M. 
O. Li & R. A. Flavell 2008). Studies attempted to address this using a dominant 
negative TGFβRII on either a CD4 or CD2 promoter (DNTGFβR)(Gorelik & R. a 
Flavell 2000)(Lucas et al. 2000). These mice, unlike TGFβ-/- mice, survive to 
adulthood but still develop an inflammatory disease. More recent studies 
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suggest this is due to incomplete ablation of TGFβ signalling in DNTGFβR mice 
as mice contain nuclear phospho-SMAD as a result of TGFβ signalling. Other 
studies attempted to study the role of TGFβ in nTreg development through the 
use of conditional knock outs of the TGFβR components (M. O. Li et al. 
2006)(Marie et al. 2006)(Ouyang, Beckett, Ma & M. O. Li 2010). These also 
report severe inflammation which is attributable to increased T-cell activation, 
but fail to come to any consensus on Treg cell dysfunction. However recently a 
more direct approach on the role TGFβ plays in nTreg development has been 
published by Harold von Boehmer’s group. In this study mice are generated 
which lack the Smad binding site exclusively on the FoxP3 CNS1 region 
(FoxP3CNS1mut). They show that binding of Smad3 to the FoxP3 CNS1 enhancer 
is dispensable for thymic Treg cell development, and only required for  
development within the gut (Schlenner et al. 2012).  
1.5.4 Plasticity  
FoxP3 expression plays a central role in maintaining the Treg transcriptional 
program. Therefore continued FoxP3 expression is critical to the stability of the 
Treg lineage and continued maintenance of peripheral homeostasis. As well as 
stimulating transcription of various genes, FoxP3 acts to repress the expression 
of others, such as IL-2, TNF-α, IFN-γ, IL-17 and IL-4 (Gavin et al. 2007)(Wan & 
R. A. Flavell 2007). Repression of pro-inflammatory cytokine secretion is of 
particular importance in Treg as they express TCRs with increased affinity for 
self peptide. Treg therefore posses the ability to potentially mount autoimmune 
responses in the absence of FoxP3 expression (Apostolou et al. 2002). 
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(Apostolou et al. 2002) (C.-song Hsieh et al. 2004). Illustrating this, in FoxP3 
deficient mice, activated T-cells express TCRs which would normally be present 
on Treg in FoxP3 sufficient animals (C.-song Hsieh et al. 2006). Suggesting self-
reactive T-cells developed into auto-reactive conventional T-cells rather than 
being diverted in the Treg lineage. This would suggest that the stability of FoxP3 
expression in Treg is of central importance in order to maintain immune 
homeostasis, and prevent ex-Treg mediated autoimmunity.  
In order to investigate the stability of FoxP3 expression in vivo the Bluestone 
group generated FoxP3-GFP Cre R26 mice (Zhou et al. 2009). This allowed the 
identification of a substantial population of YFP+ GFP- ‘exTreg’ cells. These cells 
were reported to have transiently up regulated FoxP3 expression before gaining 
an activated memory T-cell phenotype, producing inflammatory cytokines. This 
study however fails to investigate the possibility that committed Treg cells stably 
express FoxP3 and represent a stable committed cell lineage. To further 
investigate this FoxP3GFP-Cre-ERT2 R26 mice were generated by the Rudensky 
lab. In these mice the Cre-ERT2 fusion protein is sequestered in the cytosol, 
therefore YFP is not expressed. Subsequent treatment with tamoxifen allows for 
nuclear translocation of the fusion protein, excision of the R26 STOP cassette 
and YFP expression. This therefore allows the analysis of inheritable YFP 
expression in cells which expressed FoxP3 at the time. This study observed 
remarkably stable Treg FoxP3 expression, in both basal conditions and radiation-
induced lymphopenia as well as in Th1 cytokine induced inflammatory 
responses (Rubtsov et al. 2010). Therefore Treg seem to represent a stable 
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lineage with dedicated mechanisms for maintaining immune homeostasis and 
peripheral tolerance.  
 
1.5.5 Models for nTreg development 
Since the discovery that the thymic expression of FoxP3 regulates development 
of Treg much work has focussed on determining the signal cues which lead to 
induction of FoxP3 expression. As discussed above, both TCR and cytokine 
signalling appear to play crucial roles in ensuring thymocytes commit to the Treg 
lineage. However it still remains unclear how these signals co-operate to ensure 
efficient Treg differentiation. Current data appears to support self-reactivity as the 
primary determinant in committing to the Treg lineage. However some previous 
studies have hinted at a TCR-independent signal during the DN stage of 
development playing a crucial role. Hayday and colleagues show that the 
propensity of early TCRαβ+ CD4- CD8- DN thymocytes to differentiate into 
FoxP3+ Treg is regulated in trans by CD4+ CD8+ DP thymocytes (Daniel J. 
Pennington, 2006). This suggests a stochastic model for development in which 
Treg express FoxP3 prior to TCR signalling. In this model thymocytes which 
express FoxP3 and undergo strong selection signals become Treg. While FoxP3- 
cells which have increased self-reactivity undergo negative selection. 
More recent models however describe an instructive role for TCR signalling in 
FoxP3 expression (evidence for/against discussed in section (1.5.2.1). In these 
models increased self-reactivity of developing thymocytes supports FoxP3 
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expression and Treg development. Renewed support for this model came from 
studies using TCR transgenic mouse lines which express TCRs derived from 
nTregs. Contrary to what was expected, these mice contained virtually no Treg 
(C.-S. Hsieh et al. 2012). However after making bone marrow chimeras, it was 
found that reducing precursor frequency supported efficient Treg development. 
The authors suggest the experimental artefact of a thymus in which all 
thymocytes express identical TCR led to intra-clonal competition for identical 
peptide ligands. After increasing clonal frequencies Treg percentages were 
observed to plateau lower than that of conventional CD4+ SPs (Bautista et al. 
2009). This suggested a model for Treg development in which competition for a 
single interaction with a rare peptide ligand caused Treg development. This 
peptide ligand is hypothesised to be rarer than that which causes positive 
selection of convectional T-cells, as Treg percentages remain lower than that of 
FoxP3- CD4+ SPs at increasing clonal frequencies. Treg frequencies failed to 
drop at higher clonal frequencies suggesting one single competitive event for a 
high affinity peptide occurs during Treg differentiation, rather than multiple 
competitive events.  
Rare high affinity TCR/self-peptide interactions are consistent with the 
previously described ‘hit and run’ model for FoxP3 induction during thymic 
development (Ouyang & M. O. Li 2011). This model suggests that Nf-κB and 
Foxo activation are oppositely regulated by TCR and CD28 stimulation to turn 
on FoxP3 gene transcription. In the presence of high affinity antigen stimulation 
TCR and CD28 signals activate Nf-κB via IKK, while inactivating Foxo proteins 
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via Akt. Foxo proteins have been shown to co-operate with FoxP3 to control the 
differentiation of Treg (Ouyang, 2010). Therefore multiple high affinity signalling 
events are not conducive to FoxP3 expression and Treg development. However 
upon cessation of high affinity antigen stimulation, Foxo proteins can relocate 
back to the nucleus where it can co-operate with Nf-κB to induce FoxP3 gene 
transcription. This model would therefore predict that frequent high affinity 
antigen stimulation would lead to apoptosis and negative selection, while sparse 
high affinity signalling events lead to FoxP3 expression and Treg development. 
The ‘hit and run’ model however fails to include a direct role for IL-2 mediated 
STAT5 signalling in causing FoxP3 induction. It remains possible that IL-2 co-
operates with Foxo and FoxP3 in causing Treg differentiation, while it may also 
play a homeostatic role perhaps enhancing FoxP3 transcription and Treg cell 
survival.  
Following the described role for IL-2 in Treg differentiation as well as the 
characterisation of CD25Hi FoxP3- precursors of Treg cells in neonatal mice, Lio 
and Hsieh proposed a 2 step model for Treg differentiation (Chan-Wang Joaquim 
Lio & C.-S. Hsieh 2008). This 2 step model proposes a TCR dependant phase 
of development in which a high avidity TCR signal results in CD25 up-
regulation. This is followed by a cytokine dependant phase of development in 
which an IL-2 signal causes FoxP3 expression. This is likely to occur via 
STAT5, as STAT5 binding domains are located on both the FoxP3 locus as well 
as the CNS2 regulatory element (M. Burchill et al. 2008) (discussed in section 
1.5.2.2). The 2 step model therefore describes IL-2 as the main driving force in 
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causing FoxP3 expression rather than TCR/CD28 co-stimulatory signalling. 
However IL-2-/- mice still contain approximately 50% of their Treg compartment 
(Furtado et al. 2002)(Malek et al. 2002). It therefore seems unlikely this is the 
whole story. The identity of the Treg precursors as well as the mechanisms by 
which they differentiate into Treg therefore still remain unclear. The observed 
delay in Treg differentiation compared to that of conventional non-regulatory 
populations also remains incompletely understood. Further analysis of this 
delay in development may elude crucial information as to the signalling 
pathways involved in precursor differentiation.  
1.6 Aims 
Many previous studies have aimed to determine the signalling cues which lead 
to the thymic differentiation of nTreg. Many of these studies use adult mice in 
which the T-cell compartment is under homeostatic control. After thymic egress, 
studies have shown recirculation of considerable populations of FoxP3+ cells 
back to the thymus (McCaughtry et al. 2007). Therefore changes in the 
frequency of FoxP3+ cells observed after alterations in signalling may in fact be 
due to changes in peripheral homeostasis. In addition no marker currently exists 
which is capable of distinguishing peripherally derived iTreg from nTreg which are 
of thymic origin. It therefore remains difficult to distinguish between factors 
which directly affect nTreg differentiation and those which may alter frequencies 
of peripheral Treg populations. 
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Similar problems have been encountered when studying potential nTreg 
precursor populations. Adult mice which posses fully reconstituted immune 
systems contain thymic cellular compartments otherwise absent from neonatal 
mice. When studying precursor-product relationships in adults it can be difficult 
to determine between newly developed progenitor populations and thymic 
recirculants. This can be a particular problem when studying Treg as naïve T-
cells are capable of FoxP3 expression when stimulated appropriately. Therefore 
in this study our aims include :- 
1. The study of the timing of de novo Treg development relative to other T-
cell populations. 
2. Analysis of Treg precursor populations in the absence of recirculating cell 
types. 
3. Characterisation of the signalling cues required for FoxP3 expression. 
4. Identification of the thymic cell types responsible for the delivery of Treg 
differentiation signals. 
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Chapter 2 
Materials and Methods 
Table 2.1 Mice 
Strain Reference 
C57/Bl/6 / 
Rag1-/- (Mombaerts et al. 1992) 
FoxP3GFP (Ying Wang et al. 2008) 
TetZap70 (Saini et al. 2010) 
OTI (K. A. Hogquist et al. 1994) 
OTII (Barnden et al. 1998) 
IKK2Fl/Fl CD4 Cre R26 (Z.-wei Li et al. 2013; Srinivas et al. 2001) 
IL-2-/- Rag1-/- (Schorle et al. 1991) 
IL-15Rα-/- Rag1-/- (Kennedy et al. 2000) 
 
Mice 
The mice detailed above were bred and housed at NIMR animal facility under 
SPF conditions, in accordance with home office regulations. Genotyping was 
performed by a combination of flow cytometric analysis on peripheral blood 
lymphocytes and PCR using mouse tail DNA. All animals were maintained on 
normal dry feed with the exception of TetZap70 FoxP3GFP mice which when 
indicated were fed 3mg dox from birth. All mice were between 16-20 weeks of 
age when culled.  
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Tetracycline inducible Zap70 mice 
Mice were generated bearing an inducible tetracycline transgene of Zap70 
(Zap70TRE) and a tailless human CD2 (HuCD2) reporter construct. Expression 
was then be targeted within the T-cell lineage by breeding with mice which 
constitutively express the reverse tetracycline transactivator (rtTA) under the 
control of a human CD2 (HuCD2) expression element. Mice were then 
additionally back crossed onto Zap70-/- mice ensuring that all Zap70 expression 
was due to the transgene. These mice were then crossed with mice expressing 
GFP at their endogenous FoxP3 locus (GFPFoxP3), Zap70TRE rtTAHuCD2 Zap70-/- 
GFPFoxP3 mice (TetZap70 GFPFoxP3). 
Doxycycline induction of TetZap70 GFPFoxP3 mice. 
TetZap70 GFPFoxP3 mice were induced to express Zap70 by the administration 
of the tetracycline derivative doxycycline (dox) in food, at a concentration of 
3mg/g (3% w/w). 
Media. 
Phosphate buffered saline (PBS) was made in house at NIMR or purchased 
from GIBCO. Fluorescent activated cell sorting (FACs) buffer – PBS, 
supplemented with 0.5% v/v sodium azide (Sigma) and 0.5% w/v bovine serum 
album (BSA) (Sigma). Air buffered Iscove’s modified Dulbecco’s medium 
(IMDM) – made in house at NIMR. Handling media – Air buffered IMDM 
containing 1% (w/v) BSA. Ack lysis buffer – 150mM NH4Cl, 10mM KHCO3, 
0.1mM Ethylenediaminetetraacetic acid (EDTA). 
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Antibodies 
Table 2.2 Cell surface and intracellular antibodies used for flow cytometry 
Specificity Manufacturer Working concentration 
CD45.1-FITC A20 (eBioscience) 2.5μg/ml 
CD5-FITC 53-7.3 (eBioscience) 1.25 μg/ml 
HuCD2-P.E RPA-2.10 (BD) diluted 1:50 
CD45.1-P.E A20 (eBioscience) 2.5 μg/ml 
HSA-P.E M1/69 (eBioscience) 0.5μg/ml 
B220-P.E RA3-6B2 (eBioscience) 1μg/ml 
CD8α-PETR 5H10 (eBioscience) 1μg/ml 
TCR-Pecy5 H57-597 (eBioscience) 1μg/ml 
CD25-Pecy7 PC61.5 (eBioscience) 1.25μg/ml 
CD4-450eFlur L3T4 (eBioscience) 2.5μg/ml 
CD5-APC 53-7.3 (eBioscience) 1.25μg/ml 
TCR-APC H57-597 (eBioscience) 1μg/ml 
CD44-APC-EF780 IM7 (eBioscience) 0.5μg/ml 
FoxP3-APC FJK-16a (eBioscience) 4 μg/ml 
GITR-PE DTA-1 (eBioscience) 0.5μg/ml 
CTLA-4 14D3 (eBioscience)  
CD62L-PE MEL-14 (eBioscience) 0.5μg/ml 
Zap70-PE 1E7.2 (eBioscience) 4μg/ml 
Vα2-bio B20.1 (eBioscience) 0.5μg/ml 
sav-PO Invitrogen 5μg/ml 
 
Table 2.3 Blocking antibodies used. 
Specificity Clone Manufacturer Amount injected 
IL-2 
JES6-1A12 BioXcell 0.5mg/injection 
JES6-5H4 BioXcell 0.5mg/injection 
S4B6 BioXcell 0.5mg/injection 
TGFβ 1D11.16.8 BioXcell 1mg/injection 
CD40L MR1 BioXcell 0.5mg/injection 
CD80 16-10A1 BioXcell 0.5mg/injection 
CD86 GL-1 BioXcell 0.5mg/injection 
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Preparation of single cell suspensions. 
Cervical, auxiliary, brachial, mesenteric and inguinal lymph nodes (LNs), spleen 
and thymus were all dissected from mice. Lymphocytes were mashed in ice 
cold handling buffer via manual disintegration through 75μm nylon mesh. Cells 
were then washed 1-2 times (1200 rpm, 4 mins) and re-suspended in FACs 
buffer. Total lymphocytes counts were then taken using a Casy-1 cell counter 
(Schärfe System) according to the manufacturers instructions. Cells were kept 
on ice throughout. 
Obtaining bloods. 
100μl of blood was obtained by nicking the tail vein of experimental mice while 
restrained with a scalpel blade. Bloods were gathered into microfuge tubes 
containing 100μl herparin (made in PBS according to manufacturers 
instructions). 2ml of Ack buffer was then added to lyse the red blood cells 
before vigorous vortexing for 3 minutes. Samples were then washed in cold 
FACs buffer. 
Flow cytometry. 
Lymphocytes were incubated on ice with 100μl primary antibody stain per 1-
2x106 cells. Antibodies were made up to the appropriate working concentration 
indicated in table 1 and once added to the cells left for 1 hour. Cells were then 
washed 1-2 times in FACs buffer and filtered through 35μm pore cell strainers 
(BD Flacon). Flow cytometry was performed on the Cyan-ADP (Beckman 
Coulter) or BD LSR II. Data analysis was then performed using Flowjo software 
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(v8.8.6 or v9.01) (Tree star). Intracellular staining was carried out following the 
surface staining. Cells were washed and then fixed/permeabilised using the 
ebioscience FoxP3 fix/perm kit according to the manufactures instructions. 
When carrying out intracellular staining for FoxP3 in Nur77GFP mice, to avoid 
leaking of GFP, cells were pre treated with 0.5% paraformaldehyde for 15 mins 
at room temperature. Following this cells were stained using the ebioscience 
FoxP3 kit as previously described. 
 
Bone marrow isolation. 
Bone marrow was isolated from the tibiae and femora of TetZap70 
GFPFoxP3/C57B6 CD45.1/OTI/OTII/IKK2 CD4Cre R26 mice. Epiphyses were 
removed and bone marrow was obtained by flushing handling media through 
the medullary canal with a 25-guage needle. The bone marrow was then filtered 
through a 35μm cell strainer and washed twice in handling media before being 
re-suspended in handling media at a concentration of 25x106 cells/ml. 
 
Bone marrow/Thymus T-cell depletion. 
Bone marrow suspensions were treated with TCRβ–BIO at the working 
concentration (table 1) for 30 minutes at 4°C. Cells were then washed in FACs 
buffer and re-suspend in 4ml of IMDM. 80x106 dyna beads were then added 
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and left to rotate for 20 minutes at 4°C. The tube was then placed in the dyna 
magnet for 30 seconds and the supernatant removed, before repeating this 
step. The cells were then washed and re-suspended in IMDM and counted. The 
above was replicated for CD8+ thymocytes depletion using CD8-bio, prior to 3-
way sort on FACs Aria II or XDP. 
 
Irradiation and bone marrow reconstitution. 
Rag1-/- host mice were irradiated with 500 rads (caesium source) and allowed to 
rest for 12-24 hours and subsequently treated with 0.02% (v/v) Baytril® for one 
month. Transfer of bone marrow cells was performed by intraveinous injection 
of 5x106 bone marrow cells into the lateral tail vein or irradiated hosts with a 
0.5ml microfine insulin seringe (BD). Mice were then left for 6 weeks to allow full 
reconstitution of the lymphoid compartment, which was then confirmed by 
phenotypic analysis of peripheral blood, looking for the presence of B-cells by 
staining for B220 and CD19 an analysing on the FACs calibur. 
 
Intraperitoneal methacycline injections 
10mg/ml Methycycline (Sigma-Aldrich) solution, dissolved in PBS was 
neutralised using 1M NaOH. Irradiated mice then received 200μl of a 10mg/ml 
methycycline solution (2mg) in a single intraperitoneal injection using a 0.5ml 
microfine insulin syringe (BD).  
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Blocking antibody treatment 
200μl of 10mg/ml TGFβ blocking antibody (1mg) (1D11.16.8, BioXcell) was 
injected into irradiated mice via a single intraperitoneal (ip) injection using a 
0.5ml microfine insulin syringe (BD). This treatment was repeated for CD40L 
(MR1, BioXcell) blocking treatment. During IL-2 antibody blockade mice 
received 0.5mg JES6-5H4 and 0.5mg S4B6 antibody clones (BioXcell) in a 
single 400μl ip injection. CD80/CD86 blocking antibody injections contained 
0.5mg of the CD80 neutralising antibody (16-10A1, BioXcell) and 0.5mg of the 
CD86 neutralising antibody (GL-1, BioXcell). All Blocking antibody treatments 
were begun 1 day prior to feeding mice dox and repeated every 2 days until 
culling.  
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Chapter 3 
Characterisation of de novo Thymic 
Regulatory T-cell development 
 
Introduction 
Regulatory T-cells (Treg) are an essential subset of T-cells responsible for 
maintaining peripheral tolerance and immune homeostasis by applying a 
dominant inhibitory effect on lymphocytes (Seddon & Mason 2000)(Itoh et al. 
1999). Treg are αβ T cell Receptor (TCR) expressing T cells generated in the 
thymus during positive selection, and comprise approximately 5-10% total CD4+ 
SPs (Single positives). Treg are classically defined by their constitutive 
expression of CD25 (high affinity α-subunit of the IL-2 receptor), CTLA-4 and 
GITR. While these proteins may play a functional role in Treg, none of them are 
specific to Treg as activated T cells can also up-regulate expression. A forkhead 
family transcription factor FoxP3 has been shown to be a critical regulator of 
this lineage (Hori et al. 2003) (Fontenot et al. 2003) (Khattri et al. 2003) and is 
to date the most reliable marker for thymus derived Treg.  
Although it is commonly accepted that Treg develop in the thymus, the 
mechanism by which this occurs remains controversial, however cytokine 
signaling is thought to play a key role. IL-2 has been shown to be particularly 
important, since IL- 2Rβ -/- mice show a decreased number of thymic Treg (Malek 
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et al. 2002). However the observation that IL-2-/- mice still contain approximately 
50% of their Treg compartment suggests a non-essential role for thymic Treg 
induction (Fontenot, Rasmussen, Gavin & A. Y. Rudensky 2005).  
Induction of FoxP3 and commitment to the Treg lineage also requires signalling 
through the TCR. In studies using monoclonal TCR transgenic mice, Treg will 
only develop in the presence of a second transgene encoding the thymic 
expression of cognate ligand (Jordan et al. 2001). The ability of the TCR to 
engage self-ligands with a specific affinity during development instructs 
commitment into a variety of T-cell lineages, including that of Treg cells. Treg 
appear to be selected on strong self-peptide interactions, with a TCR signalling 
strength between that needed for positive and negative selection. The 
increased TCR signal strength relative to non-regulatory T-cell populations is 
evident in mice expressing GFP from the immediate early gene Nr4a1 (Nur77) 
locus (Nur77GFP). In these mice GFP is up regulated upon antigen stimulation 
but not upon inflammatory signalling. GFP expression levels correlate with the 
strength of the TCR signal received (Moran, Holzapfel, Xing, Cunningham, 
Maltzman, Punt & K. a Hogquist 2011). In Nur77GFP mice Treg have higher GFP 
expression, suggesting thymic Treg receive strong selection signals during 
development.  
Signalling through the TCR is mediated by various components associated with 
the TCR signalling complex. One of the key proximal kinases is ζ- Chain 
Associated Protein Kinase of 70 KDa (ZAP-70). Zap70 is essential for thymic 
development beyond the CD4+ CD8+ double positive (DP) stage. It is the 
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signalling cascades initiated by TCR signalling and subsequent activation of 
intracellular kinases such as Zap70 which is thought to lead to FoxP3 
expression and the commitment to the Treg lineage. However the location, the 
timing and indeed the type of ligand needed to instigate the signalling cascade 
is highly debated. A two step model for Treg development has been proposed by 
Lio and Hsieh, this combines both the requirement for TCR signaling with the 
requirement for IL-2. In this model it is proposed that strong TCR-self peptide 
interactions on developing thymocytes cause CD25 up regulation. This CD25 
high ʻprecursorʼ population are then more responsive to paracrine IL-2 which 
can cause FoxP3 expression via activation of STAT5, instructing commitment to 
the Treg lineage.  
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Results 
 
Normal CD4+ SP FoxP3+ Treg development in inducible Zap70 mice 
In order to examine de novo thymic Treg development in the adult thymus, we 
took advantage of Zap70-/- mice in which Zap70 expression is controlled by a 
tetracycline inducible Zap70 transgene (TetZap70) (Saini et al. 2010).   Feeding 
TetZap70 mice the tetracycline derivative doxycycline restores Zap70 
expression and therefore TCR signalling and positive selection. This alleviates 
the block at the CD4+ CD8+ DP (double positive) stage T-cell development in 
Zap70-/- mice. The TetZap70 mice also contain a tailless HuCD2 reporter 
allowing easy identification of thymocytes expressing the TetZap70 transgene. 
We wished to determine if thymic development of CD4+ SP FoxP3+ Treg was 
normal in TetZap70 mice. Therefore TetZap70 mice were fed doxycycline from 
birth and their thymus and lymph nodes analysed for the presence of CD4+ SP 
FoxP3+ Treg. At 16 weeks both the thymus and LNs of the TetZap70 mice 
contained FoxP3+ Treg (Fig 1.1A). The absolute numbers of CD4+ SP FoxP3+ 
Treg in TetZap70 mice were similar to the WT thymus. However the numbers 
normally observed in the LN were higher when compared to the WT (Fig 1.1B). 
Therefore constitutive Zap70 expression in TetZap70 mice is sufficient to 
generate FoxP3+ CD25Hi Treg. 
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CD4+ SP FoxP3+ Treg are detectable on d4 in TetZap70 FoxP3GFP mice 
Next we wanted to investigate more closely the timing and phenotype of the first 
wave of Treg to develop in our TetZap70 mice. To facilitate this we crossed 
TetZap70 mice with mice expressing EGFP from the endogenous FoxP3 locus 
(TetZap70 FoxP3GFP) (Ying Wang et al. 2008). These mice contain an IRES-
EGFP allowing identification of FoxP3 expressing cells, while avoiding the use 
of a fusion protein which has been reported to affect the assembly of the FoxP3 
signalling complex (Bettini et al. 2012). This allows us to identify when FoxP3 
expressing cells develop during thymic selection and how induction of FoxP3 
occurs. TetZap70 FoxP3GFP mice were fed dox and their thymus analysed at 
different timepoints for the presence of GFP+ FoxP3 expressing cells by FACs. 
After day 2 we observed restoration of the CD4+ SP compartment (Fig 1.2A) 
while CD8+ SP development was delayed until approximately day 4. Looking 
within the CD4+ SP compartment at the TCRHi CD5Hi mature T-cells, the first 
GFP expressing cells were detected at day 4, with percentages steadily 
increasing until day 8 (Fig 1.2B). Analysing the CD4+ CD8+ DP compartment 
revealed a bimodal distribution of HuCD2 reporter expression ranging from 
approximately 10 to 80% of total DPs (Fig 1.2C). Therefore the TetZap70 
FoxP3GFP mice  had a large degree of variability in their mouse to mouse Zap70 
transgene expression.  
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Thymic development in TetZap70 FoxP3GFP chimeras 
In an attempt to get more consistent mouse to mouse transgene expression we 
analysed development of TetZap70 FoxP3GFP cells in bone marrow chimeras. 
Rag1-/- mice were sub lethally irradiated (500 rads) and injected with bone 
marrow from TetZap70 FoxP3GFP mice. Mice were left for six weeks to 
reconstitute, then fed dox and their thymus analysed by FACs. Consistent with 
the intact TetZap70 FoxP3GFP mice, CD4+ SPs were first detected on day 2, 
while CD8+ SP development was delayed until day 4 (Fig 1.3A). Analysing 
HuCD2 expression revealed more consistent transgene induction as reported 
by HuCD2 expression levels in the chimeras (Fig 1.3B). Interestingly 
percentages of GFP+ Treg within the chimeras and intact TetZap70 FoxP3GFP 
mice appear similar until day 5. At which point percentages continued to 
steadily increase in the chimeras plateauing at a higher level than in the intact 
mice (Fig 1.3C). These results suggest that reconstituted TetZap70 FoxP3GFP 
chimeras express the Zap70 transgene more consistently, and appear able to 
generate increased percentages of Treg compared to intact TetZap70 FoxP3GFP 
mice. We next wished to determine if the observed differences in Treg thymic 
development were due to irradiation of the Rag1-/- hosts, or intrinsic to TetZap70 
FoxP3GFP mice. To do this we made TetZap70 FoxP3GFP chimeras using either 
TetZap70 FoxP3GFP or Rag1-/- mice as hosts. After 6 weeks mice were put on 
dox and their thymus analysed by FACs. CD4+ SP GFP+ Treg were detectable in 
the TetZap70 FoxP3GFP chimeras on day 4, their percentage as a percentage of 
total CD4+ SPs rose steadily until day 8 (Fig 1.4A). Treg in these mice were 
present at a reduced percentage compared to the Rag1-/- host TetZap70 
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FoxP3GFP chimeras (Fig 1.4A), with percentages comparable to that of the 
TetZap70 FoxP3GFP intact mice. Interestingly the frequency of cells expressing 
HuCD2 and therefore the transgene were on average 50% in both the TetZap70 
FoxP3GFP host chimeras and intact mice. This is in both cases reduced 
compared to the Rag1-/- host TetZap70 FoxP3GFP chimeras which on average 
have 65% of DPs expressing the transgene (Fig 1.4B). TetZap70 FoxP3GFP 
host chimeras did however appear to have more consistent transgene induction 
compared to the intact mice.  This suggests that the use of Rag1-/- chimeras is 
responsible for the more consistent transgene expression however it remains 
unclear what led to the increased number of cells expressing the transgene in 
these mice. 
 
Lower Treg  percentages in chimeras than constitutively dox fed mice 
Since Rag1-/- TetZap70 FoxP3GFP chimeras had more consistent transgene 
expression and slightly increased levels of thymic Treg we chose to continue 
further using Rag1-/- chimeras (TetZap70 FoxP3GFP chimeras here on in). To 
further characterise de novo Treg development TetZap70 FoxP3GFP chimeras in 
more detail, groups of mice were fed dox and analysed at days 0-8. Looking 
within the CD4+ SP TCRHi CD5Hi mature compartment, the first GFP+ Treg 
appeared at day 4 with percentages steadily increasing until day 8 (Fig 
1.5A&B). Interestingly when comparing thymic Treg percentages in the chimeras 
with WT controls, the size of the thymic FoxP3+ Treg population plateau at a 
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lower percentage of CD4+ SPs than normally observed in a Bl/6 mouse (Fig 
1.5C). This was lower than that observed in constitutively dox fed TetZap70 
FoxP3GFP mice. We therefore characterised FoxP3+ cells in TetZap70 FoxP3GFP 
mice by analysing expression of various Treg markers. TetZap70 FoxP3GFP mice 
or Rag1-/- chimeras were fed dox for 13 days and their thymic GFP+ Treg 
analysed by FACs for the presence of Treg lineage markers. Expression of 
CTLA-4, GITR, GFP and CD5 on GFP+ cells in TetZap70 FoxP3GFP chimeras 
were similar to those of GFP+ Treg from FoxP3GFP mice (Fig 1.6). Interestingly 
Treg in the dox fed mice were almost all CD62LHi, while the FoxP3GFP control 
contains both positive and negative populations (Fig 1.6). These results suggest 
that by day 13 Treg in the TetZap70FoxP3GFP mice display surface markers 
associated with the Treg lineage and can therefore appear to have undergone 
normal maturation. However we also saw a reduced percentage of the thymic 
Treg in TetZap70 FoxP3GFP chimeras when compared to both WT and 
constitutively dox fed TetZap70 mice. This suggests that the thymic Treg pool is 
not solely composed of de novo developed Treg and perhaps contains a 
recirculating Treg population.   
 
Significant proportions of thymic FoxP3+ Treg are recirculants.  
Next we looked in to the possibility that Treg recirculate back into the thymus 
from the periphery. Treg percentages in both TetZap70 FoxP3GFP chimeras and 
intact mice plateau lower than that normally observed in WT Bl/6 (Fig 1.5C). As 
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TetZap70 FoxP3GFP mice have an empty periphery at these early time points, 
the lack of a recirculating population of Treg could explain the lower percentages 
in observed in these mice. Congenically labelled lymph node cells were iv 
injected into un-induced TetZap70 FoxP3GFP mice and left for 3 weeks. The 
TetZap70 FoxP3GFP mice were then placed on dox for 6 days and their thymus 
analysed by FACs. The host CD45.1- compartment contained DN,DP and SP 
populations, indicative of normal thymic development. While donor CD45.1+ 
cells comprised mature CD4+ and CD8+ SPs injected into the periphery 3 weeks 
previously (Fig 1.7A). Looking within the CD4+ SP compartments approximately 
0.5% of host and 4% of donor CD4+ SPs cells are FoxP3+ (Fig 1.7A). Gating on 
total FoxP3+ cells; iv injected donor cells make up approximately 30% of thymic 
Treg while only comprising 6% of total CD4+ SPs (Fig 1.7B). Host FoxP3+ 
CD45.1+ cells also contain increased frequencies of FoxP3+ CD25Hi cells 
relative to FoxP3+ CD45.1= donor cells (Fig 1.7B). Taken together this indicates 
that thymic Treg are not solely comprised of de novo developing nTreg but in fact 
significant proportions of Treg in the periphery are able to recirculate into the 
thymus. Further evidence of recirculation came from constitutively dox fed mice. 
TetZap70 FoxP3GFP mice were placed on dox from birth, then at 16 weeks of 
age removed from dox and placed onto normal food, completely turning off 
Zap70 expression. The thymus of these mice were then analysed by FACs 4 
weeks later. Approximately 3.8% of mature thymic CD4+ SPs in these mice 
were GFP+ Treg. Interestingly nearly all of the GFP+ Treg showed high levels of 
helios expression, a transcription factor reported to be a marker of thymic 
derived nTreg (Fig 1.7C) (A. M. Thornton et al. 2010). The presence of GFP+ Treg 
    
 75 
in the absence of T-cell development, further indicates recirculation of Treg from 
the periphery into the thymus. It also casts some doubt over the use of helios as 
a marker of thymically derived nTreg. 
 
GITR levels increase throughout T-cell development 
FoxP3+ Treg are reported to develop from GITRHi CD25Hi FoxP3- CD4+ SP 
progenitor thymocytes. In order to identify this precursor population we 
analysed expression of these markers throughout T cell development in the 
TetZap70 FoxP3GFP chimeras. TetZap70 FoxP3GFP chimeras were fed dox for 
3-6 days and the phenotype of the CD4+ SPs analysed by FACs. Analysing 
GITR expression revealed that CD4+ SP thymocytes initially were GITRLo. GITR 
levels then begin to increase at day 4 continuing throughout the time course. 
GFP+ Treg appear at day 4 and were GITRHigh (Fig 1.8A). Since CD25High 
GITRhigh FoxP3- cells are proposed to be enriched with Treg precursors we 
analysed CD25 and GFP expression levels specifically on GITRHigh CD4+ SP 
thymocytes (Fig 1.8B). Gating specifically on GFP+ CD4+ SP GITRHigh cells (Fig 
1.8 B) revealed that GFP+ Treg develop both CD25High and CD25Low. The total 
GFP+ compartment consisted of approximately half CD25High cells and half 
CD25Low cells. Analysing the total CD4+ SP GFP- compartment; we found that 
CD25High GITRHigh population accumulate at d4, however CD25 expression is 
not confined exclusively to the GITRHigh compartment. There were also 
significant percentages of GITRHigh CD25Low cells present (Fig 1.8C). This data 
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suggests the presence of a GITRHigh FoxP3- Treg precursor population, however 
it remains unclear if the Treg precursors are enriched in either the CD25High or 
CD25Low GITRHigh compartment.  
 
Treg develop from a GITRHigh Nur77High precursor population 
Studies show that Treg precursors are selected with a strong TCR signal. We 
therefore sort to identify this population within the GITRHigh compartment. To do 
this, we took advantage of Nr4a1GFP mice (Nur77GFP). Nur77 belongs to the 
nuclear receptor superfamily and is induced upon TCR signalling in CD4+ T 
cells, including immature thymocytes (Kashiwagi & Waldmann 2011). It has 
been shown in Nurr77GFP mice that strength of TCR signalling correlates with 
GFP expression (Moran, 2011). As Treg precursors are proposed to be selected 
with a strong TCR signal, Nurr77GFP mice were analysed with the aim of 
identifying a Treg precursor population within the GITRHigh compartment. 
TetZap70 mice crossed with Nurr77GFP mice, (TetZap70 Nurr77GFP) were used 
to make bone marrow chimeras. TetZap70 Nur77GFP chimeras were then fed 
dox and their thymocytes analysed by FACs. Cells were prefixed with 0.5% 
paraformaldehyde in order to maintain intracellular GFP, before being 
permeabilised and stained for FoxP3. At day 5, percentages of FoxP3+ cells in 
the thymus were comparable to those observed in TetZap70 FoxP3GFP 
chimeras (Fig 1.9A). Gating specifically on GFP+ GITRHi cells showed a 20-fold 
enrichment in FoxP3+ cells as well as a more modest enrichment in CD25High 
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FoxP3- cells (Fig 1.9B). Treg are reported to develop following a strong defined 
TCR signal. We therefore analysed Nur77GFP expression in CD25Low GFP+, 
CD25Hi GFP+ and CD25Hi GFP- cells.  Interestingly Nur77GFP expression on 
CD25High FoxP3+ cells and CD25Low FoxP3+ cells was identical while the 
CD25High FoxP3- cells showed increased GFP expression levels (Fig 1.9C). This 
suggests the CD25Hi GFP- cells had received a stronger TCR signal that the 
GFP+ CD25Hi Treg. Next in order to look at the relative maturation of the CD25Low 
GFP+, CD25Hi GFP+ and CD25Hi GFP- populations we analysed HSA 
expression. HSA expression was highest in CD25High FoxP3- cells and reduced 
in CD25Low FoxP3+ and CD25High FoxP3+ cells respectively (Fig C1.9C). The 
above data calls into question whether the CD25High FoxP3- CD4+ SP cells are 
the sole CD25Hi FoxP3+ Treg precursor population, and suggests that CD25Low 
GFP+ cells are also capable developing into CD25High FoxP3+ Treg. 
 
GFP+ CD25Low cells can behave as precursors to CD25High GFP+ cells  
One advantage of the TetZap70 system is the ability to view the first wave of T-
cell development, and to not rely on observations made in adult mice in which 
T-cell populations are under homeostatic control. So having suggested that 
CD25Low FoxP3+ CD4+ SP thymocytes can function as precursors to CD25Hi 
FoxP3+ CD4+ SP cells, we hypothesised that these cells would develop prior to 
CD25Hi FoxP3+ CD4+ SP cells in our TetZap70 FoxP3GFP mice, followed by the 
appearance of a CD25Hi population. TetZap70 FoxP3GFP chimeras were placed 
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on dox and their thymus analysed by FACs after 1-8 days. We determined the 
timing and quantified the abundance of both the CD25High and CD25Low Treg.  
Subsequently 3 days after dox feeding, when Treg first develop; they are almost 
exclusively CD25Low. As the time course progresses the GFP+ CD25High 
population becomes more prominent, until percentages almost reach that of the 
CD25Low Treg (Fig 1.10A). The percentage of FoxP3- CD25High cells, reported to 
be enriched in Treg precursors (Chan-Wang Joaquim Lio & C.-S. Hsieh 2008), 
remain constant throughout the time course (Fig 1.10A). IL-2 is suggested to be 
the main signal driving the initial expression of Foxp3 in developing thymocytes. 
To investigate the role of IL-2 we sorted FoxP3- CD25High, FoxP3- CD25Low and 
FoxP3+ CD25Low thymocytes. Treg were sorted from FoxP3GFP mice and cultured 
for 24 hours in vitro with or without IL-2. Sorted GFP+ CD25Low cells up-
regulated CD25 expression levels upon the addition of IL-2 (Fig 1.10B). Some 
GFP- CD25+ cells also began to express GFP when cultured in media 
containing IL-2, however this was a modest increase and GFP expression 
levels remained lower that those observed in GFP+ CD25Low cells. Addition of 
IL-2 had no effect on CD25Low GFP- cells (Fig 1.10B). Taken together these 
results suggest that substantial proportions of CD25Low FoxP3+ cells can 
increase CD25 expression upon exposure to IL-2, becoming FoxP3+ CD25High 
Treg. CD25High GFP- cells also appear able to contribute to the development of 
CD25High FoxP3+ Treg however with CD25low FoxP3+ cells appearing prior to 
CD25High FoxP3+ a precursor product relationship between the two cannot be 
excluded.  
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GFP+ CD25Low cells behave as highly efficient Treg precursors 
It remained possible that both CD25low FoxP3+ and CD25High FoxP3- thymocytes 
were precursors to FoxP3+ CD25Hi Treg, In order to look at the relative 
efficiencies each of the CD25Low and CD25High precursor populations to 
differentiate into FoxP3+ Treg we analysed GITR expression. As previously we 
sorted FoxP3- CD25High, FoxP3- CD25Low and FoxP3+ CD25Low thymocytes from 
FoxP3GFP mice and cultured them with or without IL-2. We then analysed CD25 
and GFP expression on GITRHigh cells after 24 hours. Sorted CD25Low GFP- 
cells contained very few, if any GITRHigh cells, in the presence or absence of IL-
2. Upon IL-2 stimulation CD25High GFP- cells increased both their GITR and 
CD25 expression levels accompanied by modest levels of FoxP3 induction in 
the GITRHigh cells (Fig 1.11). The CD25Low GFP+ cells increased GITR levels 
upon exposure to IL-2 with a corresponding increase in CD25 expression. 
These cells also maintained their GFP expression levels. Therefore in the 
presence of IL-2 both CD25High GFP- and CD25low GFP+ cells can differentiate 
into mature CD25High GFP+ Treg. 
 
Treg thymic egress is delayed compared to non-regulatory CD4+ SPs 
We next wanted to look at the timing of egress from the thymus by the FoxP3+ 
compartment. Development of Treg in TetZap70 mice is delayed compared to 
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that of non-regulatory CD4+ SP populations. We therefore wondered if there 
was also a delay in their egress form the thymus into the periphery. TetZap70 
FoxP3GFP chimeras were fed dox their thymus and LNs analysed by FACs. 
Conventional CD4+ SP T-cells appear in the LNs at day 5 with GFP+ Treg 
appearing at day 10 (Fig 1.12A). There is therefore a significant delay in egress 
of the Treg compared to that of non-regulatory populations. Next we wondered if 
CD25 expression levels affected the cells ability to exit the thymus. We have 
shown substantial development of a GFP+ CD25Low population in the thymus of 
TetZap70 FoxP3GFP mice (Fig1.5A). However Treg are usually associated with 
having a predominantly CD25High FoxP3+ phenotype. At day 10 in our TetZap70 
FoxP3GFP chimeras we see substantial percentages of both CD25High and 
CD25Low Treg in both the thymus and periphery (Fig 1.12B). Our data therefore 
suggests that the CD25Low GFP+ and CD25High GFP+ Treg are equally capable of 
emigrating from the thymus to the periphery and that this egress is 
approximately 5 days after that of the CD4+SP non-regulatory populations. 
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Figure 1.1 Characterisation of doxycycline fed TetZap70 mice 
 
TetZap70 FoxP3GFP mice were fed doxycycline from birth followed by analysis 
of thymus and LNs by FACs at approximately 16 weeks of age. A: Representive 
FACs plots of CD4+ SP TCRHi CD5Hi cells from thymus (upper panels) and LNs 
(Lower panels) in WT Bl/6 (left panels) and TetZap70 FoxP3GFP mice (right 
panels). B: Absolute Treg cell numbers (CD4+ TCRHi CD5Hi FoxP3+) in Thymus 
(left panel) and LNs (right panel) of WT Bl/6 (n=3) and TetZap70 (n=6) mice.  
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Figure 1.2 Characterisation of doxycycline fed TetZap70 FoxP3GFP mice 
 
TetZap70 FoxP3GFP mice were fed doxycycline for 3-6 days followed by 
analysis of the thymus by FACs. A: FACs plots showing CD4 Vs CD8 
expression (upper panels) and CD25 Vs GFP expression (lower panels) in 
CD4+ SP TCRHi CD5Hi thymocytes of TetZap70 FoxP3GFP mice fed dox for 3-6 
days. B: Time course of GFP+ cells (black circles) CD8+ SPs (red circles) and 
CD4+ SPs (blue circles) as a percentage of total thymocytes after various 
durations of feeding dox. C: %HUCD2 reporter expression assessed by FACs 
when gated on CD4+ CD8+ DP thymocytes in TetZap70 FoxP3GFP mice fed dox 
for 3-6 days (n=59). 
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Figure 1.3 TetZap70 FoxP3GFP bone marrow chimeras. 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being placed on 
dox along with TetZap70 FoxP3GFP mice. A: Time course for TetZap70 
FoxP3GFP mice (left panel) and TetZap70 FoxP3GFP chimeras (right panal) 
showing CD8+ SPs (red circles) and CD4+ SPs (blue circles) as a percentage of 
total thymocytes after various durations of feeding dox.  C: %HUCD2 reporter 
expression assessed by FACs when gated on CD4+ CD8+ DP thymocytes in 
TetZap70 FoxP3GFP mice (n=59) and TetZap70 FoxP3GFP chimeras (n=48) fed 
dox for 2-8 days. 
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Figure 1.4 TetZap70 FoxP3GFP bone marrow chimeras. 
 
Rag1-/- or TetZap70 FoxP3GFP mice were irradiated and injected with 5M 
TetZap70 FoxP3GFP bone marrow cells iv. Bone marrow was harvested as 
described in materials and methods. Chimeras were left for 6 weeks to 
reconstitute before being placed on dox along with TetZap70 FoxP3GFP mice. A: 
Time course for TetZap70 FoxP3GFP mice (blue circles) and TetZap70 FoxP3GFP 
host chimeras (black circles) and Rag1-/- host chimeras (red circles) showing 
TCRHi CD5Hi CD4+ SP GFP+ cells as a percentage of total thymocytes (left 
panel) and as a percentage of TCRHi CD5Hi CD4+ SPs (right panel), fed dox 
from 1-8 days.  B: %HUCD2 reporter expression assessed by FACs when 
gated on CD4+ CD8+ DP thymocytes in TetZap70 FoxP3GFP mice (n=59), 
TetZap70 FoxP3GFP host chimeras (n=17) and Rag1-/- host chimeras (n=48) fed 
dox for 2-8 days. 
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Figure 1.5 Treg development in TetZap70 FoxP3GFP bone marrow chimeras. 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being placed on 
dox for 2-8 days. A: FACs plots from the thymus of TetZap70 FoxP3GFP bone 
marrow chimeras fed dox for 2-8 days. Plots show live singlets (upper panels) 
and CD4+ SP TCRHi CD5Hi cells (lower panels) B: Time course for TetZap70 
FoxP3GFP chimeras fed dox for 2-8 days showing TCRHI CD5Hi CD4+ SPs (blue 
circles)  TCRHI CD5Hi CD8+ SPs (red circles) and TCRHI CD5Hi CD4+ SP GFP+ 
(black circles) as a percentage of total thymocytes. C: Time course for 
TetZap70 FoxP3GFP chimeras fed dox for 2-8 days showing TCRHI CD5Hi CD4+ 
SP GFP+ (black circles) as a percentage of TCRHI CD5Hi CD4+ SPs, compared 
to percentages normally observed in FoxP3GFP mice (range of n=4). 
    
 91 
  
Fig Layout
12/3/13 14:36 Page 1 of 1 (FlowJo v9.5.2)
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CTLA-4
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD62L
Treg
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
Stain C_T4_34.fcs 3.8 CD4+
GFP
Naive
Sample % Gate
25_Nur77 GFP_Stain 2.fcs 86.3 Naive
23_d7 T1_Stain 2.fcs 1.58 Treg
25_Nur77 GFP_Stain 2.fcs 2.74 Treg
GITR
Naive
Sample % Gate
Stain C_T4_34.fcs 98.4 Naive
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD5
Fig Layout
12/3/13 14:36 Page 1 of 1 (FlowJo v9.5.2)
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CTLA-4
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD62L
Treg
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
Stain C_T4_34.fcs 3.8 CD4+
GFP
Naive
Sample % Gate
25_Nur77 GFP_Stain 2.fcs 86.3 Naive
23_d7 T1_Stain 2.fcs 1.58 Treg
25_Nur77 GFP_Stain 2.fcs 2.74 Treg
GITR
Naive
Sample % Gate
Stain C_T4_34.fcs 98.4 Naive
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD5
Fig Layout
12/3/13 14:36 Page 1 of 1 (FlowJo v9.5.2)
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CTLA-4
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD62L
Treg
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
Stain C_T4_34.fcs 3.8 CD4+
GFP
Naive
Sample % Gate
25_Nur77 GFP_Stain 2.fcs 86.3 Naive
23_d7 T1_Stain 2.fcs 1.58 Treg
25_Nur77 GFP_Stain 2.fcs 2.74 Treg
GITR
Naive
Sample % Gate
Stain C_T4_34.fcs 98.4 Naive
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD5
Fig Layout
12/3/13 14:36 Page 1 of 1 (FlowJo v9.5.2)
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CTLA-4
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD62L
Treg
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
Stain C_T4_34.fcs 3.8 CD4+
GFP
Naive
Sample % Gate
25_Nur77 GFP_Stain 2.fcs 86.3 Naive
23_d7 T1_Stain 2.fcs 1.58 Treg
25_Nur77 GFP_Stain 2.fcs 2.74 Treg
GITR
Naive
Sample % Gate
Stain C_T4_34.fcs 98.4 Naive
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD5
CTLA-4 CD62LGFP
GITRCD5
d13 TetZap70 FoxP3GFP
d13  FoxP3GFP
Naive CD4+ SP
Fig Layout
12/3/13 15:12 Page 1 of 1 (FlowJo v9.5.2)
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CTLA-4
CD4+
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 5.69 CD4+
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD62L
Treg
Sample % Gate
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
Stain C_T4_34.fcs 3.8 CD4+
GFP
Naive
Sample % Gate
25_Nur77 GFP_Stain 2.fcs 86.3 Naive
23_d7 T1_Stain 2.fcs 1.58 Treg
25_Nur77 GFP_Stain 2.fcs 2.74 Treg
GITR
Naive
Sample % Gate
Stain C_T4_34.fcs 98.4 Naive
Stain C_FoxP3-GFP_35.fcs 4.57 Treg
Stain C_T4_34.fcs 0.911 Treg
CD5
1.6
    
 92 
 
Figure 1.6 Characterisation of Treg in TetZap70 FoxP3GFP mice. 
 
TetZap70 FoxP3GFP mice were fed dox for 13 days prior to their thymus being 
analysed by FACs for expression of CTLA-4, CD62L, CD5 and GITR on TCRHi 
CD5Hi CD4+ SP GFP+ Treg (blue) and compared to that of TCRHi CD5Hi CD4+ SP 
GFP+ Treg from FoxP3GFP mice (red) and TCRHi CD5Hi CD4+ SP CD44Lo CD25Lo 
naïve cells from FoxP3GFP mice (grey) 
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Figure 1.7 After thymic egress  Treg recirculate back to the thymus. 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being injected 
with 10M CD45.1 LN cells. After 4 weeks mice were fed dox for 6 days and their 
thymus analysed by FACs A: FACs plots showing CD4 and CD8 expression on 
live singlets (top panel), TetZap70 FoxP3GFP cells are CD45.1- (left column) 
while injected Bl/6 LN cells are CD45.1+ (right column). TCRHi CD5Hi CD4+ SP 
cells were then analysed for FoxP3 and CD25 expression (bottom panel). B: 
Gating specifically on the TCRHi CD5Hi CD4+ SP GFP+ compartment, cells were 
analysed for CD45.1, FoxP3 and CD25 expression (left and right) while TCRHi 
CD5Hi CD4+ SPs were analysed for CD45.1 expression also (middle). TetZap70 
FoxP3GFP mice were fed dox from birth, then at approximately 16 weeks of age 
fed on normal dry diet for 4 weeks. C: FACs plot showing CD25 and GFP 
expression on TCRHi CD5Hi CD4+ SP cells (left). TCRHi CD5Hi CD4+ SPs (grey) 
and TCRHi CD5Hi CD4+ SP GFP+ cells (red) were further analysed for helios 
expression (histogram right).  
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Figure 1.8 Identification of a GITRHi FoxP3- Treg precursor 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being placed on 
dox for 3-6 days. A: Representive FACs plots from the thymus of TetZap70 
FoxP3GFP bone marrow gated on total TCRHi CD5Hi CD4+ SPs B: Representive 
FACs plots from the thymus of TetZap70 FoxP3GFP bone marrow gated on total 
GITRHi TCRHi CD5Hi CD4+ SPs (gating illustrated in dashed box in A) C: 
Representive FACs plots from the thymus of TetZap70 FoxP3GFP bone marrow 
gated on total TCRHi CD5Hi CD4+ SPs GFP- cells. 
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Figure 1.9 Identification of a GITRHi FoxP3- Treg precursor  
 
TetZap70 FoxP3GFP mice were crossed with Nur77GFP mice. The resulting 
TetZap70 Nur77GFP mice were fed dox and their thymus analysed by FACs after 
5&10 days A: Representive FAC plot from the thymus of a d5 TetZap70 
Nur77GFP mouse. Showing FoxP3 and CD25 expression within the CD4+ SP 
TCRHi compartment B: Representive FACs plots from d5 TetZap70 Nur77GFP 
mouse, CD4+ SP TCRHi (left panel), further gated on GFPHI GITRHi cells 
showing FoxP3 and CD25 expression (right panel). C: Representive FACs plots 
from d5 dox fed TetZap70 Nur77GFP mice gated on TCRHi GITRHi CD4+SPs. 
FoxP3+ CD25Lo cells (red) FoxP3+ CD25Hi cells (blue) FoxP3- CD25Hi cells 
(black) and FoxP3- CD25Lo (grey) (top right) compared for levels of GFP 
expression (top left) and d10 dox fed TetZap70 Nur77GFP same populations as 
(top right) but compared for HSA expression (bottom panel). 
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Figure 1.10 IL-2 culture of CD25Hi and CD25Lo Treg precursor populations 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being placed on 
dox for 1-8 days. A: (left panel) Representative FACs plot of gating strategy 
employed when studying development of TCRHi CD5Hi CD4+ SP- CD25Hi GFP- 
(black), CD25Lo GFP+ (blue) or CD25Hi GFP+ cells (red) in TetZap70 FoxP3GFP 
chimeras, illustrated using FoxP3GFP thymus. (right panel) Histogram showing 
the abundance of the populations detailed above after various durations of dox 
feeding, as a percentage of TCRHi CD5Hi CD4+ SPs.  
CD25Lo FoxP3+ Treg are able to increase CD25 expression after culture with IL-
2. TCRHi CD5Hi CD4+ SP- CD25Hi GFP-, CD25Lo GFP+ or CD25Lo GFP- cells 
were sorted from FoxP3GFP mice (n=4) and cultured with or without 10ng/µl IL-2 
in RPMI for 48 hours. B: Repsentative FACs plots of cultured cells described 
above which were analysed by FACs for CD25 and GDP expression after 48 
hours.  
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Figure 1.11 IL-2 culture of CD25Hi and CD25Lo Treg precursor populations  
 
TCRHi CD5Hi CD4+ SP- CD25Hi GFP-, CD25Lo GFP+ or CD25Lo GFP- cells were 
sorted from FoxP3GFP mice (n=4) and cultured with or without 10ng/µl IL-2 in 
RPMI. Cells were then analysed by FACs after 48 hours. The various sorted 
and cultured populations were analysed for CD25 and GITR expression by 
FACs (first left). Cultured cells were further gated for high GITR expression and 
analysed for GFP and CD25 expression (Second left). GITRHi cells were then 
analysed for GFP (second right) and CD25 expression (first right). 
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Figure 1.12 Treg Thymic egress is delayed relative to conventional T-cells  
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being placed on 
dox for 0-10 days and having their LNs analysed by FACs. A: Graph of TCRHi 
CD5Hi CD4+ SP GFP+ absolute cell numbers in LNs (left panel), and as a 
percentage of total LN cells (right panel). Data taken form the LNs of TetZap70 
FoxP3GFP mice fed dox from 0-10 days. B: Representive FACs plots from d10 
TetZap70 FoxP3GFP mice showing live singlets (left panel) analysed for CD4 
and CD8 expression, and TCRHi CD5Hi CD4+ SPs (right panel) analysed for 
CD25 and GFP expression. Cells taken from the LNs (top panels) and Thymus 
(bottom panels). 
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Discussion 
 
During thymocyte development, thymic progenitors interpret TCR dependant 
signals and commit to a variety of T-cell lineages. Treg are thought to be 
selected by self-antigens on a TCR signal strength between that needed for 
positive and negative selection; they are therefore thought to be slightly auto-
reactive. In this study we found that FoxP3 expression first occurs in thymocytes 
4 days after positive selection, approximately 3 days after the first appearance 
of conventional CD4+ SPs, which develop on day 1 (Fig 1.2). This study 
therefore identifies a relative delay in FoxP3 expression compared to other 
lineage defining transcription factors, however both the signals involved and the 
reason for this delay still remain unclear.  
 Previous studies have focussed on the neonatal thymus in order to observe the 
timing of the first wave of Treg development. There are reports of thymic Treg 
being present in neonates 3 days after birth, broadly agreeing with our findings 
(Cheng et al. 2013). However it can be difficult to draw comparisons between 
the timing in neonates where Zap70 is under endogenous control and in our 
TetZap70 FoxP3 GFP mice where development is arrested at the CD4+ CD8+ DP 
stage of development. We can however confirm a delay in the development of 
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Treg compared to that of non-regulatory populations in adult mice whereas 
previously this had only been confirmed in neonates. In adult FoxP3GFP mice, 
many reports have shown GFP expression confined primarily to the medulla 
(Liston et al. 2008). Pharmacologic blockade of migration into the medulla from 
the cortex leads to an accumulation of GFP+ cells in the cortex. This perhaps 
suggests Treg receive a signal to differentiate in the cortex followed by a 
subsequent delay, before expressing FoxP3 in the medulla. Our data is 
consistent with this idea, as it has been shown that un-induced TetZap70 
thymocytes are arrested in the cortex and are all CD4+ CD8+ DPs (White et al. 
2010). Only when mice are placed on dox are CD4+ SPs found located in the 
medulla. It therefore remains possible Treg receive a cortical signal to 
differentiate but FoxP3 expression is delayed, only becoming detectable in the 
medulla 2-3 days after CD4+ SPs develop. 
Since Tregs were first discovered in the late 90s their thymic development has 
been the focus of much research. It has been proposed that the study of their 
thymic differentiation would be hugely simplified by the discovery of an 
immediate precursor that has not yet differentiated. Our data suggests that Treg 
develop from a GITRHigh FoxP3- precursor population which has undergone 
strong TCR signalling (Fig 1.8 & 1.9). However it is currently unclear if this 
population is enriched in the CD25High FoxP3- compartment as stated by the 
current literature, or in fact develop from thymocytes with a broad range of 
CD25 expression. Currently the favoured model for Treg development is the 2 
step model (Chan-Wang Joaquim Lio & C.-S. Hsieh 2008). This model describe 
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Treg progenitors undergoing strong TCR signalling leading to CD25 up 
regulation, this CD25High FoxP3- precursor population then respond to IL-2 
which drives FoxP3 expression. This model is based on the observation that 
when sorted and transferred to WT hosts, CD25High CD4+ SPs more efficiently 
express FoxP3 than CD25Low CD4+ SPs. In support of this model, we show that 
when sorting CD25High and CD25Low GFP- cells and culturing them with IL-2, the 
CD25High cells give rise to CD25High GFP+ Treg much more efficiently than their 
CD25Low counterparts. When culturing CD25Low GFP- cells with IL-2 we see no 
rise in GFP or GITR expression whatsoever (Fig 1.11). These observations 
would seem to further support a 2 step model for Treg development where 
CD25High FoxP3- cells as act Treg precursors. Although we see CD25High GFP- 
cells acting as precursors upon culture with IL-2, we found CD25low GFP+ do so 
much more efficiently (Fig 1.11). Upon exposure to IL-2 CD25low GFP+ cells 
increase both GITR and CD25 expression, at similar levels to that undergone by 
the CD25High GFP- cells (Fig 1.11). However this CD25 expression is 
accompanied by a relatively modest level of GFP expression in the CD25High 
GFP- cells. The cultured CD25Low cells however were already expressing GFP 
when sorted from FoxP3GFP mice so this could be somewhat of an unfair 
comparison. Also previous studies have suggested that not all CD25High cells 
function as precursors, only cells transitioning from an IL-7 to an IL-2 
dependency (Chan-Wang Joaquim Lio & C.-S. Hsieh 2008). It would therefore 
perhaps be expected that not all of these cells differentiate when stimulated with 
IL-2 in our culture experiments. It therefore remains possible that Treg develop 
via either a CD25High or CD25Low precursor population, however our data 
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suggests that the CD25High FoxP3- cells may make a more minor contribution to 
Treg development than previously thought. 
During the TetZap70 FoxP3GFP time courses we see CD25Low FoxP3+ cells 
developing prior to CD25High FoxP3+ cells (Fig 1.10). However it remains 
unclear if these represent a precursor population to the CD25High GFP+ Treg in 
vivo or alternate Treg lineage all together. We considered the possibility of an 
alternative model for Treg development, where Treg solely develop via a CD25Low 
FoxP3+ precursor population and then up regulate their CD25 expression levels 
as they develop further. In support of this model we see identical Nur77 
expression levels on CD25Low and CD25High FoxP3+ cells, suggesting they have 
received a similar strength of TCR signal, while CD25High FoxP3- cells show 
increased Nur77 expression compared to the FoxP3 positive populations. As 
Nur77 is an established marker of TCR signalling strength and thought to be 
relatively stable, it is difficult to comprehend a reason why expression levels 
would drop as precursors differentiate into Treg. CD25High FoxP3- cells also 
express high levels of HSA suggesting they are immature relative to both 
CD25Low FoxP3+ cells and CD25High FoxP3+ Treg  which exhibit very low HSA 
levels (Fig 1.9C). Taken together these observations suggest CD25High FoxP3- 
thymocytes have undergone strong TCR signalling at the very early HSA high 
stage of development perhaps questioning their role as precursors to the 
CD25High Treg, perhaps instead representing T-cells on the cusp of negative 
selection. Increased Nur77 expression on these CD25High FoxP3- cells has been 
observed by previous studies but only compared to the Treg compartment as a 
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whole, and not the CD25Low Treg (Moran, 2011). In fact very few studies to date 
investigate a role for the CD25Low compartment. But Identical Nur77 expression 
coupled with lower HSA expression and their ability to increase CD25 levels 
upon exposure to IL-2 in vitro suggests there is a strong possibility of a 
precursor product relationship between these and the CD25High FoxP3+  Treg. 
This linear model for Treg development would be contrary to both the 2 step 
model and studies in neonatal mice. In neonates Treg are reported to develop 
predominantly CD25High 3 days after birth (Cheng et al. 2013)(Fontenot et al. 
2005). The discrepancy between CD25 expression levels in our TetZap70 
system and neonatal mice could be for a number or reasons. Firstly in neonatal 
mice Zap70 expression is under endogenous control, however Zap70 in 
TetZap70 FoxP3GFP mice is set by the tetracycline inducible transgene. The 
Zap70 level set by the transgene has been shown to be higher than that 
normally observed in WT CD4+ CD8+ DPs but lower than that observed in 
mature CD4+ SPs (Saini et al. 2010). It is therefore conceivable that lower 
Zap70 levels are leading to sub-optimal TCR signalling. This could lead to a 
failure to undergo complete differentiation and a developmental dead end. 
However the Treg pool in our constitutively dox fed mice appear completely 
normal, indicating no defects in Treg numbers or phenotype. The CD25Low 
FoxP3+ T-cells observed in our TetZap70 FoxP3GFP mice also have normal 
expression of characteristic Treg surface markers including CD5 a good indicator 
of TCR signalling strength, making failed development unlikely (Fig 1.6). We 
also show CD25High Treg developing from CD25Low precursors in sorted wt 
FoxP3GFP mice in which Zap70 is under endogenous control (Fig 1.10). 
    
 110 
Although Treg development in neonatal mice is dominated by the emergence of 
a CD25High FoxP3+ population there are still significant percentages of CD25Low 
Treg especially at the early time points. Large parts of our data appear to support 
a purely linear model for Treg development, however it is still hard to reconcile 
this with the observation that CD25High thymocytes are more likely to express 
FoxP3 than CD25Low thymocytes, perhaps suggesting a role for both routes 
during development. 
Our study presents evidence both for and against CD25Low FoxP3+ and 
CD25High FoxP3- cells acting as precursors to FoxP3+ CD25High Treg. It therefore 
remains possible that both populations act as precursors. Evidence that both 
routes of development can occur is apparent in our TetZap70 FoxP3GFP time 
course data. When gating on GITRHigh precursors around 90% are CD25Low 
while the remaining 10% are CD25High (Fig 1.8). GFP+ cells appear to be 
differentiating from both populations, with most cells originating from the more 
abundant CD25Low population. However due to the relatively small percentage 
of CD25High cells; the few GFP+ cells which do develop suggest an enrichment 
of precursors in this population. This goes some way to explaining the adoptive 
transfer experiments used in the literature to describe the 2 step model. Sorting 
any set number of either population before adoptive transfer would lead to the 
conclusion that the CD25High population is enriched for precursors, this is 
probably the case; however the bulk of development appears to be going via 
the CD25Low population due to the much higher percentage of these cells. If this 
is in fact the case in casts doubt over IL-2s role in FoxP3 induction. Perhaps 
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suggesting more of a correlative relationship between CD25 and FoxP3 
expression rather than an instructive role. This could indicate a role for TCR/co-
stimulatory signalling in FoxP3 induction followed by a role for IL-2 in 
homeostasis when Treg mature and egress the thymus. 
We observed delayed thymic egress of Treg compared to non-regulatory CD4+ 
SPs. We also saw egress of both CD25High and CD25Low populations suggesting 
CD25Low Treg can mature and express the necessary markers to egress the 
thymus in the absence of CD25. It still however remains uncertain if these 
CD25Low cells have undergone a full commitment to the Treg lineage or remain 
unstable and vulnerable to loosing FoxP3 expression and becoming ‘ex’-Tregs. 
Studies using Treg fate markers have shown that IL-2 blockade leads to 
decreased percentages of Treg as well as an increase in the percentage of Treg 
which have stopped expressing FoxP3 (exTreg) (Rubtsov et al. 2010). The CD25 
up regulation on CD25Low FoxP3+ cells, which according to our in vitro studies is 
dependant on IL-2; could therefore be necessary to maintain a stable Treg pool. 
Previous studies have also observed that output of Treg from the thymus is 
delayed during ontogeny and that development of autoimmune disease in 
neonatally thymectomised (nTx) mice is due to the escape of self-reactive T-
cells without Treg to maintain tolerance (Fontenot et al. 2005). Neonatal nTx at 4 
days results in T-cell mediated lesions which could be alleviated through the 
transfer of thymocytes or splenocytes from adult mice (Bonomo et al., 1995.; 
Life, 1996; Sakaguchi, 1982). Our study confirms this developmental delay also 
exists in the adult thymus. 
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Our results show that after egress into the periphery Treg can recirculate back 
into the thymus (Fig 1.7). We show a significant percentage of the thymic Treg 
pool are not de novo generated but in fact recirculants. During our experiments 
adoptively transferring CD45.1+ T-cells into TetZap70 FoxP3GFP chimeras, we 
see donor cells making up approximately 30% of the thymic Treg compartment, 
despite only making up 6% of the total CD4+ SPs. Further supporting this, 
constitutively dox fed mice which are then taken off dox for 4 weeks, still contain 
thymic Treg, even in the complete absence of TCR signalling and positive 
selection which has been shown to be crucial for their de novo development 
(Jordan et al. 2001). Interestingly these Treg also express the transcription factor 
helios, which is said to be a marker of thymic derived nTreg (A. M. Thornton et al. 
2010). However during the adoptive transfer experiments T-cells were injected 
into Rag1-/- hosts which lack a T-cell compartment. The donor cells were 
therefore most likely undergoing lymphopenia induced proliferation, meaning 
that although our studies can conclude the presence of recirculating Treg 
population it is hard to quantify the relative abundance of these compared to de 
novo generated Treg. Previous studies have attempted to quantify the 
abundance of recirculating T-cell populations in the thymus using Rag2GFP 
reporter mice (McCaughtry et al. 2007). As Rag2 expression is tightly regulated 
in developing thymocytes it is no longer expressed in the periphery, Rag2GFP T-
cells therefore loose GFP expression after thymic egress. The Treg compartment 
in these mice contained approximately 60% GFP- Treg. Although these could be 
resident Treg which remain in the thymus, taken together with our data it seems 
likely these are recirculants from the periphery. Studying Treg development in 
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our TetZap70 system therefore offers a distinct advantage compared to other 
models. Many of the previous models have been developed in mice where the 
T-cell compartment is under homeostatic control. A major advantage of the 
TetZap70 system is that we are able to look at de novo Treg development in the 
absence of inference from recirculating populations of cells. 
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Chapter 4 
TCR and cytokine requirement for 
regulatory T-cell development 
 
Introduction 
The forkhead transcription factor FoxP3 binds to and regulates hundreds of 
target genes associated with the Treg lineage. Expression of these genes 
shapes the Treg transcriptional landscape, defining the lineage and allowing 
suppression of immune responses (Hill et al. 2007). However the internal and 
external cues leading to FoxP3 expression remain poorly understood. FoxP3 
expression is thought to occur relatively late during thymic selection, in 
thymocytes which receive a strong TCR selection signal. Retroviral transfer of 
Treg or naïve T-cell TCRα libraries into RAG-/- TCR transgenic T-cells shows 
increased self reactivity of TCRs derived from Treg. Treg derived TCRs were 
more able to induce expansion and auto-immunity upon transfer into 
lymphopenic hosts but only able mount weak in vitro responses to syngenic 
APCs, when compared to the reaction to ‘foreign’ peptide recognised by their 
transgenic TCRs. Therefore although Treg bear TCR able to recognise self-
antigens, the strength of this TCR signal is weaker than that of conventional T-
cells recognising foreign antigen in immune responses (C.Hsieh et al. 2004). 
The overlap in TCR sequence between Treg and non-Treg is also reported to be 
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very small, suggesting a TCR instructive model for Treg development in which 
self-reactive thymocytes are selected on self-antigens during selection in the 
thymus.  
Co-stimulatory signalling has also been shown to have a cell intrinsic role in the 
generation of regulatory T-cells (Tai et al. 2005). CD28-/- and CD80/86-/- mice 
show large decreases in Treg frequency (Lenschow et al. 2000). The lck binding 
domain of the CD28 cytoplasmic tail has been shown to be critical for FoxP3 
expression (Tai et al. 2005), suggesting co-ordinated TCR and CD28 signalling 
play a key role in Treg development. Several transcription factors such as NFAT 
and AP-1 are downstream of TCR and CD28 signalling. These have been 
implicated in Treg differentiation and bind to the FoxP3 promoter (Cells et al. 
2006). CD40L co-stimulation is also suggested to play a role in thymic Treg 
development. Deficiency in CD40 or CD154 (CD40L) reduces thymic and 
peripheral Treg frequency by approximately 50% (Spence & Green 2008). There 
is disagreement however over whether this decrease is due to reduced thymic 
output or in fact due to homeostatic effects in the periphery. More recently it has 
been suggested that abrogation of CD40-CD154 signalling impeded the 
homeostasis of thymic resident Treg by altering IL-2 levels. It therefore remains a 
possibility that CD40-CD40L signalling plays an important role in homeostasis 
rather than thymic Treg development.  
The TGFβ-smad pathway is thought to induce FoxP3 expression in naïve CD4+ 
SPs, generating iTregs. However its role in Thymic Treg development still remains 
contentious. Numerous studies have reported severe inflammation of mice with 
    
 116 
complete or T-cell specific deletions of individual components of the TGFβ 
signalling pathway (M. O. Li et al. 2006; Gorelik & R. a Flavell 2000)(Y. Liu et al. 
2008; Lucas et al. 2000). However no consensus has been reached as to the 
affect TGFβ has on thymic Treg development. One recent study generated mice 
in which the smad binding site within the FoxP3 locus was removed. This 
showed TGFβ was dispensable for Treg development in adult and new born 
mice, while demonstrating a key requirement for TGFβ-smad signalling for Treg 
generation in the gut (Schlenner et al. 2012).  
IL-2/IL-2R signalling is essential for thymic Treg development and peripheral 
homeostasis(Malek 2008). Mice lacking IL-2 or IL2Rα (CD25) exhibit an 
approximate 50% decrease in Treg frequencies (Fontenot, Rasmussen, Gavin & 
A. Y. Rudensky 2005). IL-2-/-/CD25-/- mice undergo very severe systemic auto-
immunity paralleling that seen in FoxP3-/- mice (Fontenot et al. 2003). The T-
cells within these mice undergo uncontrolled hyper activation and animals 
succumb to lethal auto-immunity within 4-12 weeks of age (Schorle et al. 1991). 
Restoring the Treg compartment is sufficient to prevent auto-immunity, 
suggesting defective Tregs are responsible (Malek et al. 2002). One difference 
between FoxP3-/- mice and IL-2-/-/CD25-/- mice is the latter still contain 
approximately 50% of their Tregs. These Treg essentially lack all CD25 
expression and are found in very low proportions within peripheral lymphoid 
organs (Bayer et al. 2007). CD25lo FoxP3+ Treg are still able to suppress 
immune responses and inhibit T-cell proliferation but are unable to proliferate 
efficiently themselves, accounting for the slower pace of auto-immunity within 
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the IL-2-/- mice. IL-2 is described in the 2 step model as initiating thymic FoxP3 
expression via STAT5 (Chan-Wang Joaquim Lio & C.-S. Hsieh 2008). 
Conditional STAT5 deletion leads to a drastic reduction in FoxP3+ cells (M. A. 
Burchill et al. 2007). Introduction of a Bcl-2 transgene leads to Treg development 
in the absence of STAT5 signalling (Josefowicz & A. Rudensky 2009). 
Suggesting Treg require an IL-2 dependant survival signal during homeostasis, 
and may not solely rely on IL-2 to induce FoxP3 expression. IL15R-IL15 
signalling is also capable of activating STAT5 signalling. Even though IL-2 and 
IL-15 share common receptor subunits, CD122 (IL2Rβ) and γc, IL15Rα-/- mice 
are autoimmune free and contain normal numbers of FoxP3+ Treg. It is therefore 
likely that redundancy between the γc family cytokines during de novo Treg 
development exists (M. A. Burchill et al. 2007). 
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Results 
 
CD80/86 blockade reduces Treg development 
Co-stimulatory signalling is thought to play a crucial role in Treg differentiation, 
as frequencies of Treg are reduced in CD28-/- and CD80/86-/- mice (Lenschow et 
al. 2000). We therefore investigated if CD28 co-stimulation plays an important 
role in de novo Treg differentiation in TetZap70 FoxP3GFP chimeras. To achieve 
this we took advantage of CD80 and CD86 blocking antibodies, 16-10A1 and 
GL-1. TetZap70 FoxP3GFP chimeras received a 1mg dose of a CD80/86 
blocking antibody via an ip injection every 2 days beginning on day-1 before 
being fed dox. Their thymus was analysed by FACs 6 days after commencing 
dox feeding. Bl/6 mice which received the CD80/86 blockade treatment for 6 
days as controls, showed a 5-fold decrease in thymic Treg (Fig 2.1A). While 
CD80/86 blockade had no effect on CD4+ SP percentages in the chimeras, we 
did observe a significant reduction in the frequency of GFP+ Treg (Fig 2.1 B&C). 
Interestingly the Treg compartment in the chimeras which received the CD80/86 
blockade expressed low levels of CD25 while PBS controls contained both 
CD25Hi and CD25Lo GFP+ populations. The reduction in Treg frequencies 
reported in CD28-/- mice were similarly observed in Bl/6 mice which received the 
antibody blockade. This suggests blocking antibodies successfully locate to the 
thymus and block CD28 co-stimulation. The observations that this blockade 
dramatically reduces thymic Treg in TetZap70 FoxP3GFP chimeras confirm a 
crucial role for signalling elicited by CD80/86 in de novo Treg development. 
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CD40-CD40L signalling plays no role in thymic de novo Treg development 
Next we wished to investigate the roles of additional forms of co-stimulatory 
signalling on Treg development. It has been reported that during thymic selection 
CD40L is specifically up-regulated on FoxP3+ thymic Treg where it induces clonal 
expansion within the medulla (Spence & Green 2008). We therefore 
investigated the affect of blocking CD40L on de novo Treg development. 
TetZap70 FoxP3GFP chimeras received 0.5mg of a CD40L blocking antibody 
MR1 one day prior to being fed dox. The chimeras received the blocking 
antibody treatment every 2 days before their thymus was analysed by FACs. 
Bl/6 control mice which received similar CD40L blocking antibody treatment 
exhibited a ≈50% decrease in thymic Treg (Fig 2.2A). In TetZap70 FoxP3GFP 
chimeras however, treatment with the CD40L blocking antibody had no effect on 
the Treg compartment. Thymic Treg percentages in these mice were identical to 
PBS injected controls and consistent with historical pooled time course data 
(Fig 2.2 B&C) Taken together these results indicate no role for CD40L in 
development of Treg in the thymus, perhaps instead suggesting a homeostatic 
role for mature Treg which recirculate back into the thymus from the periphery. 
A short window of TCR signalling is sufficient to induce FoxP3 expression 
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TCR signalling is thought to be crucial for Treg differentiation. In TCR transgenic 
mice, Treg only develop when cognate antigen is present (Jordan et al. 2001). 
However it remains unclear when TCR signalling is required during thymic 
development of Treg. To investigate this, we studied Treg development in 
TetZap70FoxP3GFP chimeras in which Zap70 expression is restricted to the 
early stages of selection. It has been shown previously that an ip injection of 
2mg methacycline induces Zap70 expression for approximately 48 hours after 
which it is rapidly lost (Sinclair et al. 2011). TetZap70FoxP3GFP mice were 
therefore injected with 2mg methacycline (ip) and their thymus analysed by 
FACs. CD4+ SP thymocytes from Methacycline pulsed TetZap70FoxP3GFP mice 
expressed low levels of Zap70 4 days after injection, and Zap70 levels dropped 
further by day 6. CD5 attenuates TCR signalling through recruitment of the 
tyrosine phosphatase SHP-1 (Azzam et al. 2001). CD5 expression on 
thymocytes is therefore proportional to the strength of the TCR signal strength 
cells are exposed to. CD5 expression levels on methacycline pulsed TetZap70 
FoxP3GFP thymocytes were reduced compared to Bl/6 controls (Fig 2.3C). 
Surprisingly Treg frequency’s as a percentage of CD4+ SPs were identical in both 
the methacycline pulsed and dox fed controls (Fig 2.3B). As a percentage of 
total thymocytes, methacycline and dox mice appear to have similar 
percentages at day 4 but Treg percentage dropped slightly by day 6 in the 
methacycline pulsed mice. In methacycline pulsed mice CD4+ SP percentages 
drop after day 4, therefore the increase in Treg as a percentage of CD4+ SPs 
may reflect increased survival of Treg in the absence of TCR signalling. This was 
reflected by the maintenance of Treg frequency as a percentage of total thymus 
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on day 4. The drop in percentage at day 6 can be explained by a drop in CD4+ 
SP numbers most likely due to cell death in the absence of a TCR induced 
survival signal. This data suggests that an early TCR signal is sufficient to 
cause FoxP3 expression and that FoxP3 expression maintained in the absence 
of a TCR signal. 
 
TGFβ blockade has no affect on de novo Treg development. 
Since an early TCR signal was sufficient for FoxP3 induction next we aimed to 
investigate if the later stages of development were reliant on cytokine signalling. 
TGFβ is heavily implicated in causing naïve CD4+ SPs to express FoxP3 in the 
periphery, known as iTregs. However its role in FoxP3 induction in the thymus 
remains more contentious. To investigate the role TGFβ plays in the thymic 
induction of FoxP3,, TetZap70 FoxP3GFP chimeras were fed dox and treated 
with 1mg of a TGFβ blocking antibody every 2 days. The first antibody 
treatment was administered 1 day prior to dox feeding. The thymus was then 
analysed on days 4 and 6 by FACs. The frequency of GFP+ cells within the 
CD4+ SP compartment in the mice treated with TGFβ mAb appeared similar to 
controls both at d4 and d6 after dox feeding (Fig 2.4 A&B). This data suggests 
that there is no role for TGFβ in thymic de novo Treg development. However, 
since we observed no phenotype in Bl/6 mice which received the TGFβ mAb, it 
remains possible that the blocking antibody treatment did not completely 
abrogate TGFβ signalling.  
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IL-2 is critical to the development of CD4+ SP CD25Hi FoxP3+ Treg 
Next we wished to analyse the role IL-2 plays during de novo Treg development. 
IL-2 is thought to be crucial for both FoxP3 induction and Treg homeostasis 
(Chan-Wang Joaquim Lio & C.-S. Hsieh 2008)(Setoguchi et al. 2005). The 
requirement for IL-2 during de novo Treg development has not been directly 
analysed previously. To determine the effects of IL-2 neutralisation on the 
developing Treg, TetZap70 FoxP3GFP chimeras and WT controls received a 1mg 
dose of IL-2 neutralising antibodies every 2 days starting one day prior to dox 
feeding. The thymocytes from these mice were then analysed by FACs at d4 
and d6. Bl/6 control mice which received the IL-2-neutralisng antibody treatment 
for 6 days showed a 50% decrease in thymic CD4+ SP CD25High CD44Int Treg, 
consistent with observations previously made in IL-2-/- mice (Fontenot, 
Rasmussen, Gavin & A. Y. Rudensky 2005). The frequency of GFP+ cells was 
not affected by IL-2 blockade when compared to controls (Fig 2.5 A&B). 
However chimeras which received the IL-2 blocking antibody specifically lacked 
GFP+ CD25Hi cells compared to PBS treated controls,(Fig 2.5 A&C). Although 
the size of the total GFP+ compartment in IL-2 treated mice was not statistically 
different from that of controls there was a trend towards their having fewer GFP+ 
cells (Fig 2.5D). These data could suggest that CD25 up-regulation on 
developing Treg is IL-2 dependant and these develop from a CD25Low GFP+ 
precursor. It is also consistent with 2 routes of Treg development, one via a 
CD25Hi GFP- precursor, and one via a CD25Low FoxP3+ precursor where 
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development is IL-2 independent. It is possible that the lack of a prominent 
CD4+ SP CD25High GFP+ compartment in TetZap70 FoxP3GFP chimeras is due 
to the lack of the correct cytokine milieu during selection in the thymus.  
We have shown that blocking IL-2 stopped generation of CD4+ SP CD25High 
GFP+ cells. Next we asked if exogenous IL-2 was capable of enhancing 
development of CD4+ SP CD25High GFP+ Treg cells. IL-2 monoclonal antibodies 
when coupled to recombinant IL-2 have been shown to increase the biological 
half-life of IL-2 (Boyman et al. 2006). Therefore TetZap70 FoxP3GFP chimeras 
were fed dox food and injected with IL-2-antibody immune complexes every 2 
days, beginning one day prior to dox feeding. When compared to controls, IL-2 
treated chimeras showed increased CD25 expression (Fig 2.6A). This also 
corresponded with an increase in absolute Treg cell numbers on days 4 and 6  in 
the IL-2 treated mice (Fig 2.6B). Taken together this data would suggest that an 
exogenous source of IL-2, is capable of both increasing CD25 expression levels 
and causing either proliferation or increased differentiation of Treg. 
 
IL-15 plays an important role in CD4+ GFP+ CD25low Treg development 
Next we wished to investigate a role for IL-15 in Treg homeostasis. It has been 
reported that IL-15 plays a relatively minor role in Treg maintenance and 
development as IL-2Rα-/- and IL-2Rβ-/- mice have FoxP3+ populations of 
comparable size. However it remains unclear as to the extent of the redundancy 
that exists between IL-15 and IL-2 in Treg differentiation and homeostasis (M. A. 
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Burchill et al. 2007). We therefore aimed to further investigate the role for IL-15 
in Treg biology. In order to achieve this we sub lethally irradiated Rag1-/- IL-15Rα-
/- host mice and injected them with 5x106 congenically labelled Bl/6 bone 
marrow cells. These were left for 6 weeks to reconstitute before their thymus 
and LNs were analysed by FACs. The numbers of CD4+ SP cells in the thymus 
and LNs of Rag1-/- IL-15Rα-/- host chimeras were comparable to numbers in 
Rag1-/- host controls chimeras (Fig 2.7B). Rag1-/- IL-15Rα-/- chimeras contained 
similar percentages of thymic FoxP3+ Treg as Rag1-/- hosts, but showed an 
approximate 50% reduction of CD4+ SP FoxP3+ cells in the periphery (Fig 2.7 
A&B). This suggests a redundant role for IL-15 and IL-2 in the thymus and 
points towards a homeostatic role for IL-15 in maintenance of Treg in the 
periphery.  
We next decided to look more closely at the roles IL-15 and IL-2 play in de novo 
Treg development in the thymus. To investigate this we used IL-15R-/- Rag1-/- 
mice as hosts for TetZap70 FoxP3GFP chimeras and treated them with or 
without IL-2 blocking antibody whilst feeding them dox. Analysing the thymus of 
IL-15R-/- Rag1-/- TetZap70 FoxP3GFP chimeras revealed a significant reduction 
in the frequency of GFP+ cells compared to Rag1-./- control chimeras (Fig 2.8 C). 
IL-2 blockade prevented development of CD4+ SP CD25Hi GFP+ cells in both 
chimeras (Fig 2.8 A&C). In contrast development of the CD4+ SP CD25Low GFP+ 
was unaffected (Fig 2.8C). These data indicate a requirement for both IL-2 and 
IL-15 for efficient CD4+ SP CD25High GFP+ Treg development, while CD4+ SP 
CD25Low GFP+ cells rely solely on IL-15. 
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Figure 2.1 CD80/86 antibody blockade reduces Thymic Treg frequencies. 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being treated 
along with Bl/6 controls with 0.5mg of a CD80 and 0.5mg of a CD86 blocking 
antibody via a single ip injection (16-10A1, GL-1). Alternatively both chimeras 
and Bl/6 mice were treated with PBS alone. The following day chimeras were 
fed dox, receiving additional does of blocking antibody or PBS every 2 days until 
day 6 when the thymus was analysed by FACs. A: FACs plots comparing CD25 
and FoxP3 expression on Bl/6 mice treated with PBS (left) or CD80/86 blockade 
(right). B: FACs plots comparing CD4 and CD8 expression on live singlets (left 
panel) in PBS treated (top) or CD80/86 blocked mice (bottom). CD25 and GFP 
expression was then compared on TCRHi CD5Hi CD4+ SP cells (right panel) for 
PBS treated (top) and CD80/86 blocked cells (bottom). C: Line graphs 
comparing TCRHi CD5Hi CD4+ SP GFP+ frequency in PBS treated (blue) and 
CD80/86 blocked (red) mice to historical TetZap70 FoxP3GFP chimera time 
course data (grey). Expressed as a percentage of TCRHi CD5Hi CD4+ SPs (left) 
and total thymocytes (right). 
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Figure 2.2 CD40L blockade has no affect de novo Treg development. 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being treated 
along with Bl/6 controls with 0.5mg of a CD40L blocking antibody via a single ip 
injection (MR1). Alternatively both chimeras and Bl/6 mice were treated with 
PBS alone. The following day chimeras were fed dox, receiving additional does 
of blocking antibody or PBS every 2 days until day 4 or 6 when the thymus was 
analysed by FACs. A: FACs plots comparing CD25 and FoxP3 expression on 
Bl/6 mice treated with PBS (left) or CD40L blockade (right). B: FACs plots 
comparing CD25 and GFP expression on TCRHi CD5Hi CD4+ SP thymocytes 
from PBS treated (left) and CD40L blocked cells (right) on days 4 (top panel) 
and 6 (bottom panel). C: Line graphs comparing TCRHi CD5Hi CD4+ SP GFP+ 
frequency in PBS treated (blue) and CD40L blocked (red) mice to historical 
TetZap70 FoxP3GFP chimera time course data (grey). Expressed as a 
percentage of TCRHi CD5Hi CD4+ SPs (left) and total thymocytes (right). 
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Figure 2.3 Early expression of Zap70 supports de novo Treg development. 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being treated 
with 2mgs of methacycline via a single ip injection. The thymus of the 
methacycline pulsed chimeras was then analysed by FACs 4 and 6 days later. 
A: FACs plots comparing CD25 and GFP expression on TCRHi CD5Hi CD4+ SP 
thymocytes from dox fed (left) and methacycline pulsed (right) on days 4 (top 
panel) and 6 (bottom panel). B: Line graphs comparing TCRHi CD5Hi CD4+ SP 
GFP+ frequency in methacycline pulsed (blue) and dox fed mice (red) to 
historical TetZap70 FoxP3GFP chimera time course data (grey). Expressed as a 
percentage of TCRHi CD5Hi CD4+ SPs (top) and total thymocytes (bottom). C: 
Histograms comparing CD5 expression (left) and Zap70 expression (right) on 
TCRHi CD5Hi CD4+ SP thymocytes from methacycline pulsed mice analysed 
after 4 days (blue) 6 days (red), Bl/6 control mice (black) or Zap70-/- mice (grey). 
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Figure 2.4 TGFβ blockade has no affect on de novo Treg development. 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being treated 
with 1mg of a TGFβ blocking antibody via a single ip injection (1D11.11.8). The 
following day chimeras were fed dox, receiving additional does of blocking 
antibody or PBS every 2 days until day 6 when the thymus was analysed by 
FACs.  A: FACs plots comparing CD25 and GFP expression on TCRHi CD5Hi 
CD4+ SP thymocytes from PBS treated (left) and TGFβ blocked (right) on days 
4 (top panel) and 6 (bottom panel). B: Line graphs comparing TCRHi CD5Hi 
CD4+ SP GFP+ frequency in PBS treated (blue) and TGFβ blocked mice (red) to 
historical TetZap70 FoxP3GFP chimera time course data (grey). Expressed as a 
percentage of TCRHi CD5Hi CD4+ SPs (left) and total thymocytes (right). 
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Figure 2.5 IL-2 blockade reduced CD25 expression on thymic Treg. 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being treated 
with 1mg of an IL-2 blocking antibody along with Bl/6 controls via a single ip 
injection (0.5mg JES6-5H4, 0.5mg S4B6). The following day chimeras were fed 
dox, receiving additional does of blocking antibody or PBS, along with Bl/6 
controls, every 2 days until day 6 when the thymus was analysed by FACs.  A: 
FACs plots comparing CD25 and GFP expression on d6 TCRHi CD5Hi CD4+ SP 
thymocytes left panel) from PBS treated (top) and IL-2 blocked (bottom) 
chimeras. FACs plots comparing thymic Treg (CD25Hi CD44Int) percentages in 
Bl/6 mice (right panel) treated with either PBS (top) or IL-2 blocking antibody 
(bottom).  B: Line graphs comparing TCRHi CD5Hi CD4+ SP GFP+ frequency in 
PBS treated (blue) and IL-2 blocked mice (red) to historical TetZap70 FoxP3GFP 
chimera time course data (grey). Expressed as a percentage of TCRHi CD5Hi 
CD4+ SPs (right) and total thymocytes (left). C: Bar charts showing TCRHi CD5Hi 
CD4+ SP GFP+ thymocyte frequency, with or without IL-2 blockade on days 4 
and 6 (right panel). Thymocytes have then been further subdivided depending 
on CD25 expression (left panel) into CD25High (red) or CD25Low (blue) 
Frequencies displayed as a percentage of TCRHi CD5Hi CD4+ SPs. 
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Figure 2.6 In vivo IL-2 treatment increases CD25 expression on Treg. 
 
Rag1-/- mice were irradiated and injected with 5M TetZap70 FoxP3GFP bone 
marrow cells iv. Bone marrow was harvested as described in materials and 
methods. Chimeras were left for 6 weeks to reconstitute before being treated 
with IL-2-Antibody complexes via a single ip injection. 50µg of IL-2 antibody 
(JES6-1A12) we left on ice with 5µg recombinant IL-2 (peprotech) for 30 mins 
prior to injection. The following day chimeras were fed dox, receiving additional 
does of IL-2-antibody or PBS every 2 days until day 6 when the thymus was 
analysed by FACs.  A: FACs plots comparing CD25 and GFP expression on d6 
TCRHi CD5Hi CD4+ SP thymocytes from PBS treated (left) and IL-2-antibody 
treated (right) chimeras. B: Cell numbers comparing TCRHi CD5Hi CD4+ SP 
GFP+ frequency in PBS treated (blue, n=3) and IL-2-antibody treated mice (red, 
n=3) on days 4 (left) and 6 (right). 
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Figure 2.7 Characterisation of IL-15R-/- Rag1-/- host Bl/6 chimeras 
 
IL-15R-/- Rag1-/- and Rag1-/ mice were irradiated and injected with 5M Bl/6 
CD45.1 bone marrow cells iv. Bone marrow was harvested and T-cell depleted 
using MACs beads, as described in materials and methods. Chimeras were left 
for 6 weeks to reconstitute before being analysed by FACs A: FACs plots 
comparing CD25 and FoxP3 expression on TCRHi CD4+ SP thymocytes (top 
panel) and LN cells (bottom panel) from Rag1-/- hosts (left) and IL-15R-/- Rag1-/- 
(right) chimeras. B: TCRHi CD4+ SP cell frequencies (left) and TCRHi CD4+ SP 
FoxP3+ cell frequencies (right) in IL-15R-/- Rag1-/- and Rag1-/ chimeras showing 
thymocytes (red) and n cells (blue).  
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Figure 2.8 Reduced Treg frequencies in IL-15R-/- Rag1-/- host chimeras. 
 
IL-15R-/- Rag1-/- and Rag1-/ mice were irradiated and injected with 5M TetZap70 
FoxP3GFP bone marrow cells iv. Bone marrow was harvested and injected as 
described in materials and methods. Chimeras were left for 6 weeks to 
reconstitute before being treated with 1mg of an IL-2 blocking antibody along via 
a single ip injection (0.5mg JES6-5H4, 0.5mg S4B6). The following day 
chimeras were fed dox, receiving additional does of blocking antibody or PBS, 
every 2 days until days 4 and 6 when the thymus was analysed by FACs. A: 
FACs plots comparing CD25 and GFP expression on TCRHi CD5HI CD4+ SP 
thymocytes treated with either PBS (top panel) or IL-2 blocking antibody (bottom 
panel) from Rag1-/- hosts (left) and IL-15R-/- Rag1-/- hosts (right). B: Line graphs 
comparing TCRHi CD5Hi CD4+ SP GFP+ frequency in IL-15R-/- Rag1-/- hosts 
(blue) and Rag1-/- hosts (red) to historical TetZap70 FoxP3GFP chimera time 
course data (grey). Expressed as a percentage of TCRHi CD5Hi CD4+ SPs. C: 
Bar charts showing TCRHi CD5Hi CD4+ SP GFP+ thymocyte frequency, with or 
without IL-2 blockade in IL-15R-/- Rag1-/- or Rag1-/- host chimeras. Thymocytes 
have then been further subdivided depending on CD25 expression into 
CD25High (red) or CD25Low (blue). Frequencies displayed as a percentage of 
TCRHi CD5Hi CD4+ SPs. 
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Discussion 
 
FoxP3 plays a central role in establishing and maintaining the Treg 
transcriptional program. Therefore deciphering the cues which lead to FoxP3 
expression will allow greater understanding of the differentiation and 
maintenance of the Treg lineage. In this study we show that a short window of 
TCR signalling is sufficient for the generation of FoxP3+ Treg. Using the 
tetracycline derivative methacycline, we limited Zap70 expression to the first 48 
hours of development. While we saw evidence of death amongst CD4+ SP cells 
death in the absence of continued TCR signalling, FoxP3+ Treg appeared less 
vulnerable to death in the absence of Zap70, evident by their progressive 
enrichment following loss of Zap70. Previous studies reveal the critical role of 
TCR signalling in the development of Treg. However the timing and duration of 
this signal during development still remains unclear. It has been proposed that 
Treg development occurs via a TCR dependant phase followed by a cytokine 
dependant phase of development, however to our knowledge no formal 
evidence for the temporal separation of these individual signalling events yet 
exists. In this study we provide evidence detailing the precise temporal 
requirement for signalling through the TCR during thymic Treg maturation. We 
show an early TCR signal is sufficient for FoxP3 induction and that expression 
is maintained in the absence of a TCR signal. However it remains unclear 
whether other additional signals are required for FoxP3 expression and 
development of a stable Treg lineage. 
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In addition to TCR signalling, CD28 co-stimulatory signals have been shown to 
play a critical role in Treg differentiation. We confirmed this using CD80/86 
blocking antibodies. We demonstrate a 5-fold decrease in thymic Treg within Bl/6 
mice treated with a CD80/86 blocking antibody. TetZap70 FoxP3GFP chimeras 
almost completely lacked Treg altogether when receiving the blocking antibody. 
Previous work in this area has established a role for CD28-CD80/86 signalling 
in Treg differentiation. CD28-/- and CD80/86-/- mice have marked decreases in 
Treg frequencies (Lenschow et al. 2000) (Tai et al. 2005). These are directly 
comparable to the frequencies observed in Bl/6 mice treated with the CD80/86 
blocking antibody in our study, confirming the treatment blocking antibody. The 
studies in CD28-/- and CD80/86-/- mice focus on adult mice in which the T-cell 
compartment is in steady state. It therefore remains unclear as to whether the 
observed difference in the Treg compartment in these mice are due to 
homeostatic effects in the periphery or direct affects influencing de novo Treg 
development. Our study however demonstrates a direct role for signalling 
through CD80/86 in thymic FoxP3 induction. CD28 however is not the only 
signalling molecule reported to interact with the CD80/86 signalling complex, 
CTLA-4 is also known to interact with CD80/86 and is expressed at high levels 
on Treg. It therefore remains possible that the reduction in Treg frequency 
observed in the CD80/86 blocked mice was due to blocking CTLA4-CD80/86 
interactions. CTLA-4 inhibits T-cell activation through poorly defined 
mechanisms which may include delivery of inhibitory signals to the T-cell, 
competition with CD28 for CD80/86 or trans-endocytosis of CD80/86 (Reviewed 
in Wing, Yamaguchi, & Sakaguchi, 2011)(Qureshi et al. 2011). Although much 
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is still unknown about CTLA-4s role in T-cell biology the overriding conclusion 
thus far is that it plays an inhibitory role limiting T-cell activation. It therefore 
seems unlikely that the decreased Treg frequencies observed in the chimeras 
which received the CD80/86 blocking antibody were due to blocking CTLA4-
CD80/86 interaction, and instead much more likely CD28-CD80/86 interactions 
play a key role in Treg development.  
Another form of co-stimulation implicated in Treg biology is CD40-CD154 
(CD40L) signalling. We found that blocking CD40-CD40L interaction during 
development had no affect on de novo Treg development in TetZap70 FoxP3GFP 
mice. We did however see a reduction in thymic Treg in Bl/6 mice after 6 days of 
CD40-CD40L blockade. Although CD40L-CD40 interactions appear to have no 
role in de novo Treg development, they may instead provide important signals for 
peripheral Treg homeostasis. The T-cell compartment in Bl/6 mice, unlike the 
TetZap70 FoxP3GFP chimeras, is full and under steady state homeostatic 
control. A contraction of the Treg compartment in the periphery could therefore 
lead to reduced frequencies of Treg recirculating back to the thymus. Many 
previous studies attempt to link reduced thymic Treg percentages to defects in 
de novo Treg development, without taking into account recirculant populations. It 
has been reported that CD40L induces the clonal expansion of FoxP3+ Treg as 
CD40L blockade led to reduced thymic Treg frequencies (Spence & Green 
2008). This was later explained by abrogation of the CD40-CD40L signalling 
pathway inhibiting homeostasis of thymic resident Treg (Cuss & Green 2012). 
Although we cannot rule this out as a possibility, we have shown large 
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percentages of Treg egress the thymus before re-entering and therefore feel it is 
much more likely that the reduced thymic Treg frequencies observed in these 
mice are a consequence of reduced recirculation.  
After a period of TCR dependant development, our data suggest that Treg enter 
a TCR-independent cytokine phase of maturation. We found no effect on Treg 
frequency in either Bl/6 or TetZap70 FoxP3GFP mice treated with a TGFβ 
blocking antibody. As we observed no phenotype in the Bl/6 mice treated with 
the TGFβ blocking antibody, there remains the possibility that the TGFβ 
blockade was not complete in vivo. However the blocking antibody used has 
been extensively reported to function both in vitro and in vivo at lower does than 
those used in this study (Dasch et al. 1989)(X. Zhang et al. 2001). This study 
therefore casts doubt over a role for TGFβ in de novo Treg development, but with 
the lack of an effective positive control we still cannot be certain if TGFβ 
signalling has completely ceased. Previous studies into the role of TGFβ in 
thymic Treg development have drawn several conclusions. Using TGFβRII-/- OTII 
TCR transgenic mice it has been shown that TGFβ functions to protect both 
nTreg cells and antigen experienced conventional T-cells from negative selection 
(Ouyang, Beckett, Ma & M. O. Li 2010). It has also been reported that TGFβ is 
required to maintain suppressor function in mice expressing a DN TGFβR1 on a 
CD2 T-cell specific promoter  rather than to aid in Treg development itself (Marie 
et al. 2005). However one recent publication in which smad3 binding to the 
FoxP3 enhancer is removed, showed no requirement for TGFβ signalling in 
FoxP3 induction in the thymus (Schlenner et al. 2012). These mice contained 
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normal numbers of Treg and were not at increased susceptibility to colitis. This 
study would fit with our findings that TGFβ plays no role in Treg development 
maintenance or homeostasis, explaining our inability to observe any Treg defects 
in Bl/6 mice receiving the TGFβ blockade. 
IL-2 is strongly implicated in Treg development, homeostasis and function. We 
showed that IL-2 antibody blockade has no effect on de novo development of 
FoxP3+ cells in TetZap70 FoxP3GFP chimeras. In contrast, blockade in WT mice 
caused a 50% reduction in the Treg numbers. We did however observe a 
specific requirement for IL-2 signalling in the development of CD4+ SP CD25Hi 
GFP+ Treg. Development of CD4+ SP CD25Low GFP+ Treg did not require IL-2. 
Adding an exogenous source of IL-2 to the TetZap70 FoxP3GFP chimeras 
enhanced development of CD4+ SP CD25High GFP+ Treg. The current literature 
describes a major role for IL-2 in induction of FoxP3 expression and Treg 
development. Hsieh and colleagues propose in their two step model that a 
strong early TCR signal leads to CD25 up regulation and the formation of a 
cytokine responsive Treg precursor population. CD25High FoxP3- Treg can then 
respond to paracrine IL-2 in the thymus and begin to express FoxP3 (Chan-
Wang Joaquim Lio & C.-S. Hsieh 2008). However in the presence of an IL-2 
blockade we see similar percentages of Treg to PBS injected control mice. This 
suggests that the early TCR/co-stimulatory signal is the main driver of FoxP3 
expression, while the role of IL-2 maybe is to increase CD25 expression and 
stabilise the newly developed Treg. It remains possible that the IL-2 blockade 
incompletely abrogated IL-2 signalling or is being compensated for by other γc 
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cytokines. However IL-2-/- mice are reported to have a 50% reduction in thymic 
Treg (Fontenot, Rasmussen, Gavin & A. Y. Rudensky 2005), a phenotype 
replicated by the IL-2 blockade treatment in Bl/6 mice. A study describing IL-
2Rβ-/- mice describes the Treg compartment comprising predominantly of CD4+ 
CD25- FoxP3lo cells, which expressed low levels of the proliferation marker Ki67 
(Cheng et al. 2013). This supports our view that IL-2 is important for maintaining 
CD25 expression and homeostasis, rather than FoxP3 induction. We therefore 
suggest TCR and co-stimulatory signals drive initial expression of FoxP3 while 
IL-2 enhances expression and promotes survival.  
The 50% reduction in Treg frequency observed in IL-2-/- mice could suggest 
redundancy with other γc cytokines such as IL-15. We found that development 
of CD4+ CD25Lo FoxP3+ cells was dependent on IL-15, while development of 
CD4+ CD25Hi FoxP3+ cells in dependent on IL-15 & IL-2. Previous studies have 
shown IL-2Rα-/- mice contain relatively normal frequency’s of CD4+ FoxP3+ Treg 
(Fontenot, Rasmussen, Gavin & A. Y. Rudensky 2005). We also see no affect 
on Treg frequency after IL-2 blockade. In contrast CD122-/- (IL-2Rβ) and IL-2-/-x 
IL-15-/- mice are reported to exhibit significant decreases in Treg frequency 
(Soper et al. 2007) (M. A. Burchill et al. 2007). This is consistent with the Treg 
frequencies observed in our IL-15R-/- chimeras which received the IL-2 
blockade. This study coupled with the current literature suggests some 
redundancy between IL-15 and IL-2 in Treg development. However the 
requirement of the CD4+ CD25Lo FoxP3+ cells for IL-15 and the CD4+ CD25Hi 
FoxP3+ cells for IL-2 has not previously been described. It remains a possibility 
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that 2 routes of development of CD4+ CD25Hi FoxP3+ cells exist, 1 via a CD4+ 
CD25Lo FoxP3+ precursor which is dependant on IL-15, and a second via a 
CD4+ CD25Hi FoxP3- precursor which is dependant on IL-2. It also remains 
possible that this observation is exclusive to development of Treg in the 
TetZap70 FoxP3GFP mice, which may lack the correct cytokine milie for efficient 
Treg development. WT mice contain fewer CD4+ CD25Lo FoxP3+ cells than 
TetZap70 FoxP3GFP mice, perhaps suggesting a more abundant source of 
thymic IL-2 in WT mice. TetZap70 FoxP3GFP mice lack a mature T-cell 
compartment, and therefore recirculating populations of cells. This could lead to 
an immature thymic microenvironment and less efficient de novo Treg 
development. 
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Chapter 5 
The Role of Additional Cell Types  
in nTreg development 
Introduction 
 
FoxP3+ Treg predominantly express the high affinity α-subunit of the IL-2R, 
CD25, however the precise role played by IL-2 signalling in Treg biology remains 
contentious. Previous studies find an essential role for IL-2 signalling in the 
induction of FoxP3 expression during thymic Treg development. This is proposed 
to occur in a 2 step model, strong TCR/co-stimulatory signalling first leads to 
increased CD25 expression. CD25HI FoxP3- T-cells are then instructed to 
express FoxP3 by IL-2 (Chan-Wang Joaquim Lio & C.-S. Hsieh 2008). IL-2-/- 
mice have been shown to contain reduced frequencies of Treg and to succumb 
to lethal auto-immunity (Sadlack et al. 1993). However transfer of highly purified 
WT CD4+ CD25+ T-cells is sufficient to prevent the autoimmunity associated 
with IL-2 deficiency. This provides direct evidence that the IL-2-/- mice have 
defects in Treg production (Malek et al. 2002). However IL-2 independent FoxP3 
induction is present in IL-2-/- mice which only contain an approximate 50% 
decrease Treg frequencies (Fontenot, Rasmussen, Gavin & A. Y. Rudensky 
2005). This casts doubt over a role for IL-2 as the sole signalling cue leading to 
FoxP3 expression, and suggests a redundancy for IL-2 with other signalling 
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events. A previous study has shown IL-2Rβ-/- mice contain thymic Treg with low 
expression of CD25, FoxP3 and the proliferation marker Ki67 (Cheng et al. 
2013). This suggests a crucial homeostatic role for IL-2 functioning to enhance 
CD25 and FoxP3 expression as well as stimulating Treg proliferation. Genetic 
mouse models which involve the selective inhibition of IL-2R signalling in the 
periphery, confirm a role for IL-2 in up-regulating FoxP3 and CD25 in the 
thymus as well as promoting expansion. These mice contained peripheral Treg 
which were unresponsive to IL-2 and showed slower growth and lower 
suppressive activity (Bayer et al. 2007). Taken together these studies indicate 
an important role for IL-2 in Treg homeostasis, however it remains uncertain if IL-
2 plays a key role in FoxP3 induction during development in the thymus.  
IL-2 belongs to the common γc cytokine family who broadly belong to the class I 
cytokine receptor superfamily. The IL-2R consists of 3 subunits, IL-2Rα (CD25), 
IL-2Rβ (CD122) and the common gamma chain (CD132). The IL-2R shares 
both CD122 and γc subunits with the IL-15R which is additionally comprised of 
the IL-15Rα. The structural similarity between the IL-15R and IL-2R has lead to 
many studies indicating varying degrees of redundancy existing between the 2 
cytokines. The IL-15R comprises of IL-15Rα, CD122 and the common gamma 
chain. CD122-/- mice have been shown to contain lower frequencies of thymic 
Treg than IL-2-/- mice, implying a contribution by IL-15 signalling in Treg biology 
(M. A. Burchill et al. 2007). However this impairment was not observed in a 
second study (Fontenot, Rasmussen, Gavin & A. Y. Rudensky 2005). Even 
though IL-2 and IL-15 contain similar receptor components, IL-15Rα deficient 
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mice are auto-immune free and contain normal frequencies of FoxP3+ cells. 
This suggests IL-2 is the main cytokine involved in Treg development and 
homeostasis.  
During steady state conditions IL-2 is produced mainly by CD4+ SP TH cells in 
secondary lymphoid organs. CD8+ SPs, NK cells and NKT cells are also 
capable of IL-2 secretion but to a lessor extent (Reviewed in Boyman & Sprent 
2012). IL-2 production is induced in T-cells following activation by antigen 
(Yang-snyder & Ellen V Rothenberg 1998). However, prolonged exposure to 
antigen leads to BLIMP1 expression which progressively reduces the capacity 
of these cells to secrete IL-2 (Kallies et al. 2009). IL-2 reporter mice show IL-2 
secretion isolated to 3 major sites, the thymus, the skin and the gut. Within 
these mice TCRαβ and TCRγδ T-cells are described as secreting ‘halos’ of IL-2 
which diffuse over many cell diameters (Yang-snyder & Ellen V Rothenberg 
1998). The pattern of expression for IL-2 seems to indicate expression is 
confined to contexts where T-cells are stimulated by antigen. Expression within 
the thymus suggests the possibility of IL-2 secretion occurring during negative 
selection, upon exposure to self-antigens. This is supported by observations of 
IL-2 being detected during T-cell apoptosis (Bassiri & Carding 2001). Therefore 
negative selection within the thymus and the establishment of central tolerance 
may play an additional role in maintaining peripheral tolerance also.  
The thymic stroma has been shown to be crucial for both central and peripheral 
tolerance. cTECs and mTECs differentiate from bipotent progenitors present in 
the embryonic and postnatal thymus (Rossi et al. 2006). Currently experimental 
    
 152 
evidence favors the terminal differentiation model for mTEC development 
(Kyewski & Klein 2006)(Gillard & Farr 2005). According to this model mTECs 
are thought to be in various stages of development, constantly proliferating, with 
less mature mTECs gradually replacing a short lived fully mature population. 
The most mature mTECs are thought to be characterised by high levels of Aire, 
CD80/86, CD40 and MHCII (Gray et al. 2007). The gradual maturation of the 
mTECs is also thought to be associated with an expansion of TSA repertoire. 
Maturation of mTECs is proposed to occur via the nuclear factor kappa B (NfκB) 
in both the canonical and non-canonical pathways. This occurs via activation of 
CD40 and RANK by CD40L and RANKL present on mature SP thymocytes 
(Akiyama et al. 2008), as well as lymphotoxin β signals from positively selected 
T-cells (White et al. 2010). The presence of mature SP thymocytes are 
therefore heavily implicated in the maturation of the thymic medulla and 
therefore both central and peripheral tolerance. We therefore examined the 
effect on de novo Treg development in TetZap70 FoxP3GFP chimeras which 
already contained a fully reconstituted lymphoid compartment. This allowed us 
to examine Treg development in mice which contain a fully reconstituted T-cell 
compartment and therefore a fully mature thymic stroma. We found no effect on 
the timing or frequency of Treg which develop in these mice. But instead found 
that a hematopoietic source of IL-2 is required for CD25Hi FoxP3+ Treg 
development. 
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Results 
Increase CD25 expression in TetZap70 FoxP3GFP mixed chimeras 
Un-induced TetZap70 FoxP3GFP mice are lymphopenic. The presence of a 
mature CD4+ SP compartment has been shown to be critical for full maturation 
of the thymic stroma (White et al. 2010)(Gill et al. 2008; Hikosaka et al. 2008). A 
fully mature stroma is heavily implicated in FoxP3 expression and the induction 
of central tolerance (Cowan et al. 2013). Therefore the lack of a mature CD4+ 
SP compartment in TetZap70 FoxP3GFP mice may suggest an immature thymic 
microenvironment leading to inefficient Treg development. In order to investigate 
this we made mixed bone marrow chimeras in which irradiated Rag1-/- hosts 
were injected with TetZap70 FoxP3GFP and T-cell depleted Bl/6 CD45.1 bone 
marrow in a 1:1 ratio (Bl/6 : TetZap70 FoxP3GFP mixed chimeras here on in). 
These mice were then left for 6 weeks to reconstitute before being fed dox and 
their thymus analysed by FACs. Zap70 induction in these mice would therefore 
be in the context of pre-existing thymic development from the WT partner cells. 
GFP+ cells were first detected on day 4 in both mixed chimeras and single 
chimera controls (Fig 3.1 A&B). The total GFP+ cell frequency as a percentage 
of CD4+ SPs and total thymus increased steadily throughout the time course 
until day 8, (Fig 3.1B). Total CD4+ SP GFP+ cell percentages were similar in 
both single and mixed chimeras. As described previously TetZap70 FoxP3GFP 
single chimeras specifically lacked a CD4+ SP GFP+ CD25High compartment 
until day 5, at which point it constituted a very small percentage of total GFP+ 
cells. However beginning with their detection on day 4, the GFP+ compartment 
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within the mixed chimeras was dominated by CD4+ SP GFP+ CD25High cells. 
The ratio of CD25High:CD25Lo cells within the GFP+ compartment of these mice 
was higher than single chimeras throughout development (Fig 3.2). Therefore 
the presence of WT Bl/6 development in Bl/6 : TetZap70 FoxP3GFP mixed 
chimeras permitted more efficient development of CD4+ SP GFP+ CD25High Treg 
cells without appearing to affect the timing or overall magnitude of Treg 
development. 
Treg exit the thymus on day 7 in TetZap70 FoxP3GFP mixed chimeras 
We next investigated the timing of Treg emigration to the periphery in Bl/6 : 
TetZap70 FoxP3GFP mixed chimeras. In order to achieve this Bl/6 : TetZap70 
FoxP3GFP mixed chimeras were fed dox for 1-13 days and their thymus and LNs 
analysed by FACs. GFP+ Treg were first detected in the LNs approximately 7 
days after dox feeding (Fig 3.3B). Interestingly CD4+ SP GFP+ CD25Lo cells 
were equally able to migrate from the thymus to the LNs as CD4+ SP GFP+ 
CD25Hi cells in both TetZap70 FoxP3GFP mixed chimeras and single chimera 
controls. The ratio of CD25Hi : CD25Lo cells present in the thymus during 
development was maintained in the periphery in mixed and single chimeras (Fig 
3.3A). We also observed increased GFP+ Treg percentages in the periphery of 
Bl/6 : TetZap70 FoxP3GFP mixed chimeras (Fig 3.3A). Therefore the presence of 
WT Bl/6 cells in mixed chimeras has no effect on the timing of Treg emigration to 
the periphery. CD25 expression levels on de novo generated Treg also appear to 
have no effect on their subsequent ability to emigrate to the periphery, where 
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we see increased GFP+ Treg percentages in mixed chimeras compared to single 
chimera controls.  
Mixed chimeras contain thymic recirculants and newly developed T-cells 
Since Bl/6 bone marrow in mixed chimeras allows induction of larger 
percentages of CD4+ SP GFP+ CD25Hi Treg, we next aimed to investigate the 
thymic composition of the mixed chimeras. We investigated the expression of 
HSA, Qa-2 and CD62L maturation markers in an attempt to determine the 
proportion of the various T-cell compartments contained within the mixed 
chimeras which had re-circulated from the periphery. The vast majority of 
CD45.1+ Bl/6 CD4+ SPs within the mixed chimeras showed high Qa-2 and low 
HSA expression levels (Fig 3.4A). This indicates the presence of a mature T-
cell compartment which has most likely re-circulated back to the thymus after 
maturation in the periphery. The CD45.1- TetZap70 FoxP3GFP cells however 
exhibited primarily low surface expression of Qa-2 while maintaining high HSA 
levels (Fig 3.4A). This is consistent with newly developed T-cells which are yet 
to fully mature and exit the thymus. However newly developed CD45.1- 
TetZap70 FoxP3GFP cells have already began to express Qa-2 and down 
regulate HSA expression. Therefore these 2 markers alone are insufficient to 
exclusively distinguish between newly developed and recirculating populations 
of T-cells. Expression of CD62L however appears to be confined primarily to 
newly developed Treg. CD45.1+ Bl/6 CD4+ SPs Treg exhibit bimodal expression of 
CD62L while de novo developed CD45.1- TetZap70 FoxP3GFP cells express 
high levels of CD62L (Fig 3.4B). Taken together this indicates Bl/6 : TetZap70 
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FoxP3GFP mixed bone marrow chimeras contain mature thymic T-cell 
populations which are not present in TetZap70 FoxP3GFP single chimeras. 
These T-cells are HSALow and Qa-2High but also appear to have low expression 
of CD62L.  
IL-2 blockade in mixed chimeras prevent GFP+ CD25High Treg development 
Next we wished to investigate the signalling cues responsible for the 
development of the prominent CD4+ GFP+ CD25Hi Treg in the Bl/6 : TetZap70 
FoxP3GFP mixed chimeras. As IL-2 is shown to both initiate FoxP3 expression 
and increase CD25 expression levels, we investigated if a thymic source of IL-2 
was responsible for the increased development of CD4+ GFP+ CD25Hi Treg in 
mixed chimeras. In order to investigate this Bl/6 : TetZap70 FoxP3GFP mixed 
chimeras along with Bl/6 controls were treated with an IL-2 blocking antibody 
every 2 days commencing 1 day before being fed dox. Their thymus was then 
analysed on day 6 by FACs. Bl/6 mice which received the IL-2 blockade 
exhibited an approximate 50% decrease in CD4+ GFP+ CD25Hi Treg while CD4+ 
GFP+ CD25Lo frequency’s were maintained when compared to PBS injected 
controls (Fig 3.5A). Bl/6 : TetZap70 FoxP3GFP mixed chimeras which received 
the IL-2 blockade completely lacked CD4+ SP GFP+ CD25Hi Treg. In contrast 
PBS injected controls maintained development of a prominent CD4+ GFP+ 
CD25Hi compartment (Fig 3.5 B&C). Therefore development of CD4+ GFP+ 
CD25Hi Treg in TetZap70 FoxP3GFP chimeras requires IL-2 and argues that the 
thymic source of IL-2 is more abundant in chimeras containing WT cells 
compared to TetZap70 FoxP3GFP single chimeras. 
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CD40-CD40L signalling does not affect Treg frequencies in mixed chimeras 
It has been shown that abrogation of CD40-CD40L signalling impedes the 
homeostasis of thymic Treg through altering IL-2 levels (Cuss & Green 2012). It 
was therefore possible that signalling through CD40 by WT Bl/6 cells was 
responsible for increased thymic IL-2 present in Bl/6 : TetZap70 FoxP3GFP 
mixed chimeras. We therefore decided to investigate a role for CD40-CD40L 
signalling in de novo Treg development in Bl/6 : TetZap70 FoxP3GFP mixed 
chimeras. To do this, we treated mixed chimeras with 0.5mg of a CD40L 
blocking antibody (MR1). The Bl/6 : TetZap70 FoxP3GFP chimeras received an 
injection of the blocking antibody every 2 days commencing one day before 
being fed dox. Their thymus was then analysed on day 6 by FACs. We 
observed a 2-fold decrease in thymic Bl/6 CD45.1+ CD4+ SP CD44Int CD25Hi 
Treg within mice which received the CD40-CD40L blockade (Fig 3.6). We also 
observed a significant but more modest decrease in Bl/6 CD45.1+ CD4+ SP 
CD44Int CD25High Treg percentages within the LNs However we saw no effect on 
CD45.1- CD4+ SP GFP+ de novo Treg development (Fig 3.6A).. Frequencies of 
total GFP+ cells remained unchanged with or without CD40L blockade, as well 
as the distribution of CD25 expression levels within the GFP+ compartment (Fig 
3.6 A&B). CD40L blockade did therefore not alter the development of CD45.1+ 
CD4+ SP CD25High Treg in mixed chimeras. We therefore provide further 
evidence for a homeostatic role for CD40-CD40L signalling in the periphery 
rather than a role in de novo Treg development. We also see no evidence for 
CD40L-CD40 signalling in regulating thymic IL-2 through observations of 
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unchanged CD25 expression levels on developing Treg, a process which we 
have shown to be IL-2 dependant (Fig 3.5).  
Treg develop in the absence of IL-2 and IL-15 signalling in mixed chimeras. 
We previously demonstrated a requirement for IL-2 and IL-15 during de novo 
Treg development in TetZap70 FoxP3GFP single chimeras. We have shown a 
stromal source of IL-15 is important for Treg development in these mice. It was 
therefore possible that stromal maturation by Bl/6 T-cells in Bl/6 : TetZap70 
FoxP3GFP mixed chimeras was enhancing stromal IL-15 signalling. Due to a 
requirement for the IL-15Rα to be trans-presented by the thymic stroma for IL-
15 signalling during T-cell development, we took advantage of IL-15Rα-/- mice 
which cannot provide IL-15 in vivo. Rag1-/- IL-15Rα-/- mice were sub-lethally 
irradiated and injected with T-cell depleted Bl/6 CD45.1+ and TetZap70 
FoxP3GFP bone marrow in a 1:1 ratio, (Bl/6 : TetZap70 FoxP3GFP - Rag1-/- IL-
15Rα-/- host mixed chimeras here on in). Chimeras were left for 6 weeks to 
reconstitute before being fed dox and analysed by FACs 6 days later. Groups of 
Bl/6 : TetZap70 FoxP3GFP - Rag1-/- IL-15Rα-/- host mixed chimeras along with 
Bl/6 : TetZap70 FoxP3GFP mixed chimeras controls were then treated with an IL-
2 blocking antibody every 2 days, commencing one day before being fed dox. 
Thymic Treg frequencies in Bl/6 : TetZap70 FoxP3GFP - Rag1-/- IL-15Rα-/- host 
mixed chimeras were unchanged from Bl/6 : TetZap70 FoxP3GFP mixed 
chimeras controls (Fig 3.7 A&B). Upon treatment with an IL-2 blocking antibody 
the prominent, GFP+ CD25High Treg population normally present in mixed 
chimeras was completely removed, in both sets of chimeras (Fig 3.7 A&C). The 
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abrogation of IL-2 signalling completely blocked development of CD4+ SP GFP+ 
CD25Hi Treg (Fig 3.7 A&C). We therefore show no effect on Treg development in 
Bl/6 : TetZap70 FoxP3GFP - Rag1-/- IL-15Rα-/- host mixed chimeras. Suggesting 
no role for T-cell dependant maturation of the thymic stroma contributing to 
development via IL-15 signalling. Instead we further confirm an essential role for 
IL-2 signalling in CD4+ SP CD25Hi Treg development.  
No evidence that stroma provide IL-2 for Treg development 
We have shown a role for the thymic stroma in IL-15 signalling during de novo 
Treg development in single chimeras (Fig 2.8). We wondered if the thymic 
stroma could also be a source of IL-2. To investigate this we sub-lethally 
irradiated Rag1-/- IL-2-/- mice and injected them with TetZap70 FoxP3GFP bone 
marrow (TetZap70 FoxP3GFP IL-2-/- host chimeras here on in). These mice were 
then left for 6 weeks to reconstitute before being fed dox and their thymus 
analysed by FACs after 6 days. The TetZap70 FoxP3GFP IL-2-/- host chimeras 
contained normal percentages of CD4+ SP and CD8+ SP T-cells (Fig 3.8A). 
Frequencies of CD4+ SP GFP+ Treg were also similar to TetZap70 FoxP3GFP 
Rag1-/- host chimera controls, CD25 expression levels on CD4+ SP GFP+ Treg 
were also unaltered (Fig 3.8B). We therefore found no evidence for a stromal 
source of IL-2. Since the stroma appeared not to be a crucial source of IL-2 
during de novo Treg development, we investigated whether there was a 
haematopoietic source of IL-2. In order to achieve this we injected Rag1-/- hosts 
with TetZap70 FoxP3GFP and IL-2-/- bone marrow in a 1:1 ratio (CD45.1+ IL-2-/- : 
TetZap70 FoP3GFP mixed chimeras here on in). After 6 weeks the CD45.1+ IL-2-
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/- : TetZap70 FoP3GFP mixed chimeras were fed dox and their thymus analysed 
by FACs. Treg frequencies within the IL-2-/- CD45.1+ compartment in CD45.1+ IL-
2-/- : TetZap70 FoP3GFP mixed chimeras were reduced compared to Bl/6 
CD45.1+ : TetZap70 FoP3GFP mixed chimera controls (Fig 3.9). This is 
consistent with previous observations made regarding Treg frequencies in IL-2-/- 
mice (Fontenot, Rasmussen, Gavin & A. Y. Rudensky 2005). CD45.1+ IL-2-/- : 
TetZap70 FoP3GFP mixed chimeras contained reduced frequencies of CD45.1- 
GFP+ Treg. The GFP+ de novo Treg within the chimeras also expressed much 
lower levels of CD25 when compared to Bl/6 control chimeras (Fig 3.9A). This 
suggests a hematopoietic source of IL-2 for de novo Treg development. However 
we noted that CD45.1+ IL-2-/- : TetZap70 FoP3GFP mixed chimeras also 
contained an enlarged CD4+ SP Tmem cell compartment along with signs of 
thymic involution. This may be a result of autoimmunity due to peripheral 
reconstitution with IL-2-/- cells. The effects of this on de novo Treg development 
can therefore not be excluded. Taken together these data further suggest a 
hematopoietic source of IL-2 which is necessary for efficient CD4+ SP GFP+ 
CD25Hi Treg development.  
TCR transgenic T-cells do not enhance GFP+ CD25High Treg development 
Next we aimed to identify the cell type within the hematopoietic compartment 
which was responsible for enhancing development of CD4+ SP GFP+ CD25Hi 
Treg in the TetZap70 FoxP3GFP mixed chimeras. IL-2 is reported to be produced 
in activated CD4+ SP and CD8+ SP and to a lesser extent activated DCs 
(Reviewed in Malek 2008). We therefore took advantage of OT1 and OTII TCR 
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transgenic mice which are MHCII and MHCII restricted expressing TCR specific 
for OVA peptide. 
Developing T-cells within these mice are restricted to the CD8+ SP and CD4+ 
SP lineage respectively. In order to investigate the role played by CD4+ SP T-
cells in Treg development we made mixed bone marrow chimeras containing 
TetZap70 FoxP3GFP and either OTII Rag1-/- or OTI Rag1-/- bone marrow in a 1:1 
ratio (OTI/OTII : TetZap70 FoxP3GFP mixed chimeras here on in). OTII : 
TetZap70 FoxP3GFP mixed chimeras and TetZap70 FoxP3GFP single chimera 
controls were left for 6 weeks to reconstitute before being fed dox and their 
thymus analysed by FACS. OTII : TetZap70 FoxP3GFP mixed chimeras 
contained approximately 50% Vα2+ HuCD2- OTII T-cells, which were restricted 
to the CD4+ SP lineage (Fig 3.10A). When excluding Vα2+ HuCD2- CD4+ SP 
OTII T-cells, we observed no effect on CD4+ SP GFP+ Treg development in OTII 
mixed bone marrow chimeras compared to TetZap70 FoxP3GFP single chimera 
controls. CD25 expression levels on GFP+ cells remained lower than in Bl/6 : 
TetZap70 FoxP3GFP mixed chimeras in both sets of mice (Fig 3.10B). 
Generating similar chimeras using OTI bone marrow generated similar 
observations (Fig 3.10C). These data suggest that solely restoring positive 
selection of either CD4+ SP or CD8+ SP T-cells is not sufficient to support CD4+ 
SP GFP+ CD25Hi Treg development by IL-2 secretion. As OTI and OTII TCR 
transgenic T-cells fail to undergo negative selection, this would suggest a 
possible role for negative selection in the supply sufficient quantities of thymic 
IL-2. However this data is also consistent with the requirement for an additional 
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hematopoietic cell type which is not present in the OTII : TetZap70 FoxP3GFP 
mixed chimeras such as Treg of Tmem cells. 
IL-2 dependant CD25Hi Treg development does not require Tmem or Treg 
We have shown that significant proportions of thymic T-cells have re-circulated 
from the periphery. As T-cell activation accompanies IL-2 production (Naramura 
et al. 1998) we next investigated the recirculation of activated T-cell populations 
as a source of IL-2 for de novo Treg development. To achieve this we took 
advantage of IKK2 Fl/Fl CD4 Cre R26 mice. These contain naïve CD4+ SP T-
cells but lack both Tmem and Treg cells. We injected Rag1-/- mice with TetZap70 
FoxP3GFP and IKK2 Fl/Fl CD4 Cre R26 or IKK2 Fl/WT R26 bone marrow in a 1:1 
ratio (IKK2 Fl/Fl : TetZap70 FoxP3GFP mixed chimeras here on in). IKK2 Fl/Fl : 
TetZap70 FoxP3GFP mixed chimeras therefore allow analysis of de novo Treg 
development in the presence of polyclonal CD4+ and CD8+ SPs while excluding 
Tmem and Treg cells. After 6 weeks reconstitution chimeras were fed dox and 
their thymus analysed by FACs. As expected YFP+ CD4+ SP cells completely 
lacked CD44Int CD25Hi Treg along with CD44Hi CD25Lo Tmem cells when compared 
to IKK Fl/WT mixed chimera controls (Fig 3.11). YFP- cells in both IKK2 Fl/Fl and 
IKK2 Fl/WT TetZap70 FoxP3GFP mixed chimeras contained large percentages of 
CD4+ SP GFP+ CD25Hi Treg (Fig 3.11). These data indicate that Tmem and Treg 
cells are not required for the IL-2 dependant generation of CD4+ SP GFP+ 
CD25Hi Treg. This is also consistent but not indicative of a requirement for a 
polyclonal T-cell compartment for efficient Treg induction. T-cells in IKK2 Fl/Fl : 
TetZap70 FoxP3GFP mixed chimeras contain polyclonal TCRs. Therefore unlike 
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the TCR transgenic OTI/OTII : TetZap70 FoxP3GFP mixed chimeras cells in the 
thymus of IKK2 Fl/Fl : TetZap70 FoxP3GFP mixed chimeras are undergoing 
negative selection. As IL-2 secretion occurs upon activation of the TCR, IL-2 
production in the thymus may reflect T-cells undergoing negative selection as T-
cell activation accompanies this (Naramura et al. 1998). 
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Figure 3.1 Bl/6 CD45.1:TetZap70 FoxP3GFP mixed chimeras. 
 
Rag1-/ mice were irradiated and injected with 3M T-cell depleted Bl/6 CD45.1 
bone marrow cells along with 3M TetZap70 FoxP3GFP bone marrow cells in a 
single iv injection. Alternatively Rag1-/- mice were injected with 3M TetZap70 
FoxP3GFP bone marrow cells alone, as controls. Bone marrow was harvested, 
T-cell depleted and injected as described in materials and methods. The 
resulting chimeras were left for 6 weeks to reconstitute before being fed dox for 
3-7 days and analysed by FACs. A: FACs plots comparing CD25 and GFP 
expression on CD45.1- TCRHi CD5HI CD4+ SP thymocytes from TetZap70 
FoxP3GFP single chimeras (Top panel) or Bl/6 CD45.1 : TetZap70 FoxP3GFP 
mixed chimeras (bottom panel), after 3-7 days of dox feeding. B: Line graphs 
comparing CD45.1- TCRHi CD5Hi CD4+ SP GFP+ frequency in TetZap70 
FoxP3GFP single chimeras (blue) or Bl/6 CD45.1 : TetZap70 FoxP3GFP mixed 
chimeras (red). Frequencies expressed as a percentage of TCRHi CD5Hi CD4+ 
SPs (left) or as a percentage of total thymocytes (right). 
 
 
 
  
    
 166 
 
  
1 2 3 4 5 6 7
0.0
0.2
0.4
0.6
0.8
1.0
%
 C
D
4+
 S
P
1 2 3 4 5 6 7
0.0
0.2
0.4
0.6
0.8
1.0
Time (d)
%
 C
D
4+
 S
P
3.2
Single
Mixed
 CD4+ GFP+ CD25 High
CD4+ GFP+ CD25Low
    
 167 
Figure 3.2 Prominent GFP+ CD25Hi compartment in mixed chimeras. 
 
Rag1-/ mice were irradiated and injected with 3M T-cell depleted Bl/6 CD45.1 
bone marrow cells along with 3M TetZap70 FoxP3GFP bone marrow cells in a 
single iv injection. Alternatively Rag1-/- mice were injected with 3M TetZap70 
FoxP3GFP bone marrow cells alone, as controls. Bone marrow was harvested, 
T-cell depleted and injected as described in materials and methods. The 
resulting chimeras were left for 6 weeks to reconstitute before being fed dox for 
0-7 days and analysed by FACs. Bar graphs showing the frequency of TCRHi 
CD5Hi CD4+ SP GFP+ CD25Hi cells (red) or TCRHi CD5Hi CD4+ SP GFP+ CD25Lo 
cells (blue) as a percentage of TCRHi CD5Hi CD4+ SPs each day after dox 
feeding, for the TetZap70 FoxP3GFP single chimeras (top) and Bl/6 CD45.1: 
TetZap70 FoxP3GFP mixed chimeras (bottom).  
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Figure 3.3 GFP+ CD25Hi and CD25Lo cells in mixed chimera LNs. 
 
Rag1-/ mice were irradiated and injected with 3M T-cell depleted Bl/6 CD45.1 
bone marrow cells along with 3M TetZap70 FoxP3GFP bone marrow cells in a 
single iv injection. Alternatively Rag1-/- mice were injected with 3M TetZap70 
FoxP3GFP bone marrow cells alone, as controls. Bone marrow was harvested, 
T-cell depleted and injected as described in materials and methods. The 
resulting chimeras were left for 6 weeks to reconstitute before being fed dox for 
0-13 days before analysis of thymocytes and LN cells by FACs. A: FACs plots 
comparing CD25 and GFP expression on thymocytes (left) and LN cells (right) 
of CD45.1- TCRHi CD5HI CD4+ SP cells from TetZap70 FoxP3GFP single 
chimeras (Top panel) or Bl/6 CD45.1 : TetZap70 FoxP3GFP mixed chimeras 
(bottom panel). B: Line graphs comparing CD45.1- TCRHi CD5Hi CD4+ SP GFP+ 
LN cell frequency Bl/6 CD45.1 : TetZap70 FoxP3GFP mixed chimeras. 
Frequencies expressed as a percentage of total TCRHi CD5Hi CD4+ SPs LN 
cells (left) and absolute Ln cell number (right). 
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Figure 3.4 Mixed chimeras contain mature recirculant T-cell populations 
 
Rag1-/ mice were irradiated and injected with 3M T-cell depleted Bl/6 CD45.1 
bone marrow cells along with 3M TetZap70 FoxP3GFP bone marrow cells in a 
single iv injection. Bone marrow was harvested, T-cell depleted and injected as 
described in materials and methods. The resulting chimeras were left for 6 
weeks to reconstitute and fed dox for 13 days before the thymus was analysed 
by FACs. A: FACs plots comparing HSA and Qa-2 expression on TCRHi CD5Hi 
CD4+ SPs (top) and TCRHi CD5Hi CD4+ SP GFP+ Treg (bottom) from Bl/6 
CD45.1+ cells (left) or CD45.1- TetZap70 FoxP3GFP cells (right) from within the 
same Bl/6: TetZap70 FoxP3GFP mixed chimeras. B: Histograms comparing L-
selectin (CD62L), HSA and Qa-2 expression on TCRHi CD5Hi CD4+ SP CD25Hi 
CD44Int Treg from the CD45.1+ Bl/6 compartment (red) and CD45.1- TetZap70 
FoxP3GFP compartment (blue) of d13 dox fed Bl/6 CD45.1: TetZap70 FoxP3GFP 
mixed chimeras.  
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Figure 3.5 Reduced CD25 expression on mixed chimeras treated with an 
IL-2 blockade 
 
Rag1-/ mice were irradiated and injected with 3M T-cell depleted Bl/6 CD45.1 
bone marrow cells along with 3M TetZap70 FoxP3GFP bone marrow cells in a 
single iv injection. Bone marrow was harvested, T-cell depleted and injected as 
described in materials and methods. The resulting Chimeras were left for 6 
weeks to reconstitute before being treated with 1mg of an IL-2 blocking antibody 
along with Bl/6 FoxP3GFP controls via a single ip injection (0.5mg JES6-5H4, 
0.5mg S4B6). The following day chimeras were fed dox, receiving additional 
does of blocking antibody or PBS, along with Bl/6 controls, every 2 days until 
day 6 when the thymus was analysed by FACs. A: FACs plots comparing GFP 
and HSA expression on TCRHi CD5Hi CD4+ SPs from Bl/6 FoxP3GFP mice 
treated with an IL-2 blocking antibody (right) or PBS (left). B: FACs plots 
comparing CD25 and GFP expression on d6 TCRHi CD5Hi CD4+ SP thymocytes 
from PBS treated (left) and IL-2 blocked (right) Bl/6 CD45.1:TetZap70 FoxP3GFP 
mixed chimeras. C: Bar charts showing d6 TCRHi CD5Hi CD4+ SP GFP+ 
thymocyte frequency, with or without IL-2 blockade. Thymocytes have then 
been further subdivided depending on CD25 expression, CD25High (red) or 
CD25Low (blue) Frequencies displayed as a percentage of TCRHi CD5Hi CD4+ 
SPs. 
 
 
    
 174 
 
  
0
5
10
15
20
25
%
 C
D
4+
 S
P
CD40L blockade - + - +
Thymus LN
*ns
Fig Layout
14/2/13 11:41 Page 1 of 2 (FlowJo v9.5.2)
Mature
Sample_Controls_13_T4.fcs
Event Count: 32983
Mature
Sample_MR1-Treated_14_T1.fcs
Event Count: 27450
Mature
Sample_Controls_13_T4.fcs
Event Count: 25080
Time
Sample_MR1-Treated_14_T1.fcs
Event Count: 32423
Ly5.1+
Sample_Controls_21_L4.fcs
Event Count: 81577
Ly5.1+
Sample_MR1_22_L1.fcs
Event Count: 24334
Sample %
Sample_MR1-Treated_14_T1.fcs 0.766
Fig Layout
14/2/13 11:41 Page 1 of 2 (FlowJo v9.5.2)
Mature
Sample_Controls_13_T4.fcs
Event Count: 32983
Mature
Sample_MR1-Treated_14_T1.fcs
Event Count: 27450
Mature
Sample_Controls_13_T4.fcs
Event Count: 25080
Time
Sample_MR1-Treated_14_T1.fcs
Event Count: 32423
Ly5.1+
Sample_Controls_21_L4.fcs
Event Count: 81577
Ly5.1+
Sample_MR1_22_L1.fcs
Event Count: 24334
Sample %
Sample_MR1-Treated_14_T1.fcs 0.766
Fig Layout
14/2/13 11:41 Page 1 of 2 (FlowJo v9.5.2)
Mature
Sample_Controls_13_T4.fcs
Event Count: 32983
Mature
Sample_MR1-Treated_14_T1.fcs
Event Count: 27450
Mature
Sample_Controls_13_T4.fcs
Event Count: 25080
Time
Sample_MR1-Treated_14_T1.fcs
Event Count: 32423
Ly5.1+
Sample_Controls_21_L4.fcs
Event Count: 81577
Ly5.1+
Sample_MR1_22_L1.fcs
Event Count: 24334
Sample %
Sample_MR1-Treated_14_T1.fcs 0.766
Fig Layout
14/2/13 11:41 Page 1 of 2 (FlowJo v9.5.2)
Mature
Sample_Controls_13_T4.fcs
Event Count: 32983
Mature
Sample_MR1-Treated_14_T1.fcs
Event Count: 27450
Mature
Sample_Controls_13_T4.fcs
Event Count: 25080
Time
Sample_MR1-Treated_14_T1.fcs
Event Count: 32423
Ly5.1+
Sample_Controls_21_L4.fcs
Event Count: 81577
Ly5.1+
Sample_MR1_22_L1.fcs
Event Count: 24334
Sample %
Sample_MR1-Treated_14_T1.fcs 0.766
Fig Layout
14/2/13 11:41 Page 1 of 2 (FlowJo v9.5.2)
Mature
Sample_Controls_13_T4.fcs
Event Count: 32983
Mature
Sample_MR1-Treated_14_T1.fcs
Event Count: 27450
Mature
Sample_Controls_13_T4.fcs
Event Count: 25080
Time
Sample_MR1-Treated_14_T1.fcs
Event Count: 32423
Ly5.1+
Sample_Controls_21_L4.fcs
Event Count: 81577
Ly5.1+
Sample_MR1_22_L1.fcs
Event Count: 24334
Sample %
Sample_MR1-Treated_14_T1.fcs 0.766
Fig Layout
14/2/13 11:41 Page 1 of 2 (FlowJo v9.5.2)
Mature
Sample_Controls_13_T4.fcs
Event Count: 32983
Mature
Sample_MR1-Treated_14_T1.fcs
Event Count: 27450
Mature
Sample_Controls_13_T4.fcs
Event Count: 25080
Time
Sample_MR1-Treated_14_T1.fcs
Event Count: 32423
Ly5.1+
Sample_Controls_21_L4.fcs
Event Count: 81577
Ly5.1+
Sample_MR1_22_L1.fcs
Event Count: 24334
Sample %
Sample_MR1-Treated_14_T1.fcs 0.766
GFP
C
D
25
CD44
Thymus LN
CD45.1- CD45.1+ CD45.1+
0.54
0.31
0.40
0.33
16.6 19.5
6.25 13.2
PBS
CD40L 
blockade
CD4+ TCRHi CD5Hi:
A
B
3.6
0 2 4 6 8 10 12
0.01
0.10
1
10
Time (d)
%
 C
D
4+
 S
P
PBS
CD40L blockade
Historical
CD45.1- CD45.1+C
    
 175 
Figure 3.6 Normal Treg frequencies in CD40L blocked mixed chimeras  
 
Rag1-/ mice were irradiated and injected with 3M T-cell depleted Bl/6 CD45.1 
bone marrow cells along with 3M TetZap70 FoxP3GFP bone marrow cells in a 
single iv injection. Bone marrow was harvested, T-cell depleted and injected as 
described in materials and methods. The resulting Chimeras were left for 6 
weeks to reconstitute before being treated with 0.5 mg of a CD40L blocking 
antibody via a single ip injection (MR1). The following day chimeras were fed 
dox, receiving additional does of blocking antibody or PBS every 2 days until 
day 6 when the thymus and LNs were analysed by FACs. A: FACs plots 
comparing thymocytes GFP and HSA expression (far left) or CD25 and CD44 
expression (middle, right) on TCRHi CD5Hi CD4+ SPs from Bl/6 CD45.1: 
TetZap70 FoxP3GFP mice treated with PBS (top) or a CD40L blocking antibody 
(bottom). B:  Line graph comparing CD45.1- TCRHi CD5Hi CD4+ SP GFP+ 
thymocyte frequency from Bl/6 CD45.1 : TetZap70 FoxP3GFP mixed chimeras 
treated with PBS (blue) or CD40L blockade (red) compared to historical Bl/6 
CD45.1 : TetZap70 FoxP3GFP mixed chimera time course data. Frequencies 
expressed as a percentage of TCRHi CD5Hi CD4+ SP cells. C: CD45.1+ TCRHi 
CD5Hi CD4+ SP CD25Hi CD44Int frequency in Bl/6 CD45.1 : TetZap70 FoxP3GFP 
mixed chimera thymus (left) or LN (right) treated with PBS (blue) or CD40L 
blockade (red). Frequencies expressed as a percentage of TCRHi CD5Hi CD4+ 
SP cells. 
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Figure 3.6 Normal Treg frequencies in CD40L blocked mixed chimeras  
 
Rag1-/ mice were irradiated and injected with 3M T-cell depleted Bl/6 CD45.1 
bone marrow cells along with 3M TetZap70 FoxP3GFP bone marrow cells in a 
single iv injection. Bone marrow was harvested, T-cell depleted and injected as 
described in materials and methods. The resulting Chimeras were left for 6 
weeks to reconstitute before being treated with 0.5 mg of a CD40L blocking 
antibody via a single ip injection (MR1). The following day chimeras were fed 
dox, receiving additional does of blocking antibody or PBS every 2 days until 
day 6 when the thymus and LNs were analysed by FACs. A: FACs plots 
comparing thymocytes GFP and HSA expression (far left) or CD25 and CD44 
expression (middle, right) on TCRHi CD5Hi CD4+ SPs from Bl/6 CD45.1: 
TetZap70 FoxP3GFP mice treated with PBS (top) or a CD40L blocking antibody 
(bottom). B:  Line graph comparing CD45.1- TCRHi CD5Hi CD4+ SP GFP+ 
thymocyte frequency from Bl/6 CD45.1 : TetZap70 FoxP3GFP mixed chimeras 
treated with PBS (blue) or CD40L blockade (red) compared to historical Bl/6 
CD45.1 : TetZap70 FoxP3GFP mixed chimera time course data. Frequencies 
expressed as a percentage of TCRHi CD5Hi CD4+ SP cells. C: CD45.1+ TCRHi 
CD5Hi CD4+ SP CD25Hi CD44Int frequency in Bl/6 CD45.1 : TetZap70 FoxP3GFP 
mixed chimera thymus (left) or LN (right) treated with PBS (blue) or CD40L 
blockade (red). Frequencies expressed as a percentage of TCRHi CD5Hi CD4+ 
SP cells. 
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Figure 3.7 Characterisation of IL-15R Rag1-/- host mixed chimeras 
 
IL-15R-/- Rag1-/- or Rag1-/- mice were irradiated and injected with 3M T-cell 
depleted Bl/6 CD45.1 bone marrow cells along with 3M TetZap70 FoxP3GFP 
bone marrow cells in a single iv injection. Bone marrow was harvested, T-cell 
depleted and injected as described in materials and methods. The resulting 
Chimeras were left for 6 weeks to reconstitute before being treated with either 
PBS or 1mg of an IL-2 blocking antibody (0.5mg JES6-5H4 + 0.5mg S4B6) via 
a single ip injection (MR1). The following day chimeras were fed dox, receiving 
additional doses of blocking antibody or PBS every 2 days until day 6 when the 
thymocytes were analysed by FACs. A: FACs plots comparing thymocytes GFP 
and HSA expression on CD45.1- TCRHi CD5Hi CD4+ SPs from Bl/6 CD45.1: 
TetZap70 FoxP3GFP IL-15R-/- Rag1-/- (Right panel) or Rag1-/- (left panel) host 
mixed chimeras. Mice treated with PBS (top) or an IL-2 blocking antibody 
(bottom). B: Line graph comparing CD45.1- TCRHi CD5Hi CD4+ SP GFP+ 
thymocyte frequency from Bl/6 CD45.1 : TetZap70 FoxP3GFP mixed chimeras in 
IL-15R-/- Rag1-/- (red) or Rag1-/- (blue) hosts. Historical Bl/6 CD45.1 : TetZap70 
FoxP3GFP mixed chimera Rag1-/- hosts in grey. Frequencies expressed as a 
percentage of TCRHi CD5Hi CD4+ SP cells (left) or total thymocytes (right). C: 
Bar charts showing CD45.1- TCRHi CD5Hi CD4+ SP GFP+ thymocyte frequency 
in IL-15R-/- Rag1-/- or Rag1-/- chimeras (left) with or without IL-2 blockade (right). 
Thymocytes have then been further subdivided depending on CD25 expression 
(right) into CD25High (red) or CD25Low (blue) Frequencies displayed as a 
percentage of TCRHi CD5Hi CD4+ SPs. 
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Figure 3.8 Non-stromal source of IL-2 required for CD25Hi Treg induction 
 
IL-2-/- Rag1-/- or Rag1-/- mice were irradiated and injected with 3M TetZap70 
FoxP3GFP bone marrow cells in a single iv injection. Bone marrow was 
harvested and injected as described in materials and methods. The resulting 
chimeras were left for 6 weeks to reconstitute before being fed dox until day 6 
when the thymocytes were analysed by FACs. A: FACs plots comparing CD4 
and CD8 expression on live singlets from IL-2-/- Rag1-/- (top right) or Rag1-/- (top 
left) host TetZap70 FoxP3GFP chimeras. (bottom panel) FACs plots comparing 
CD25 and GFP expression on TCRHi CD5Hi CD4+ SP GFP+ thymocytes in IL-2-/- 
Rag1-/- (bottom right) or Rag1-/- (bottom left) host TetZap70 FoxP3GFP chimeras.  
B: Bar charts showing CD45.1- TCRHi CD5Hi CD4+ SP GFP+ thymocyte 
frequency in IL-2-/- Rag1-/- or Rag1-/- chimeras (left). Thymocytes have then 
been further subdivided depending on CD25 expression (right) into CD25High 
(red) or CD25Low (blue) Frequencies displayed as a percentage of TCRHi CD5Hi 
CD4+ SPs. 
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Figure 3.9 Hematopoietic source of IL-2 required for CD25Hi Treg induction. 
 
Rag1-/- mice were irradiated and injected with 3M TetZap70 FoxP3GFP bone 
marrow cells and either 3M Bl/6 CD45.1 (Bl/6 CD45.1:TetZap70 FoxP3GFP) or 
3M IL-2-/- bone marrow cells (IL-2-/-:TetZap70 FoxP3GFP) in a single iv injection. 
Bone marrow was harvested, T-cell depleted and injected as described in 
materials and methods. The resulting chimeras were left for 6 weeks to 
reconstitute before being fed dox until day 6 when the thymocytes were 
analysed by FACs. FACs plots comparing GFP and CD25 expression (left) on 
CD45.1- TCRHi CD5Hi CD4+ SP thymocytes from IL-2-/-:TetZap70 FoxP3GFP 
mixed chimeras (bottom) or Bl/6 CD45.1:TetZap70 FoxP3GFP mixed chimeras 
(top). FACs plots comparing CD44 and CD25 expression (right panel) on 
CD45.1+ TCRHi CD5Hi CD4+ SP thymocytes from IL-2-/-:TetZap70 FoxP3GFP 
mixed chimeras (bottom) or Bl/6 CD45.1:TetZap70 FoxP3GFP mixed chimeras 
(top). 
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Figure 3.10 TCR transgenic TetZap70 FoxP3GFP mixed chimeras 
 
Rag1-/- mice were irradiated and injected with 3M TetZap70 FoxP3GFP bone 
marrow cells and 3M OTII or OTI bone marrow cells (OTII/OTI:TetZap70 
FoxP3GFP) contained within  a single iv injection. Irradiated Rag1-/- mice were 
also injected with 3M TetZap70 FoxP3GFP only, as controls. Bone marrow was 
harvested and injected as described in materials and methods. The resulting 
chimeras were left for 6 weeks to reconstitute before being fed dox until day 6 
when the thymocytes were analysed by FACs. A: FACs plots comparing CD4 
and CD8 expression (top panel) on live singlets (left) or Vα2+ live singlets (right) 
from OTII/OTI:TetZap70 FoxP3GFP chimeras (right) and TetZap70 FoxP3GFP 
chimers (left). (bottom panel) FACs plots comparing HuCD2 and Vα2 
expression on TCRHi CD5+ CD4+ SPs for OTII/OTI:TetZap70 FoxP3GFP 
chimeras (right) and TetZap70 FoxP3GFP chimers (left). B: FACs plots 
comparing CD25 and GFP on TCRHi CD5+ CD4+ SP Vα2- cells from 
OTII/OTI:TetZap70 FoxP3GFP chimeras (right) and TetZap70 FoxP3GFP chimers 
(left). C: Bar chart showing frequencies of TCRHi CD5+ CD4+ SP Vα2- GFP+ 
CD25Hi  (red) and CD25Lo (Blue) cells from OTII:TetZap70 FoxP3GFP, 
OTI:TetZap70 FoxP3GFP and TetZap70 FoxP3GFP chimeras, as a percentage of 
TCRHi CD5+ CD4+ SP Vα2- cells.  
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Figure 3.11 IKK2Fl/Fl CD4 Cre R26:TetZap70 FoxP3GFP Rag1-/- host chimeras 
 
Rag1-/- mice were irradiated and injected with 3M TetZap70 FoxP3GFP bone 
marrow cells and 3M IKK2Fl/Fl CD4 Cre R26 bone marrow cells (IKK2Fl/Fl CD4 
Cre R26:TetZap70 FoxP3GFP) or IKK2Fl/WT CD4 Cre R26 bone marrow cells 
(IKK2Fl/WT CD4 Cre R26:TetZap70 FoxP3GFP) contained within  a single iv 
injection. Bone marrow was harvested and injected as described in materials 
and methods. The resulting chimeras were left for 6 weeks to reconstitute 
before being fed dox until day 10 when the thymocytes were analysed by FACs. 
FACs plots comparing CD44 and CD25 expression (left panel) on TCRHi CD5+ 
CD4+ SP YFP+ cells from IKK2Fl/Fl CD4 Cre R26:TetZap70 FoxP3GFP mixed 
chimeras (bottom) or IKK2Fl/WT CD4 Cre R26:TetZap70 FoxP3GFP mixed 
chimeras (top). FACs plots comparing GFP and CD25 expression (right panel) 
on TCRHi CD5+ CD4+ SP YFP- cells from IKK2Fl/Fl CD4 Cre R26:TetZap70 
FoxP3GFP mixed chimeras (bottom) or IKK2Fl/WT CD4 Cre R26:TetZap70 
FoxP3GFP mixed chimeras (top). 
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Discussion 
IL-2 has long been thought to play a central role in Treg development and 
homeostasis. However its role during thymic Treg development remains only 
partially understood. In this study we confirm IL-2 dependant generation of 
CD4+ SP CD25Hi GFP+ Treg. TetZap70 FoxP3GFP single chimeras appeared to 
lack the ability to drive efficient development of CD25Hi GFP+ Treg. Enhanced 
development in Bl/6 : TetZap70 FoxP3GFP mixed chimeras appeared to be due 
to the presence of an IL-2 producing cellular compartment which was reduced in 
TetZap70 FoxP3GFP single chimeras. We speculate a haematopoietic source for 
this IL-2-producing cell type, which is most likely derived from the Bl/6 WT bone 
marrow. IL-2 is predominantly produced by activated CD4+ SPs and to a lesser 
extent CD8+ SP T-cells. Activated DCs, NK and NKT cells may also produce IL-
2, however the biological relevance of IL-2 production by these cell types 
remains incompletely understood (Reviewed in Malek 2008). It has been shown 
that activated CD4+ SPs are the primary producers of IL-2 in the immune 
system (Naramura et al. 1998). This is inconsistent with our observations made 
in TetZap70 FoxP3GFP mixed chimeras using TCR Tg partner bone marrow. 
MHCII restricted CD4+ SP OTII TCR transgenic T-cells were incapable of 
supporting CD4+ SP CD25Hi GFP+ Treg development. As IL-2 is secreted by T-
cells upon activation (Yang-snyder & Ellen V Rothenberg 1998), the absence of 
cognate ligand in the OTII chimeras would have lead to no T-cell activation and 
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IL-2 production. Such a scenario may suggest that peripherally derived Tmem 
cells could be the primary source of thymic IL-2, which they secrete after 
recirculating back into the thymus. We previously demonstrated the recirculation 
of mature T-cells into the thymus in chapter 1. Mature CD4+ SP and CD8+ SP T-
cells were shown to recirculate back to the thymus of TetZap70 FoxP3GFP mice. 
However these did not support efficient CD4+ SP CD25Hi GFP+ Treg generation, 
casting doubt over the role played by mature recirculating cells as a source of 
IL-2 in the thymus. Further doubt over a role for recirculating activated T-cells 
comes from IKK2 Fl/Fl CD4-Cre R26 TetZap70 FoxP3GFP mixed chimeras which 
were able to support efficient CD4+ SP CD25Hi GFP+ Treg development in the 
absence of an activated memory T-cell compartment. Taken together it seems 
unlikely that IL-2 from a recirculant activated T memory cell population is driving 
CD4+ SP CD25Hi GFP+ Treg generation. However a further explanation for the 
OTII mixed chimeras inability to support CD4+ SP CD25Hi GFP+ Treg generation 
is sub-optimal TCR stimulation during thymic selection. As T-cells in the thymus 
of TCR transgenic mixed chimeras are selected on self-antigens it remains a 
possibility that competition by identical TCR clones for similar epitopes may 
have lead to sub-optimal TCR stimulation during selection. This scenario could 
suggest a role for positive and negative selection as the main source of thymic 
IL-2. This is supported by data from IKK2 Fl/Fl CD4-Cre R26 TetZap70 
FoxP3GFP mixed chimeras which contain naïve polyclonal CD4+ SPs and were 
able to support CD4+ SP CD25Hi GFP+ Treg generation. T-cells in these mice 
may have received stronger selection signals due to less competition for thymic 
epitopes, leading to increased T-cell activation and IL-2 secretion. Previous 
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studies have also found an important role for IL-2 in generating CD25Hi FoxP3+ 
Treg, however to our knowledge no work to date has focussed on the source of 
this thymic IL-2. Previous studies suggest that thymic IL-2 is most likely to be T-
cell derived, as bone marrow chimeras using IL-2 deficient donors and WT 
hosts were phenotypically similar to that of IL-2 deficient mice (Tai et al. 2005). 
IL-2 was also shown to exert its effect in a paracrine manner as IL-2 deficient 
and sufficient cells showed equal expression of CD25. Furthermore it has been 
shown that T-cells undergoing apoptosis can release IL-2 (Bassiri & Carding 
2001). These studies would seem to support our suggestion of a role for T-cells 
undergoing negative selection as a source of paracrine IL-2 in the thymus in 
order to drive efficient CD4+ SP CD25Hi GFP+ Treg generation. 
Most studies focus on IL-2 as the primary signalling cue which initiates FoxP3 
induction. Previous studies have shown that the first detectable FoxP3+ cells in 
neonates have high surface expression of CD25 (Fontenot, Rasmussen, 
Williams, et al. 2005)(Cheng et al. 2013). This has been put forward as support 
for Treg developing via a CD25Hi FoxP3- precursor population in an IL-2 
dependant manner. However we show IL-2 independent FoxP3 induction in 
mixed chimeras treated with an IL-2 blocking mAb. In these mice we see Treg 
developing with low expression of CD25. IL-2 producing T-cells can be found in 
neonates from day 14 of gestation (Yang-Snyder & E V Rothenberg 1998). 
Neonatal development may therefore be analogous to that of the mixed 
chimeras, in which IL-2 producing cells cause Treg to rapidly increase CD25 
expression without necessarily directly inducing FoxP3. We did however 
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observe decreased Treg frequencies in TetZap70 FoxP3GFP mixed chimeras 
which received the mAb blockade. It therefore remains a possibility that an IL-2 
dependant and independent routes of development exist. CD25Hi FoxP3- cells 
may be driven to express FoxP3 by IL-2, becoming CD25Hi FoxP3+ cells. While 
CD25Lo FoxP3+ cells may develop independently of the IL-2 signal. IL-2 
blockade in TetZap70 FoxP3GFP mixed chimeras may block the IL-2 dependant 
development and leave the second route of development intact, leading to 
decreased Treg frequencies. If true this would further support a 2 step model for 
IL-2 dependant FoxP3 expression. IL-2 however is not only implicated in FoxP3 
induction but suggested to play a crucial role in Treg expansion and homeostasis 
(Reviewed in Malek 2008). A recent study has shown that in the absence of IL-
2Rβ signalling Treg develop predominantly CD25Lo and express low levels of the 
proliferation marker Ki67 (Cheng et al. 2013). Reduced Treg frequencies in 
mixed chimeras which received the IL-2 mAb blockade could therefore be 
explained by reduced proliferation of Treg in the absence of an IL-2 signal. 
Further to this we observe increased Treg frequencies in TetZap70 FoxP3GFP 
mice treated with IL-2-mAb complex. Bl/6 : TetZap70 FoxP3GFP mixed chimeras 
contain a hematopoietic source of IL-2 which could support enhanced Treg 
proliferation compared to single chimera controls. This proliferative capacity 
appears to be most likely occurring at later time points when Treg frequencies 
are at their highest.  
An additional explanation for the increased frequencies of Treg observed in Bl/6 : 
TetZap70 FoxP3GFP mixed chimeras is the maturation of the thymic stroma. Un
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induced TetZap70 FoxP3GFP mice completely lack a T-cell compartment. 
Development in these mice is therefore analogous to that of a neonate, in which 
mature T-cells have not yet developed. A fully mature thymic T-cell 
compartment has been shown to be crucial for the development of a fully 
mature thymic microenvironment. Activation of CD40 and RANK by CD40L and 
RANKL on mature SPs supply signals leading to the maturation of the thymic 
stromal cells (Akiyama et al. 2008). Lymphotoxin β signals have also been 
shown to be crucial for the differentiation of involucrin+ mTECs, a specific 
subset of terminally differentiated mTECs which are themselves implicated in 
Treg development (White et al. 2010)(Cowan et al. 2013). A fully mature T-cell 
compartment may therefore be essential to ensure maturation of the thymic 
stroma and maintenance of central and peripheral tolerance. TetZap70 
FoxP3GFP mixed chimeras unlike TetZap70 FoxP3GFP single chimeras contain a 
full T-cell compartment. Development in these mice is therefore more analogous 
to that of development in an adult mouse. We showed increased Treg 
frequencies in TetZap70 FoxP3GFP mixed chimeras at later time points 
compared to single chimera controls. It therefore remains a possibility that in the 
presence of a fully mature thymic stroma TetZap70 FoxP3GFP mixed chimeras 
are more able to support efficient Treg development, leading to increased 
frequencies. This however fails to account for the increased expression on 
CD25 on developing Treg. Using IL-2-/- Rag1-/- host chimeras, we show no role 
for the thymic stroma as a source of IL-2 during development. Although it 
remains a distinct possibility that important contributions from the thymic stroma 
exist, it seems likely that the main reason for increased Treg frequencies in 
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TetZap70 FoxP3GFP mixed chimeras is additional proliferation in the presence of 
IL-2.  
We previously suggested a redundancy existed between IL-2 and IL-15 
signalling during de novo Treg development in TetZap70 FoxP3GFP chimeras.  In 
Bl/6 :TetZap70 FoxP3GFP mixed chimeras we show a small difference in Treg 
frequencies between IL-15R-/- Rag1-/- and Rag1-/- hosts however this was not 
statistically significant. This is a much smaller difference than previously 
observed in TetZap70 FoxP3GFP chimeras. Previous studies show normal 
proportions of Treg in IL-15-/- and IL-15Rα-/- mice (M. A. Burchill et al. 2007) 
suggesting no role for IL-15 in normal Treg development and homeostasis. 
However one study has shown that IL-2Rβ-/- mice contain fewer thymic Treg than 
IL-2-/- mice (M. A. Burchill et al. 2007), suggesting contributions by both IL-2 and 
IL-15 to Treg biology. IL-15 and IL-2 both share components of their receptors 
and activate the STAT5 signalling pathway. Therefore it remains highly likely 
that some degree of redundancy exists between the two cytokines. This is 
consistent with the slight contraction we observe in Treg frequencies in Bl/6 : 
TetZap70 FoxP3GFP IL-15R-/- mixed chimeras. We have suggested that the 
mixed chimeras contain much higher levels of thymic IL-2 than single chimera 
controls. Therefore ablating IL-15 signalling in these mice may have less effect. 
Conversely in the TetZap70 FoxP3GFP single chimeras which appear to be 
lacking in thymic IL-2, ablation of IL-15 signalling leads to an approximate 50% 
decrease in thymic Treg. Our data therefore appears consistent with a 
redundancy existing between IL-2 and IL-15 where IL-2 plays the dominant role 
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in Treg development and IL-15 is capable of compensating in situations of low IL-
2 concentration. Blockade of IL-2 however in IL-15R-/- chimeras does not 
completely halt Treg development altogether, suggesting possible roles for 
additional factors. Another γc cytokine, IL-7 has been shown to play a role in 
Treg homeostasis (Latour et al. 2013). However IL-7-/- mice contain normal Treg 
frequencies (Latour et al. 2006). It remains a possibility that IL-7 is capable of 
supporting low levels of Treg development in the absence of IL-2 and IL-15, 
perhaps though promoting survival. But in thymi where IL-2 is abundant, 
knocking out IL-7 has very little effect. Taken together our data coupled with the 
current literature suggest an important role for IL-2 in FoxP3+ CD25Hi Treg 
development. IL-2-/- mice however still contain approximately 50% of their Treg 
compartment while γc-/- have no FoxP3+ Treg whatsoever (Fontenot, 
Rasmussen, Gavin & A. Y. Rudensky 2005). It therefore seems likely that 
multiple γc cytokines co-operate during Treg development.  
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Chapter 6 
Discussion 
The overall aim of this study was to investigate the mechanisms regulating the 
thymic development of Treg. More specifically we aimed to identify the 
immediate precursors to Treg and the differentiation signals required for FoxP3 
induction. Where previous studies have attempted this analysis in 
lymphoreplete animals, we studied the first wave de novo Treg development 
without the added complication of recirculant mature populations. This allowed 
analysis of the timing, phenotype and the signalling cues required for efficient 
Treg development. Further to this were able to identify a requirement for 
additional cell types in Treg differentiation, suggesting multiple cell types co-
operate in-order to establish peripheral tolerance.  
Which thymic populations act as Treg precursors? 
It has been suggested that the identification of a Treg precursor population would 
simplify future studies aiming to understand the Treg differentiation process.  
Current models for Treg development suggest that differentiation occurs via a 
CD25Hi FoxP3- precursor population. In support of this we show that upon 
sorting CD25Lo GFP+, CD25Hi GFP- cells, the CD25Hi GFP- cells display the 
most efficient FoxP3 induction when stimulated with IL-2. However gating on 
GITR (a marker which is elevated in Treg precursors) dramatically reduces 
efficiency of FoxP3 induction in these cells, making CD25Lo GFP+ cells the most 
efficient precursors to CD25Hi GFP+ Treg. Previous studies fail to investigate the 
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potential of these cells as CD25Hi FoxP3+ Treg precursors, instead solely 
focussing on CD25Hi FoxP3- cells. This observation suggests CD25Hi GFP+ Treg 
may develop via a CD25Lo FoxP3+ precursor as well as via the previously 
described CD25Hi FoxP3- subset. Further to this, in time courses with TetZap70 
FoxP3GFP mice, Treg are detectable on day 4. These Treg initially express low 
levels of CD25, appearing to increase CD25 and FoxP3 expression levels at 
later time points In addition to this we observe CD25Hi GFP- ‘precursors’ have 
high HSA expression levels that are progressively lower on CD25Lo GFP+ and 
CD25Hi GFP+ cells respectively. This could imply that CD25Lo GFP+ cells are the 
direct precursor to CD25Hi GFP+ Treg. Taking advantage of Nur77GFP mice we 
show enrichment for Treg precursors in GITRHi Nur77Hi cells. When combined 
with TetZap70 mice, the resulting TetZap70 Nur77GFP thymocytes have identical 
Nur77GFP expression levels on CD25Lo GFP+ and CD25Hi GFP+ cells, 
suggesting similar TCR signalling processes are involved in generating both 
populations. In contrast, CD25Hi GFP- cells express higher levels of GFP relative 
to both populations implying they may represent a distinct TCR repertoire, 
having experienced strong selection signals. To summarise, this study presents 
data suggesting that Treg develop via a CD25Lo GFP+ precursor. It does not 
however exclude the possibility that development is also occurring via CD25Hi 
GFP- cells as described by the 2 step model (Chan-Wang Joaquim Lio & C.-S. 
Hsieh 2008).  
Although our data suggests a strong possibility that Treg differentiate from 
CD25Lo FoxP3+ precursors, it remains entirely possible that differentiation 
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occurs via both CD25Lo and CD25Hi routes. If true this would cast doubt on the 
role played by IL-2 in the initiation of FoxP3 induction. CD25 expression may 
instead only correlate with induction of FoxP3, with cells receiving a stronger 
selection signal simply expressing CD25 before FoxP3, while weaker selecting 
cells begin FoxP3 expression before CD25. In support of this we observe 
increased Nur77GFP expression on CD25Hi FoxP3- cells relative to CD25Lo 
FoxP3+ cells. These two precursor populations may therefore represent 2 
alternate routes, with the same ultimate development fate. Alternatively each 
population may represent two distinct routes of development, by two different 
cell types. The CD25Lo FoxP3+ population, not having expressed CD25 and 
therefore gained IL-2 responsiveness, may represent an immature intermediate 
still auditioning to become a fully committed Treg. IL-2 is known to be essential 
for maintenance of Treg homeostasis, CD25Lo FoxP3+ cells may therefore be 
prone to loosing FoxP3 expression and becoming ‘exTregs’. In support of this we 
observed the lower levels of FoxP3 expression in CD25Lo FoxP3+ Treg than the 
mature CD25Hi subset. Further to this the Rudensky lab has reported an 
increase in exTreg in mice which receive an IL-2 antibody blockade, a treatment 
which we shown to decrease CD25 expression on developing Treg (Rubtsov et 
al. 2010).  
In order to confirm development of CD25Hi FoxP3+ Treg is occurring via CD25Lo 
FoxP3+ cells, future studies should focus on sorting sufficient numbers of the 
precursor populations that can be followed following intrathymic injection. 
Analysis of the thymus 2-3 days post injection would allow us to follow both the 
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survival and developmental fate of the various populations. With analysis of this 
kind it would be possible to draw conclusions regarding precursor-product 
relationships between the CD25Lo FoxP3+, CD25Hi FoxP3- and CD25Hi FoxP3+ 
cells. If this were to be carried out using wt mice care would have to be taken on 
sorting immature de novo generated cells, while avoiding more mature 
recirculating populations. Recirculating T-cells are likely to be a heterogeneous 
population containing both iTreg, nTreg amongst other T-cell populations, possibly 
complicating the interpretation of results. It may also be interesting to further 
study the methylation status of the FoxP3 locus in the various precursor 
populations. This would reveal crucial information about the ability of the various 
populations to both express FoxP3 and maintain expression.  
What are the signalling cues required for FoxP3 expression? 
Understanding the molecular cues which lead to FoxP3 expression will allow 
greater insights into both the thymic differentiation of Treg and how expression of 
the FoxP3 gene is regulated. Understanding this process remains a continuing 
focus for researchers, with an aim to identifying therapeutic targets for 
autoimmune diseases. In this study, using TetZap70 FoxP3GFP mice pulsed with 
methacycline, we present evidence describing a requirement for a short early 
TCR signal during thymic selection for Treg. Further to this we describe an 
essential role for CD28 co-stimulatory signalling. When treating TetZap70 
FoxP3GFP chimeras with an anti-CD28 blocking antibody, Treg development is 
almost completely absent. This data would suggest that an early selection 
signal involving both TCR and CD28 co-stimulation is needed for FoxP3 
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induction. Although it appears an early TCR signal is sufficient for development, 
we can only speculate as to the temporal requirement for CD28. Indeed further 
work should aim to confirm whether the role for CD28 in re-enforcing TCR 
induced Treg selection or if CD28 activates crucial pathways in parallel of TCR 
signalling.  
Although we appear to show early signalling is sufficient to support Treg 
induction, the precise nature of this signal remains poorly understood. It 
remains unclear if the signal received by DP thymocytes during positive 
selection is enough to trigger a commitment to the Treg lineage or in fact multiple 
rounds of continuous TCR-peptide interactions support development. 
Observations made during experiments in which TetZap70 FoxP3GFP mice were 
pulsed with methacycline appears to suggest that an early signal is enough to 
signal development into Treg. Observations in these experiments also showed a 
gradual enrichment of Treg compared to conventional T-cell populations. This 
would appear to suggest that Treg are better equipped to survive in the absence 
of TCR signalling, perhaps due to increased expression of anti-apoptotic 
proteins many of which are the target of FoxP3. This may reflect a requirement 
for Treg to go for long periods in the periphery without TCR-ligation dependant 
survival signals. As activated T-cells are proposed to be the main source of IL-
2, a reliance of Treg on an IL-2 dependant survival signal would enable the Treg 
compartment to mirror that of activated T-cells. Peripheral tolerance could 
therefore be maintained by the existence of a negative feedback loop in which 
activated T-cells and the Treg compartment are able to inhibit one another and 
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therefore avoiding auto-immunity while maintaining an immune system which is 
fit for purpose.  
We demonstrate IL-2 independent Treg development in TetZap70 FoxP3GFP 
mice treated with an IL-2 blocking antibody. Numerous studies describe an 
essential role for IL-2 in thymic de novo Treg development despite the 
observation that IL-2-/- mice still contain 50% of their Treg compartment (Vang et 
al. 2008). IL-2 is suggested to cause FoxP3 expression via STAT5 signalling, as 
the FoxP3 promoter contains a STAT5 binding motif. Indeed STAT5 deficient 
cells show defects in Treg frequencies, however studies in which the pro-survival 
molecule Bcl-2 is expressed in these cells, rescues the defect in Treg 
frequencies (Malin et al. 2009). This perhaps suggests an important role for IL-2 
in facilitating survival of Treg. Further to this, we observed increased Treg 
percentages in mice treated with IL-2-Ab complexes This data is consistent with 
studies in which a constitutively active form of STAT5 results in expansion of 
the Treg compartment in the absence of IL-2 (Yao et al. 2007). A more recent 
study in IL-2Rβ-/- mice demonstrates development of Treg with low expression of 
CD25 as well as low levels of the proliferation marker Ki67 (Cheng et al. 2013). 
It therefore remains unclear whether IL-2 functions to directly drive FoxP3 
expression, induce changes in chromatin structure making cells more 
permissive to expression or promote survival and expansion. Our studies 
however show that FoxP3 expression can be induced in the absence of IL-2, 
and would seem to suggest a role for IL-2 in Treg survival and expansion is most 
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likely. Reduced Treg proliferation would successfully explain previous 
observations in IL-2-/- mice in which the Treg compartment is reduced by 50%.  
What is the source of thymic IL-2? 
It is firmly established that IL-2 plays a pivotal role in peripheral tolerance 
through maintenance of the Treg compartment. Although other γc cytokines 
seem to play a semi-redundant role with IL-2, IL-2 appears the most crucial for 
Treg differentiation/homeostasis. Previous studies have shown TCR+ T-cells 
secreting ‘halos’ of IL-2 within the thymus of IL-2 reporter mice (Yang-Snyder & 
E V Rothenberg 1998). It has therefore been proposed that paracrine IL-2 from 
a T-cell source is the primary source of IL-2 within the thymus. We present data 
suggesting a possible requirement for selecting T-cells in order to generate 
sufficient quantities of IL-2 to drive development of CD25Hi GFP+ Treg cells. 
Within TetZap70 FoxP3GFP mice injected with CD45.1+ mature T-cells, we 
observed only low levels of CD25 expression by thymic Treg compartment (Fig 
1.12), indicating that the presence of mature recirculant T-cells alone is 
insufficient to support CD25Hi Treg development in the thymus. Conversely 
TetZap70 FoxP3GFP mixed chimeras which contain Bl/6 bone marrow and 
therefore normal thymic selection, contain a prominent CD25Hi GFP+ Treg cell 
population (Fig C3.1/3.2). The observation that negatively selecting T-cells may 
be an important source of IL-2 in the thymus can be seen in TCR transgenic 
mixed bone marrow chimeras. It has been previously observed that TCR 
transgenic T-cells fail to undergo negative selection without thymic expression 
of cognate antigen (Ohashi et al. 1991). Therefore the observation that both OTI 
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and OTII restricted mixed bone marrow chimeras were unable to support 
efficient CD25Hi GFP+ Treg development may suggest a requirement for negative 
selection. This study therefore implies a requirement for efficient negative 
selection in order to drive thymic expression of IL-2 for Treg 
development/homeostasis. Perhaps suggesting an important link between the 
establishment of central and peripheral tolerance.  
If true this hypothesis suggests that negative selection in TetZap70 FoxP3GFP 
mice generates low amounts of IL-2 relative to WT mice. In time courses of 
Zap70 induction with TetZap70 FoxP3GFP mice, we observed Treg emerging with 
low CD25 expression before CD25 levels gradually increase. This is perhaps 
characteristic of increased levels of thymic IL-2 as more cells enter selection. 
However, the proportion of Treg expressing high levels of CD25 never reached 
that observed in Bl/6 : TetZap70 FoxP3GFP mixed chimeras. This is perhaps 
indicative of impaired IL-2 secretion in TetZap70 FoxP3GFP mice, possibly due 
to sub-optimal TCR proximal signalling. It also remains possible that TetZap70 
FoxP3GFP mice lack a fully mature thymic microenvironment and therefore the 
IL-2 secreting cell type normally present in WT mice. 
A complete T-cell compartment has been shown to be crucial for the generation 
of a mature thymic microenvironment (Akiyama et al. 2008)(Hikosaka et al. 
2008)(White et al. 2010). Un-induced TetZap70 FoxP3GFP mice lack a mature T-
cell compartment and have therefore been shown to contain an immature 
thymic stroma (White et al. 2010). As a mature thymic medulla has been shown 
to be crucial for the development of FoxP3+ Treg, it remains possible that 
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development in TetZap70 FoxP3GFP mice remains inefficient (Cowan et al. 
2013). DCs make up one of the many cell types contained within the thymic 
microenvironment and have been suggested to play an important role in thymic 
Treg development. Populations of DCs have been shown to migrate from the 
periphery to the thymus where they display peripheral antigens, supporting 
tolerance to peripherally expressed peptides (Proietto et al. 2008). DCs have 
also been shown to transiently express low levels of IL-2 (Granucci et al. 2001). 
A lack of thymic DCs contained within TetZap70 FoxP3GFP mice could therefore 
explain the low IL-2 levels observed within these mice. Although the low levels 
of IL-2 generated by thymic DCs may not be sufficient to generate large 
amounts of paracrine IL-2, local secretion whilst Treg interact with DCs during 
selection could be sufficient to drive CD25/FoxP3 expression. Previously within 
this study, we suggested a role for the trans-presentation of the IL-15Rα by the 
thymic stroma in order to support Treg development by IL-15. Trans-presentation 
of CD25 has also been suggested to occur by some populations of DCs. This 
could suggest a possible mechanism in which DC-mediated IL-2 signalling 
could support FoxP3 expression in CD25Lo precursors cells (Wuest et al. 2011). 
If true and TetZap70 FoxP3GFP mice do indeed lack this DC cell population, this 
could explain the low levels of IL-2 activity observed in these mice.  
What are the dynamics of de novo Treg development? 
The data in this thesis suggests a delay in the development of Treg relative to 
conventional CD4+ SP cells. We show that Treg are first detectable 4 days after 
positive selection in the adult thymus, whereas conventional CD4+ SPs were 
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detectable by day 1. In addition to this we see the first wave of Treg developing 
with low CD25 expression levels. CD25 expression then increases, along with 
FoxP3 levels, as the cells develop further. Unexpectedly we demonstrate 
significant proportions of Treg recirculating back into the thymus from the 
periphery, suggesting the need for caution when interpreting data derived from 
thymocytes of lymphoreplete mice. The lack of this recirculant population of T-
cells in TetZap70 FoxP3GFP mice goes some way to explaining the reduced 
thymic Treg frequencies in these mice when compared to WT animals. We 
further demonstrate a relative delay in thymic egress of Treg compared to 
conventional T-cell populations.  
Our data appears to support observations made by previous studies which 
observe a delay in the development and egress of Treg compared to non-
regulatory T-cell populations. However, why this delay exists remains poorly 
understood. The delay in FoxP3 induction compared to other lineage defining 
transcription factors has been the focus of numerous studies. This delay was 
previously observed in the first wave of T-cell development within neonatal 
mice. Delayed development of Treg compared to non-regulatory populations in 
these studies was suggested to be due to the lack of a cytokine signal 
(Fontenot et al. 2005). It was observed however that Treg in these mice express 
high levels of CD25, a phenotype we have shown to be characteristic of an 
environment rich in IL-2. The use of TetZap70 FoxP3GFP mice within our study 
has enabled the analysis of do novo Treg development in adult mice. We further 
confirm the previously described delay in development of Treg 
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this was not due to the lack of a cytokine signal. The delay in development 
could instead be characteristic of an extra round of differentiation and protein 
synthesis in addition to that already instructed upon commitment into the CD4+ 
SP lineage, or perhaps due to a requirement for Treg to undergo multiple strong 
TCR-peptide signalling events in order to begin FoxP3 expression. Either 
scenario would explain the increased length of time Treg appear to spend 
developing in the thymus, prior to their delayed egress into the periphery. We 
show Treg present in the LNs of TetZap70 FoxP3GFP mice in substantial 
numbers 10 days after positive selection. This is a delay of approximately 5 
days compared to that of non-regulatory CD4+ SP populations. However it must 
be noted that extremely small numbers/percentages of cells coupled with large 
degrees of error mean care must be taken when interpreting this result. In fact 
small numbers of mice show evidence of Treg in the periphery as early as day 5, 
perhaps casting some doubt about the delayed egress of Treg compared to 
conventional CD4+ SPs. More recent studies have also cast doubt over the 
precise timing of conventional and regulatory T cell egress from the thymus. In 
mice that have undergone day 3 neonatal thymectomy, they found significant 
proportions of FoxP3+ Treg in spleen at early timepoints, yet mice succumb to 
auto-immunity (Samy et al. 2008; Dujardin et al. 2004). Whether this result 
illustrates the functional differences between peripherally derived iTreg and their 
inability to control autoimmunity when compared to thymic nTreg, that are 
missing in these mice, remains to be determined. However these studies would 
suggest there is a smaller difference in the dynamics of Treg development 
compared to conventional T-cells than perhaps previously thought.  
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Alternative model for de novo Treg development 
According to the data presented in this thesis we propose an alternate linear 
model for thymic Treg differentiation. This model is composed of a TCR 
dependant phase, followed by a cytokine dependant phase for development. 
We suggest that strong early TCR/CD28 stimulation initiates FoxP3 gene 
transcription. It remains likely that histone modifications to the FoxP3 locus and 
regulatory region CNS1 precede FoxP3 expression. However acquisition of an 
activated chromatin state at these sites has been shown to be coincident with 
FoxP3 expression (Y. Zheng et al. 2010). Therefore it remains possible that 
chromatin modifications on alternative regulatory regions such as CNS3 play an 
important role in readying the FoxP3 locus for transcription. Following 
TCR/CD28 signalling, akt inactivation leads to enhanced FoxP3 expression via 
nuclear translocation of Foxo factors. This functions to further increase FoxP3 
expression in the absence of TCR/CD28 selection signals. Multiple rounds of 
strong selection signals meanwhile lead to negative selection, while more 
infrequent signalling leads to FoxP3 expression. Treg precursors on the cusp of 
negative selection express CD25 prior to expressing FoxP3, while weaker 
selecting Treg precursors delay CD25 expression.  
Following this, FoxP3+ CD25Lo precursors continue to undergo multiple rounds 
of auditioning to become FoxP3+ CD25Hi Treg. In the absence of a functional IL-2 
receptor these cells rely on stroma derived IL-15 for survival as well as other γc 
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cytokines. If FoxP3+ CD25Lo precursors increase CD25 expression following 
further rounds of high affinity selection signals they differentiate into FoxP3+ 
CD25Hi Treg. If they fail the auditioning process they may loose FoxP3 
expression and become exTreg or undergo negative selection. IL-2 secreted by 
negatively selecting T-cells in the thymus and activated T-cells in the periphery 
then stimulate proliferation of FoxP3+ CD25Hi Treg, maintaining survival of the 
fittest Treg clones as well as controlling the size of the Treg compartment. This 
further enhances FoxP3 expression via STAT5 as well as enhancing expression 
of pro-survival factors.  
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